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Chapter 1
A. Introduction to spinal cord injury
Each year, m any people worldwide suffer from sp inal cord injury (SCI). These injuries cause 
death o f neural cells, severance and dem yelination o f descending and ascend ing axons, and, 
consequently, loss o f  m otor and sensory function. Endogenous repair efforts fail to repair the 
spinal cord and, as a result, the functional im p airm ents are perm anent. M ost people who 
experience SCI are destined to spend the rem ainder o f  their life in a w heelchair3, 35, ” 8, 145, 340 345. 
Potential treatm ents for SCI are being tested in the c lin ic  but so far none o f these have 
em erged as one that reverses the devastating functional consequences o f SCI. H ere we review 
SCI with an em phasis on the current status o f clin ical care and clin ical trials. In an 
accom panying review we discuss the app lication o f stem cells for sp inal cord repair.
EP ID EM IO LO G Y  A N D  ETIOLOGY O F SCI
In co n sisten t data reporting m akes it difficult to accurately estim ate the worldw ide incidence o f 
S C I3, ” 4, 254, 301 315 388. The an nual incidence in the United States is about 4 0  cases per m illion 
population or about 12,000 cases per year2’6, 4’7, 452. O ver 77 %  o f  SCI occurred am ong m ales. A 
num ber o f studies profiling the epidem iology o f SCI indicated that the population o f SCI 
people has grown over 255,000 (in 2 0 0 7 ) with estim ates between 2 2 7.0 8 0  and 300,938 
patients. In the United States and m ost W estern European countries, the average age at 
injury has increased over the last 3 decades from 28.7 to 39.5 years. M ost injuries occur 
between the ages o f  16 and 30. The percentage o f people older than 6 0 that suffered from SCI 
has increased from 4 .7%  in 1980 to 11.5% am ong injuries since 2 0 0 0 .
In the United States, the m ain causes o f  SCI are m otor vehicle crashes (42% ), falls (27.1% ), 
violence (15.3%), unknown (8.1% ), sports (7.4% ). These num bers are sim ilar in other countries 
although the percentage o f  violence may be sm aller216, 417, 452. Over 70 %  o f injuries are 
contusive in ju rie s54, 195.
CONSEQUENCES O F SCI
Pathophysiological and anatomical consequences
A force to the vertebral colum n causes dam age to the ligam ents and vertebrae (Fig. 1A, B). The 
torn ligam ents cause instability o f the vertebral colum n. Dislocated bone fragm ents of 
dam aged vertebrae m ay com press the sp in al cord (Fig. 1A, B). This causes im m ediate neural 
cell death, axon dam age and d em yelin ation155 (Fig. 2A). The cellular dam age results in instant 
loss o f m otor and sensory function. After the first destructive events, a sequence o f  m olecular 
and cellular pathophysiological events (Fig. 2A) including an aggressive inflam m atory 
respon se w ithin the dam aged tissue leads to additional tissue loss at the injury epicen ter and 
at distant sites34, 65, 155, 192 (secondary injury). On the other hand, there are also various cellular
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events during the early and later stages o f SCI that could be interpreted as attem pts to correct 
for the inflicted dam age (Fig. 2B).
Functional consequences
The functional consequences o f SCI are highly variable and depend on the degree o f tissue 
dam age, which in turn d epend s on the im pact severity. In patients with SCI with a relatively 
sm all am ount o f  tissue dam age, som e endogenous recovery offu nction can be observed, which 
is m ost likely resulting from plasticity o f  the spinal nervous tissue102, '°7. In people with SCI 
with large tissue dam age the neurological deficits are generally  m ajor and perm anent. There 
are very few reports o f people with a large injury that regain m otor function to a degree that 
indep en dence can be achieved. In these few cases the injury was generally  inflicted to the 
lower (lum bar) level o f the sp in al cord'97.
Fig . 1 . Imaging o f human spinal cord compressive injury. (A) Sagittal view  o f  the cervical spinal cord on m agnetic  
resonance  im aging dem onstrating the dislocated C 5 and C 6 vertebra com pressing  the spinal cord (arrow ). Th e  
form ation o f  a haem ato m a ventral to the spinal colum n C 1-C4  indicates possible ligam ent d am ag e  (aste risk ). (B) 
C lo ser view  o f  the dam ag ed  C 5 and C 6 cervical vertebrae on com puted tom ography scan , clearly show ing bony dam age  
o f  the vertebrae, with dislocating fractures in the spinal canal (a rro w ). (C ) Conventional X-ray lateral view  o f  the cervical 
spinal colum n after dorsal stabilization from  C 2 to T h 2 . B ecau se  o f  the d am ag e  to tendons and vertebrae stabilization  
surgery n eeds to be im plem ented in a large num ber o f  ca se s  o f  S C I. (D ) Conventional X-ray antero-posterior view  o f  
the sa m e  patient with stabilized cervical vertebrae as in panel C .
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A  A C U TE  -  S EC O N D A R Y - CH RO NIC
Fig . 2 . Degenerative and regenerative events after spinal cord injury. A  schem atic  representation o f  the degenerative (A) 
and regenerative (B) events that take  place after spinal cord contusion injury. Rostral is to the left. In B , the  
regenerative events that take  place relatively early after injury and over a limited tim e period are upregulation o f  
regeneration-associated  genes (R A G s) , axon sprouting, ang iogenesis, trophic factor upregulation, Schw ann cell 
invasion. O th e r regenerative events such as  debris rem oval, stem  cell birth/proliferation, m yelination, and plasticity m ay  
also  occur at later tim e points and over a longer tim e period.
Social consequences
The critical-care m edicine practice for people with SCI has considerably im proved during the 
last decade and is nowadays more widely available. Accordingly, m ore than 95%  o f SCI 
patients survive their initial hospitalizatio n. SCI decreases the lifespan by about 7%  each 
year401. A functionally com plete and high level (cervical) injury im pact the lifespan m ore 
dram atically than a functionally incom plete or low level (thoracic-lum bar) injury40’. Together, 
the relatively young age when SCI occurs, the im proved m edical care, and the lack o f effective 
therapies are respon sib le  for the con tinually  increasing num ber o f  paralyzed people with SCI. 
This puts a high financial burden on the patient, h is/her fam ily, and society3, ’3’ 348. SCI is the 
second m ost expensive condition to treat in the United States after respiratory distress 
syndrom e in infants and is ranked third in m edical conditions requiring the longest stay in 
hospitals442. The costs o f lifetim e care for a SCI patient varies between ’ and 3 m illion 
dollars263. The Centre for D isease Control in the United States estim ated that about ’ 0 billion 
dollars are sp en t yearly on SCI treatm ent excluding the m anag em en t o f  pressure ulcers, a 
com m on side-effect o f SCI, which adds another billion dollars per year263.
12
Introduction and Outline Thesis
CLIN ICA L ASSESSMENT O F FUNCTION AFTER SCI
The Am erican Sp inal In jury Association (ASIA) im pairm ent scale is often used to assess the 
level and the com pleteness o f S C I’54, 2° 5, 251 259. This scale grades the preserved dermatome for 
sensory function and the strength o f 2 °  “key” muscles in the upper and lower lim bs25’. It 
provides clin ic ians with a standard for grading sensory and motor function im pairm ent after 
SCI. Table ’ provides the 5 A SIA  scores and their im plications. Testing the intrinsic foot 
muscle, could com plem ent the A SIA  score as, in the m ajority o f SCI patients, it provides an 
earlier and superior indicator of supraspinal influence over motoneurons projecting to lower 
extremity m uscles57.
Another frequently used scale is the A SIA  Lower Extremity Motor Score (LEM S), an ASIA 
subscore, which provides a prediction of the ability to walk. The LEM S scale is com m only used 
together with and supplem ents the A SIA  scale. A  person without neurological deficits scores 
5 °  on the LEM S scale. A  score of 3 °  or more is predicative for com m unity am bulation ’ year 
after injury and a score of 2 °  or less predicts limited am bulation’97, 251 252 259, 428.
Classification o f SCI can also be achieved by m easuring functional ability using the 
Functional Independence M easure (F IM )’° 5; a 7-point scale that m easures ’ 8 items 
concerning mobility, locomotion, self-care, bowel a n d /o r bladder function, com m unication, 
and social cognition. A  score of ’ indicates total dependence on a caregiver and a score of 7 
indicates complete independence’° 6, 264 Other scales to assess functional ability are the 
Q uadriplegic Index of Function (QIF), Modified Barthel Index (M BI), and W alking Index for 
SCI (W ISCI), Capabilities o f Upper Extremity Instrum ent (CUE), Spinal Cord Independence 
M easure (SCIM ) and the Canadian O ccupational Performance M easure (CO PM ).
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ASIA
grade
Classification Level of impairment
A Com plete No motor or sensory function preserved in the S4 and S5 segments
B Incom plete
Sensory but not motor function preserved below neurological level 
and including S4 and S5 segments
C Incom plete
Motor function preserved below neurological level and more than 
half o f key muscles below that level have a muscle grade o f < 3
D Incom plete
Motor function preserved below neurological level and at least half of 
key muscles below that level have a muscle grade o f > 3
E Normal Motor and sensory functions are normal
Table 1 . Standard neurological classification o f spinal cord injury. The presence of motor and sensory function per 
dermatome (neurological level) can be tested with the ASIA (American Spinal Injury Association) scale. For motor 
function, 10 key muscles in all four limbs are scored 0-5 (0 = total paralysis; 5 = normal) for a maximum score of 10 0 . 
For sensory function, light touch and pin prick are being used at key sensory points on the right and left side of 28 
dermatomes to assess the absence (score will be 0) , impaired presence (1 ) or normal presence (2) of sensory function. 
The maximum sensory score is 224  (112 for each of the tests; 56 for each side). The scoring sheet can be found at 
http://www.asia-spinalinjury.org/publications/2006_Classif_worksheet.pdf
TREATMENT O F SCI
An acute and a chronic phase can be distinguished after SCI. Since SCI is often a consequence 
of severe accidents, clinical care during the acute phase is generally focused on stabilization of 
the patient. D uring the chronic phase the m ain attention will need to be on preventing and, if 
unsuccessful, treating SCI consequences such as pain, infections, and pressure ulcers among 
others.
Clinical care acutely after SCI
To date there is insufficient evidence that would support standards o f care during the acute 
phase o f SCI. It is advised to m aintain patients in an intensive care unit for close m onitoring 
of respiratory and hem odynam ic com plications. For adequate spinal perfusion, which is at risk 
due to injury-induced edema, a mean arterial pressure of 85-90 m m H g should be 
m aintained42. D epending on the type o f injury, surgical interventions should be considered to 
relieve the spinal cord from com pressing bone fragm ents49, 126. The physician may decide to
14
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perform surgery to decompress or stabilize dislocated vertebrae and the vertebral column (Fig. 
1C, D). Decom pression surgeries49, 126 may accelerate functional im provem ents and result in 
shorter hospitalization and rehabilitation periods264, 316. However, it does not necessarily result 
in an improved final outcome71.
The lack of standards o f care during the acute phase of SCI is in part due to the large 
variability am ong injuries and makes its early m anagem ent com plicated. If bone fragments 
continue to com press the spinal cord, early surgery may be vital to prevent exacerbation of 
spinal cord tissue destruction. However, in cases without a clear sign of such urgency there is 
no consensus on whether and what type of early surg ical/clin ical interventions must be 
im plem ented126. The lack of standards of care is demonstrated by a case presented in figure 1. 
Due to a fall this patient had m ultiple fractures of the cervical spinal cord, including 
dislocation fractures of the C5 and C6 vertebrae resulting in com pression of the spinal cord. In 
the acute phase, the patient was admitted at the intensive care unit and monitored. At first, a 
decom pression lam inectom y and dorsal spondylodesis from C2-TI12 was performed. However, 
the C5 dislocation fracture was not repositioned sufficiently requiring a second surgery where a 
corporectomy C5 and C6 including a ventral spondylodesis was performed. The type o f surgical 
intervention should be considered on a case-to-case basis, which makes it com plicated to study 
the efficacy of intervention in the acute phase after SCI in random ized and controlled clinical 
trials.
Besides surgical interventions, pharmacological treatm ents to lim it the secondary injury 
after SCI are often considered. The best-known treatm ent is a high dose o f the 
glucocorticosteroid, m ethylprednisolone sodium succinate (M PSS) within 8 hours after the 
injury44'46. Experim entally it was dem onstrated that a high dose o f M PSS reduces the 
inflam m atory response and lim it tissue loss after damage to the spinal cord311. The effects of 
M PSS in patients with SCI were investigated in 3 consecutive National Acute Spinal Cord 
Injury Studies44'46 (NASCIS). The results demonstrated that M PSS treatm ent in the acute 
phase of SCI resulted in neurological im provem ents up to 6 months after injury. M PSS was 
the standard of care in the United States and other countries. After a thorough review of the 
results from the N A SCIS studies and a more com prehensive assessm ent o f the benefits and 
risks involved in high dose M PSS treatment, the therapeutic benefits became disputed64, 225, 287, 
288, 344, 425. Especially in patients with complete SCI high dose steroid treatm ent can lead to 
adverse effects such as myopathy and wound infection that m ay negatively influence 
functional outcome and in some cases may be life-threatening225, 344. Currently, m any SCI 
clinics worldwide have discontinued the ‘standard' acute adm inistration o f M PSS after SCI. 
The debate on the use of M PSS should be accom panied by efforts to develop alternative 
treatm ents that counteract the early destructive events occurring during the acute phase of 
SCI.
15
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Clinical care at later stages after SCI: Preventing complications
Different com plications may occur during the later stages of SCI (Fig. 3) that each dem ands 
specific actions and/or interventions. For instance, SCI can lead to pain439 , 44°, decreased 
fertility327, and autonom ic dysreflexia with loss of bladder and bowel control436. It has to be 
taken into consideration that m any SCI patients get accustomed to the specific injury-related 
pain they experience and as a result reveal their distress to their physician often at a late 
stage250 374. For some SCI-related conditions, such as decreased fertility, it is the patient's 
personal desire that should guide the physician's actions.
Other common problems that arise after SCI are septicem ia, respiratory insufficiency, and 
pneum onia due to muscle atrophy (Fig. 3). These com plications may cause clinical 
deterioration and could eventually result in death. They often occur without typical symptoms. 
For example, pyelonefritis can occur without flank pain or a femur fracture can occur without 
pain. This may lead to delay or errors in diagnosis and treatm ent’04, ’56. It is im perative that 
SCI patients receive annual screenings and long-term follow-ups to prevent these secondary 
com plications. It is advised to treat patients on a regular basis with pneumococcal and 
influenza vaccine to prevent opportunistic infections20’  2°2. M onitoring the skin and urinary 
tract and im plem enting aggressive treatm ents against pressure ulcers and urinary tract 
infections is needed to reduce the risk of septicem ia20’  2°2. Appropriate nutrition and exercise 
should also be incorporated in the (new) lifestyle. Rehabilitation programs should be 
im plem ented to reduce the risk o f cardiovascular disease40’.
Generally, the possible medical com plications of SCI patients are known, mostly 
recognizable, and their treatm ent often straightforward. It is different for the psychological 
problems that arise after SC I37, 397. It may be possible to recognize some o f these but treatm ent 
and responses to the treatm ent are depending greatly on the individual. O ne can expect an 
initial period o f denial and /o r inability to fully comprehend the functional consequences 
caused by the injury. Next a period of acceptance will have to run its course37, 397. The patient 
needs to learn to live with the disabilities and this may be accom panied by bouts of 
depression. The mental state o f the patient can have its effect on medical treatm ents439. The 
psychological consequences o f SCI should not be underestimated and appropriate guidance of 
patient and fam ily should have an im portant place in the late care m anagem ent of S C I37, 44’.
16
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First years Chronic
Fig. 3. Complications after spinal cord injury. The most common complications that occur during the first years after SCI 
are listed on the left and those that occur mostly at later (chronic) stages are listed on the right. Spasticity and pressure 
sores occur during the first years but are also common at chronic stages of SCI (UTI = urinary tract infection).
CLIN ICALLY TESTED APPROACHES TO  ELICIT FUNCTIONAL RECOVERY
Continuing m edical care after SCI is necessary to m aintain the patient's health and quality of 
life. However, this generally does not result in dram atic im provem ents in function that would 
allow the patient to live an independent life. Repair-prom oting pharm aceutical and/or 
surgical interventions will be necessary to significantly change the functional outcome after 
SCI (Fig. 4). Here we will review some o f the current treatm ents that are aim ed at lim iting 
functional loss and/or im proving outcome after SCI. In addition we discuss possible future 
treatm ents for spinal cord repair. Table 2 provides a list o f clinical treatm ents for SCI.
17
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Neuroprotection
Limit cell/tissue loss
1
Plasticity
Formation new circuits
Transplantation
Substitute/replace cells
Functional
— ► recovery
Rehabilitation
Recruitment new circuits
\  t
Axon regeneration
Growth-myelination-synaptogenesis
Fig. 4 . Different approaches that could result directly and/or indirectly in functional recovery after SC I
Neuroprotective approaches
D uring the last 30 years, m any experim ental studies have targeted neuroprotection (i.e., 
tissue sparing) early after SCI to improve outcome. Experim ental evidence has shown that the 
functional loss after SCI can be lim ited by im plem enting neuroprotective approaches. The 
best known neuroprotective approach is acute adm inistration o f M PSS. This has been tested 
clin ically and is still being used around the world44-46. M PSS treatm ent after SCI was first 
thought to improve functional outcome, but at present its true therapeutic potential is 
intensely debated225, 287, 288, 344, 425. The m ain goal o f M PSS treatm ent after SCI is to decrease the 
aggressive inflam m atory response norm ally present within the damaged tissue. This would 
lim it the contribution o f macrophages and activated microglia to the secondary loss o f nervous 
tissue.
Another exam ple o f a molecule that could elicit neuroprotective effects after SCI is the 
tetracycline derivative, m inocycline’8-20. M inocycline m ay exert its protective effects through 
m echanism s that decrease injury-induced glutam ate-m ediated excitotoxicity’8, 421 and/or 
im m unom odulatory m echanism s such as blocking microglial activation’9, ’’0. Moreover, 
m inocycline may reduce oligodendrocyte and neuronal apoptosis as well as dieback of 
damaged axons’30 399. These experim entally studies have established m inocycline as a 
prom ising candidate for early treatm ent after SCI. Currently, a phase I/II clinical study is 
underway in the United States to assess the efficacy of intravenously adm inistered 
m inocycline in the acute phase after S C I2’.
18
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Fig. 5. Axon regeneration after spinal cord injury. Schematic representation o f axon regeneration that could contribute to 
functional recovery after SCI. There are 3 types of damages that are inflicted to axons after SCI. Axons may be still in 
contact with their target neurons but demyelinated (A) due to immediate or delayed death of oligodendrocytes. These 
axons can become ‘functional’ and contribute to motor recovery when they are remyelinated (A’) by either endogenous 
oligodendrocytes derived from local stem cells or oligodendrocyte precursor cells, or by transplanted stem/precursor 
cells or Schwann cells. Axons may be severed and thereby devoid of contact with their target neurons and demyelinated 
(B ). In that case, the axons need to regenerate across/beyond the injury, establish synaptic contacts with target 
neurons, and be myelinated by endogenous or transplanted cells (B’) . Unmyelinated axons may be severed and 
without contact with target neurons (C). These need to regenerate and establish synaptic connections with the original 
or new target neurons (C’).
Axon growth-promoting approaches
Functional im provem ents after SCI could be elicited by axon growth-promoting approaches as 
this could result in either restoration of damaged axonal circuits or elicit p lastic events’36, ’6’  363 
(Fig. 5). Examples of axon growth- or plasticity-prom oting treatm ents are the adm inistration of 
Cethrin® or N O G O  antibodies. Cethrin® is a Rho antagonist that reduces the levels of 
intracellular GTPase-associated signaling proteins Rho and Rac to physiological levels’’6, 443. 
Elevated Rho has axon growth-inhibitory effects through the above m entioned pathway294. 
N O G O  antibodies neutralize axon growth-inhibitory effects o f oligodendrocyte m yelin-bound 
Nogo2’  72. Thus, both Cethrin® and N O G O  antibodies may result in enhanced axon growth 
and /o r axon plasticity after SCI. Both treatm ents are currently tested clin ically for their efficacy 
to repair the injured spinal cord2’.
After SCI axons may still be intact but not functional due to injury-induced conduction 
block. A dm inistration o f the potassium  channel blocker, 4-am inopyridine (4-AP) may restore 
such a conduction block and this could restore axon function and thus contribute to improved
19
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function. The efficacy of 4-AP in SCI patients has been tested clin ically but so far the outcome 
has been modest95, 1,2 ,57.
Cell transplantation-based approaches
Neuroprotection as well as axonal regeneration could be achieved by transp lanting growth- 
promoting cellular or a-cellular substrates. Examples of cellular substrates that are clin ically 
tested are olfactory ensheathing cells, peripheral nerves, and activated macrophages. Grafting 
olfactory ensheathing cells into the spinal cord is being examined in China, Australia, and 
Portugal94, ,27, 231. Autologous peripheral nerves are being grafted into the injured spinal cord in 
Taiw an80 173 and activated autologous m acrophages in Israel378 and Belgium 209. Thus far, there 
is no clear evidence that these transplantation strategies elicit m ajor functional changes.
Approach Main objectives Examples
Elicit neuroprotection Limit cell/tissue loss *M P, ^minocycline, riluzole
Elicit axon regeneration Promote growth, myelination, *Cetrin^, *NOGO
Provide growth substrate Support axon regeneration SCs, *OEG, *PNG
(transplantation) Promote cell survival / axon growth ^Activated macrophages
Facilitate plasticity Promote formation new circuits *Cetrin^, *anti-NOGO-A
Restore conduction block Increase axon excitability * 4-AP
Limit spasticity Decrease reflex activity *Baclofen, Fampridine
Limit osteoporosis Prevent fractures Risedronate, vibration
Improve bowel/bladder Limit uncontrolled release Gut stimulants, Ditropan 
Colostomy tube
Alleviate (neuropathic) pain Decrease hyperexcitability Amitryptaline, botulinum toxin
Manage infertility Facilitate erection, ejaculation Sildenafil, vibration, levitra
Elicit neuroprotection Limit cell death Hypothermia
Add/silence repair genes Promote regenerative events Gene therapy: Viral vectors
Enhance effects other interventions siRNA
Cell replacement Replace the lost neural cells Stem cells/progenitors
Increase proliferation endogenous cells *AIT-o82 (Neotrofin)
Elicit muscle strength/use Prevent muscle atrophy Targeted physical therapy:
Promote regenerative events? *Locomat, *treadmill training
Enable movements Facilitate (controlled) movements Robotic prosthetics
Enable movements Facilitate muscle action Electrical stimulation:
Promote regenerative events? ^Alternating currents, IST-12
Table 2 . Therapies for the injured spinal cord. Most of the listed approaches are or have been extensively studied in 
experimental models of spinal cord injury. For each a few examples are given that are investigated in the laboratory or 
clinic (indicated by asterisks). The approaches listed under the line are comparatively novel.
20
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Frontiers in treatment o f SCI
A relatively new concept that does not focus on anatom ical and /o r functional repair but rather 
on supporting the patient to achieve some degree of independence is the use o f robotics to 
enable execution of specific motor tasks. Currently, there are concerted efforts to em ploy 
cerebral (cortical) control for steering robotic devices in com bination with micro-chip 
technologies that would enable fine-tuning of the robotic movements depending on the 
tasks’", 227 33’.
Other com paratively novel approaches im plem ent physical and /o r electrical activity to 
elicit spinal cord repair. Although these approaches are generally designed to improve muscle 
strength/use, it has been hypothesized that these particular approaches could also elicit 
regenerative cellular events that could contribute to improved outcome’32 ’82. Moreover, 
locomotor activity27, 67, 362 446 and electrical stim ulation5’  342 369 may promote spinal cord repair 
via stim ulation of plastic m echanism  within existing axon circuits involved in motor function.
A relatively new concept within the more conventional field of cell-based approaches to 
repair the spinal cord is the transplantation of stem cells to either replace lost cells or elicit 
regenerative cellular events after SCI. Stem cells have been studied for their potential to 
restore degenerative diseases in the central nervous system, such as Parkinson's disease, 
A lzheim er's disease, amyotrophic lateral sclerosis, and m ultiple sclerosis2’4, 276, 3’7 or in 
traum atic injuries such as transient brain traum a235, 357 or S C I’2’  122 2° 4.
Stem cells hold prom ise for spinal cord repair, but their true potential has not yet clearly 
been shown. At this time, stem cell-based therapies are at an early stage, and the associated 
risks are still unclear. To enable future use of stem cells for therapeutic purposes, discussions 
on all related issues and especially the moral aspects need to be held today. As with any 
medical intervention, the questions to be asked are whether this approach is the most likely 
one to achieve success and whether the risks justify the benefits. The challenges are to further 
develop these concepts within current ethical and social boundaries to increase our knowledge 
and, through experim ental research, evaluate if  they provide any clinical benefit for patients.
B. Stem cell-based therapies
Stem cells proliferate, migrate, and differentiate to form organism s during em bryogenesis. 
D uring adulthood, stem cells are present within tissues/organs including the central nervous 
system6, ’5’  26’  347, 4’6 where they may differentiate into neurons’23. After the identification and 
characterization o f stem cells, a great deal of interest has been given to their potential for 
treatm ent o f spinal cord injury (SCI), traum atic brain injury, and degenerative brain d iseases52 
’33, 141 339, 393, 394. Considering their characteristic abilities to self-renew and differentiate into any 
cell type in the body the therapeutic promise o f stem cells is justified. Before effective 
therapies can be developed there are several issues that need to be addressed and resolved.
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These issues range from increasing our basic knowledge about the stem cell's biology to 
prevailing over moral concerns fueled by religious and /o r political ideas.
STEM CELL D EFIN ITIO N S
A stem cell is defined by its ability o f self-renewal and its totipotency. Self-renewal is 
characterized by the ability to go through an asym m etric division in which one of the resulting 
cells rem ains a ‘stem cell', without signs of aging, and the other (daughter) cell becomes 
restricted to one o f the germ layers. A  stem cell may become quiescent and at later stages 
reenter the cycle o f cell division309, 343.
A true stem cell is a totipotent cell; it can become any cell type present in an organism . 
By m any the zygote is considered to be the only true totipotent (stem) cell because it is able 
to differentiate into either a placenta cell or an em bryonic cell. Others define the cells o f the 
inner cell m ass within the blastocyst as embryonic stem cells (ESC). These cells are 
pluripotent as they cannot become a placenta cell (Fig. 6). Besides ESCs, undifferentiated 
cells can be found among differentiated cells o f a specific tissue after birth. These cells are 
known as adult stem cells, although a better term would be ‘som atic stem cell' since they are 
also present in children and umbilical cords. There is am ple evidence that adult stem cells are 
not restricted to a particular germ layer and can transdifferentiate82 2,1 2,7,282, 46°. An im portant 
advantage o f adult stem cells over ESC is that they can be harvested without destruction of an 
embryo. As a result, adult stem cells have gained am ple interest for their application in a 
variety o f disorders.
DIFFERENTIATION
The pluripotent stem cell differentiates into a m ultipotent cell o f the three germ layers. These 
three layers are the ectodermal layer (from which skin and neural tissue originate), the 
mesodermal layer (connective tissue, muscle, bone and blood cells), and the endodermal layer 
(gastrointestinal tract and internal glandular organs) (Fig. 7). The m ultipotent cell 
differentiates into a unipotent cell of a particular cell lineage within its own germ layer. The 
unipotent cell is capable of becoming a cell type within that particular cell lineage. At the 
successive phases of differentiation (or determ ination), the resulting progeny are known as 
progenitor cells; ‘stem cell-like' cells capable of self-renewal. W ithin the central nervous 
system, unipotent neural progenitors become the neurons and glial cells present in brain and 
spinal cord (Fig. 6).
In the classic embryology, the totipotent stem cell becomes unipotent through successive 
phases of fate restriction. The steps in this process were thought to be irreversible. However, 
recently it was shown in vitro that the fate of m ultipotent cells can be chanced to another
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germ layer82' 2"' 2’7'282' 46°. This process is known as transdifferentiation. The unlim ited potential of 
transdifferentiation prompted m any investigators to obtain cells that norm ally derive from 
stem cells that are more difficult to harvest from stem cells that are easier to harvest. For 
instance, it is less complicated to harvest stem cells from skin262' 447 or bone marrow382' 4’°  than 
from the brain’90' 336.
Transdifferentiation has often been shown using non-specific markers and ignoring 
possible artifacts due to culturing methods122,335. Therefore, the existence of transdifferentiation 
is still debated335,412. It should be kept in m ind that forced differentiation into a cell from a 
lineage within an unnatural germ layer could result in abnorm al phenotypes that after 
grafting could induce carcinogenesis392.
N eu ra l
P ro g e n ito r
P ro g e n ito r
N eu ro n
Fig. 6. From embryonic stem cell to 
differentiated neural cell. Embryonic stem cells 
from the inner cell mass of the blastocyst are 
pluripotent and go through phases of 
differentiation that changes them into unipotent 
cells. Here this process is depicted for the 
generation o f neural cells; oligodendrocytes, 
neurons, and astrocytes.
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Fig. 7. All tissues in an organism originate from the 
3 germ layers. These layers are the ectoderm layer, 
endoderm layer, and the mesoderm layer. Neural 
cells that form the central and peripheral nervous 
system derive from the ectoderm.
POTENTIAL O F STEM CELLS FOR SPINAL CORD REPAIR
After SCI, endogenous regenerative events occur indicating that the spinal cord attempts to 
repair itself. Schwann cells, the m yelinating and regeneration-prom oting cell in the 
peripheral nervous system, migrate from spinal roots into the damaged tissue and m yelinate 
spinal cord axons’38, 4o8. The expression of regeneration-associated genes is increased in 
damaged neurons’44. There is a surge in proliferation o f local adult stem cells and progenitor 
cells’98, 253, 278 However, axonal growth is thwarted by growth-inhibitors present on 
oligodendrocyte myelin debris and on cells that form scar tissue’42 389 , 420. Also, the new-born 
stem cells and progenitor cells do not integrate functionally into the injured spinal cord 
tissue. Thus, the endogenous regenerative events that occur after injury fail to repair the 
spinal cord.
Improved functional outcome after SCI m ay be elicited by neuroprotective approaches 
that lim it secondary tissue loss and thus the loss of function. Alternatively, functional recovery 
could be elicited by axon growth-promoting approaches that result in restoration of damaged 
and /o r formation o f new axon circuits that could become involved in function. There is little 
doubt that stem cells and neural progenitor cells could become invaluable com ponents of 
repair strategies for the spinal cord. They can become neural cells that m ay support 
anatom ical/functional recovery. A lternatively, they may secrete growth factors that could 
support neuroprotection and /o r axon regenerat ion. The potential o f stem cells or progenitor
^ B la s to c y s t  
Zygote Gastrula
Muscle
Bone
Blood
Connective tissue
G-I tract
Glandular organs
24
Introduction and Outline Thesis
cells to support spinal cord repair has been investigated extensively90' ’59, 4’4. Their 
shortcomings for repair are also understood75' 47’. Over the last decade, stem cells have often 
been studied without im plem enting explicit criteria that would define the used cells as such. 
Consequently, the therapeutic potential o f true stem /progenitor cells is still unknown. Other 
matters related to the use of stem /progenitor cells for SCI also need to be resolved before 
effective therapies can be developed. How can the cells be best obtained? Do they need to be 
differentiated in vitro before transplantatio n? How can survival of grafted stem /progenitor 
cells be improved and uncontrolled division and differentiation be prevented’99? How can 
functional integration of the transplanted cells be improved?
Cell replacement in the injured spinal cord
Considering the ability of stem cells to become any cell type, their potential use for cell 
replacem ent strategies is com m onsense. W ith the appropriate com bination of (growth) 
factors (induction cocktail), ESC can be used to obtain neurons and glial cells3’' 232. ES-derived 
neurons can survive and integrate following injection into the injured rat spinal cord’0’. It was 
shown that transplanted mouse ESC m yelinate axons in the m yelin-deficient shiverer rat 
spinal cord53. Also, mouse ESC grafted into the injured (normal) rat spinal cord result in 
improved functional recovery260. Im portantly, ESC were found to survive well within the injured 
spinal cord suggesting that long-term treatm ents could be achieved using this approach’84.
Hum an ESC can be directed towards m ultipotent neural precursors63, motor neurons224, 228 
and oligodendrocyte progenitor cells200. The latter were found to differentiate into mature 
oligodendrocytes in vitro and in vivo297. Moreover, these cells are able to m yelinate axons after 
transplantation into the spinal cord of m yelin-deficient shiverer m ice and adult rats200.
Neural progenitor cells (i.e., m ultipotent cells from which the cells o f the central nervous 
system arise) often aggregate into neurospheres. Cao and colleagues58 showed that neural 
progenitor cells transplanted into the injured rat spinal cord favored differentiation into 
astrocytes. These results indicated the need for differentiation protocols prior to grafting59. 
Fetal neural precursor cells genetically modified to express noggin, an antagonist o f bone 
morphogenetic protein, differentiate preferably into neurons and oligodendrocytes383. 
Transplantation of these cells into the injured mouse spinal cord resulted in improved 
functional outcome383. However, this result could not be shown by others using the same
approach’22.
Hum an neural progenitor cells can be harvested from blastocyst-stage embryos and 
m anipulated to generate functional neurons and glia299. When human neural progenitor cells 
were grafted into the injured rat spinal cord some of them were found to differentiate into 
oligodendrocytes92 93. Moreover, this finding was accom panied by improved functional 
outcome92 93 (Fig. 8).
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M esenchym al stem cells from bone marrow may also have therapeutic prom ise for SC I285, 
322. Although still debated66, these particular adult stem cells have been shown to differentiate 
into bone, fat, tendon and cartilage cells337. It has been published that these cells can also 
transdifferentiate in vitro into liver333, skeletal’28, ,29, 432 and cardiac muscle249, 3,0 cells, and into 
central nervous system cells’3, 47, 2,2 270 27’  333, 37°. This makes m esenchym al bone marrow stromal 
stem cells interesting for strategies for repair of the injured spinal cord. M any medical fields 
are exploring m esenchym al stem cells for instance for repair of the heart after myocardial 
infarction’’9, 365, osteogenesis imperfecta in orthopedics68, ’72, organogenesis in internal 
m edicine255, 3° 7, intervertebral disc disease in neurosurgery’64, 366-368, and stroke/ 
neurodegenerative diseases in neurology222, 404.
Neuroprotection
A neuroprotective strategy im plem ented soon after SCI would be the first line o f defense 
against injury-induced tissue loss, and could contribute to an improved neurological outcome. 
It has been demonstrated that neural progenitor cells can protect against excitotoxicity233, 24’. 
Also, neural progenitor cells secrete a variety o f molecules that could protect neural cells from 
death m echanism s other than excitotoxicity233, 24’. Thus, transplantation o f these cells into the 
injured spinal cord could in fact exert neuroprotective effects. Bone marrow stromal cells have 
also been shown to elicit neuroprotective effects as grafting into the injured adult rat spinal 
cord resulted in tissue sparing’70, 3° 4. This may have resulted from the secretion of a number of 
growth factors’43, 2’9, 247, 457.
Axon regeneration
Promoting axon growth in the injured spinal cord could contribute to restoring function. The 
ability of neural progenitor cells to secrete a variety of neurotrophic factors indicates that they 
could promote growth of damaged axons233, 24’. Adult neural progenitor cells were found to 
provide a perm issive guiding substrate for corticospinal axon regeneration after spinal cord 
injury334. The stem cell-like olfactory ensheathing cells assist axon regeneration in the injured 
spinal cord in a different m anner. These cells are capable o f preventing axons from 
recognizing growth-inhibitory molecules thereby allow ing them to elongate into otherwise 
inhibitory terrain346, 349.
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Totipotent 
embryonic stem cell
Fig. 8. Potential effects o f stem cells on spinal cord repair. Although transplanted stem cells could elicit axon 
regeneration and/or neuroprotection through secretion of growth factors, the most logical contribution to repair could 
come from their ability to replace lost neural cells. This could result in remyelination of de-myelinated axons if they 
become oligodendrocytes, restoration of (new) circuits if they become neurons, and providing scaffolding and nutrition 
of the injured area if they become astrocytes. Generally, the latter is not preferred because astrocytes express a number 
of axon growth inhibitory molecules that could prevent axon regeneration and thus limit the overall restoration.
CLIN ICA L APPLICATION O F STEM CELLS FOR SCI
The translation of approaches developed in the laboratory involving stem cells into the clin ic 
is in progress. The use o f stem cells harvested from tissue from an adult has facilitated the use 
of stem cells in the c lin ic  as it has practically dism issed the moral objections surrounding the 
use o f stem cells derived from an embryo. Nevertheless, for reasons described below the use of 
ESC is often preferred over that o f adult stem cells. The use of human ESC for spinal cord 
repair in the United States has been proposed by Geron, a California-based biotechnology 
company. The application o f adult human stem cells for treatm ent o f SCI is in progress in 
m any countries around the world257. For instance, autologous bone marrow-derived stem cells 
have been transplanted in the injured spinal cord o f 25 patients in Guayaquil, Ecuador, a trial 
that is supported by a California-based biotechnology company, Prim eCell Therapeutics LLC. 
Encouraging results have been reported such as improved walking and sensory perception. It 
has been suggested that surm ounting the ethical hurdles (see below) could benefit the clinical 
application of ESC2’.
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EM BRYONIC VERSUS ADULT STEM CELLS
ESC can develop into more than 20 0  different cell types present in the human body379 and 
under the appropriate circum stances into an entire organism 283. Hum an ESC have been 
isolated from blastocyst-stage embryos4’9. They have also been created using som atic cell 
nuclear transfer’4, ’5 or parthenogenetic activation o f eggs83, 43’. Isolated ESC do not undergo 
senescence and retain high telomerase activity and normal cell cycle signaling, which explains 
their rapid proliferation in culture28’  320. These plastic characteristics make the ESC suitable for 
central nervous system repair strategies. However, transplantation o f ESC can result in 
teratom as due to uncontrollable cell proliferation300 353, 386. Also, ESC in culture may undergo 
genom ic and epigenetic changes that could lead to transformation although this can be 
prevented using proper culture techniques467. Transplanted ESC are prone to be rejected after 
injection into adult tissue and long-term treatm ent with im m unosuppressive drugs may be 
required to prevent this loss300. These findings have to some extent tempered the enthusiasm  
for application o f ESC in repair strategies for the central nervous system, despite the fact that 
ESC possess by far the greatest potential and could be applied in a broad selection of 
reparative cell therapies.
An alternative for ESC are stem cells obtained from tissue after birth. For instance, neural 
progenitor cells have been harvested from adult brain234, 426 and spinal cord258. However, adult 
stem cells are less plastic than ESC and divide less frequently in culture’08. Also, their 
differentiation potential may decrease in tim e450. This makes them a possible but somewhat 
lim ited alternative for ESC. On the other hand, they offer the advantage that they can be 
transplanted without genetic modifications or pre-treatm ents. Im m une rejection would not be 
an issue with adult stem cells when the cells are isolated from the patient’49 (autografting). 
Also, adult stem cells show a high degree o f genom ic stability during culture’35, 429 and usually 
do not result in tumor form ation’35. Finally, there is much less moral concern surrounding the 
use of adult stem cells because they can be harvested from the patient. These latter features 
support the use of adult stem cells over ESC for strategies aimed at repairing the central 
nervous system. This is certainly true if  strategies can be developed that circum vent the 
potential drawbacks of using adult stem cells such as the lower plastic ability and lower rate of 
proliferation in vitro compared to ESC.
ETHICAL A N D  SOCIAL CO NCERNS
O ne o f the issues that surround the use of ESC is the tim e point at which we consider an 
embryo a person’48, 332 36°. According to the Roman Catholic Church and other religious 
institutions an embryo “must be treated from conception as a living person”36’. This im plies 
that a blastocyst cannot be used to harvest. Others consider an embryo to be a person only 
after the 20 th week of gestation’48, 332 im plying that ESC can be harvested from blastocysts. Also,
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in that case, ESC could be harvested form embryos that were generated but not selected for in 
vitro fertilization. These would otherwise be discarded.
D iscussions on what constitutes ‘life' and when does ‘life' start are often intense as they 
are driven by moral concerns fueled by religious and political ideas. These issues need to be 
addressed with respect to all opponents. Rules regarding the harvest and use o f stem cells can 
only be set after full agreem ent by all groups within a society.
Ethical issues that surround the use o f adult stem cells mostly involve their possible 
m isuse437. For instance, oocytes can be derived from stem cells o f m ale origin which allows the 
production o f a child from one or two male biological parents’74, 293, 438. The potential biological 
problems and psychological effects on the child are unknown. It would also be possible that 
the offspring develops defects due to acquisition of pairs o f (recessive) genes’74, 293, 438.
Therapeutic cloning and genetic m anipulation are other issues that surround the use of 
stem cells. C loning o f cells, genetically matched for the host, could in theory be beneficial for 
organ transplantation as it may solve issues such as organ shortage and rejection. G enetic 
m anipulation could convert ESC into gametes, which would allow germ line gene therapy 
(GLGT)293.
IN D U CED  PLURI POTENT STEM CELLS
It is now possible to obtain pluripotent cells by reprogram m ing differentiated cells, such as 
fibroblasts, via the introduction o f 4  transcription factors, O CT3/4, SO X2, KLF4, and M YC 
(induced pluripotent stem (iPS) cells)295, 3’9. This new technology which was first described by 
Takahashi and Yam anaka407 for mouse fibroblasts and has now been applied for other mouse 
cells306 and for human som atic cells465. O f the 4 transcription factors, M YC and KLF4 can be 
substituted by others33, 466. The underlying m echanism s for this typically straightforward and 
robust reprogram m ing procedure are still unknown and intensely debated. At present it is still 
unclear in how closely iPS-cells resemble conventional ESC and whether application of iPS- 
cells would result in sim ilar functional results as can be obtained with ESC. Com parative gene­
expression profiles o f human ESC and human iPS-cells is now ongoing239, 465. Several hurdles 
need to be overcome before iPS-cell technology can produce cells for clinical use295 such as the 
use of retroviral vectors to introduce the transcription factors and the need for selection 
markers to identify the reprogrammed cells, as well as the use of the oncogene M YC and the 
integration o f retroviral vectors into the genome. These needs are required for proper 
reprogram m ing but they modify the cell genetically and modified cells face regulatory 
obstacles for therapeutic applications. Nevertheless, it is evident that the iPS-cell technology 
is prom ising and has opened exciting avenues for the clinical application o f pluripotent cells 
without the ethical obstacles that come along with the use of ESC.
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In Chapter 1 a general introduction to the etiology, clinical grading, and treatm ent options for 
spinal cord injury are reviewed in Part A. Aspects o f stem cell term inology, advantages and 
disadvantages of stem cell application are reviewed in Part B. I n Chapter 2 the literature on 
the use of the Bone M arrow Stromal Cell (BM SC), a specific type o f adult stem cells, for repair 
of the injured spinal cord is reviewed. Transdifferentiation, neural induction based on 
morphology and electrophysiological properties are some o f the aspects that are discussed. In 
Chapter 3 we compared the gene profiles o f BM SC early and late in culture and discuss their 
potential for spinal cord repair in light o f our results. In Chapter 4 we present an in vivo study, 
in which we have investigated BM SC survival as well as their neuroprotectyive effects in the 
contused adult rat spinal cord. Chapter 5 describes a study on the effects of different 
im m unosuppressive agents on BM SC survival within the contused adult rat spinal cord. In 
Chapter 6 we studied whether a com bination therapy of BM SC transplantation and 
im m unosuppression would improve the overall outcome in term o f locomotor and sensory 
function after a contusive injury in the rat spinal cord. Finally, in Chapter 7 and 8 the findings 
are sum m arized and discussed in light o f future scientific anc clinical perspectives
C. Outline ofthe thesis
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INTRO DUCTIO N
Stem cells are defined by their capacity for self-renewal and differentiation into different cell 
types343, 355, 379. In the early embryonic phase, stem cells are totipotent but after a few divisions 
the cells are determ ined to become specific for one of the three germ layers; the ectodermal 
layer, which will give rise to skin and neural tissue, the mesodermal layer, which will give rise 
to connective tissue, muscle, bone and blood cells, and the endodermal layer, which will give 
rise to gastrointestinal tract and internal glandular organ cells. In the classic embryology, this 
‘determ ination' o f the stem cells is thought to be an irreversible process. Recently, it has 
become clear that the determined stem cell is in fact phenotypically p lastic and is able to give 
rise to cells from different germ layers, a process known as transdifferentation30, ,9,, 270 27’  277.
Because of their versatility, stem cells have gained am ple attention over the last years for 
their potential in replacem ent/repair approaches. However, the term ‘stem cells' has been 
used loosely without clear and appropriate criteria that define the used cell types. For 
example, CNS-derived neurospheres have been used extensively as a source for neural stem 
cells (NSCs), whereas it is now clear that they are in fact heterogeneous cell populations 
consisting mostly of neural progenitors and precursors, i.e., cells that are already directed 
towards the neural lineage. Recently, Parker and colleagues321 elegantly demonstrated an 
overlap of , 8 %  o f stem ness genes between CNS-derived neurospheres and the O 7 .2  N SC 
clone, which fulfills the in vitro and in vivo operational definition of a stem cell32’  395, 413. 
Interestingly, this percentage of overlap increased two-fold when the O 7 .2  N SC  clone was 
cultured as a neurosphere reflecting a shift from a “stem -like” to a “differentiated” gene 
expression pattern32,.
The stroma o f bone marrow houses m ultipotent cells that can differentiate into lineages 
of blood cells, stromal and skeletal tissue88, 96, 152 ,78, ,79 , 245. It has been reported that these stem 
cells can also transdifferentiate into liver cells333, skeletal129, 432 and cardiac249, 3,0 muscle cells, 
and C N S  cells13, 47, ,29, ,66 ,8°, 2,2 238, 27°, but this is still debated66, 435. Bone marrow is relatively easy 
to obtain, which circumvents the ethical concerns that surrounds the use of embryonic stem 
cells. Because of its availability and its reported aptitude to transdifferentiate, stem cells from 
bone marrow are thought to serve as an alternative source for other types o f stem cells that 
are needed for specific therapeutic approaches.
As with stem cells in general, there is much confusion regarding the correct term inology 
and abilities of cells derived from bone marrow. These cells have been referred to as “bone 
marrow stromal cells (BM SCs)” or “stromal cells”, because they reside in the stroma o f bone 
marrow, or as “bone marrow stem cells” or “bone marrow-derived stem cells”, because a 
percentage o f the cells have stem cell abilities. The cells have also been referred to as 
“m esenchym al stem cells” or “bone marrow-derived m esenchym al stem cells”, because of 
their origin from the mesodermal germ layer. Due to this confusing term inology it is difficult to 
have a clear understanding of the true identity o f the cells used in the various studies. In
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addition, their ability to differentiate or transdifferentiate is unclear due m ainly to the large 
variety of induction protocols used by different groups. For example, one group reported that 
about 1 %  of human and mouse BM SCs can be induced into the neural lineage370, whereas 
another group using a different induction protocol reported that 8 0 %  of human and rat 
BM SCs could become neural cells448. Clearly, different protocols lead to highly variable results 
and this makes it difficult to fully understand the abilities of the BM SC and thus its potential 
for therapeutic approaches.
The majority of groups working with cells derived from the stroma o f bone marrow does 
not attem pt to further isolate subpopulations and thus study a heterogeneous cell population 
that includes true stem cells as well as precursor and progenitor cells. Therefore, we propose 
that “bone marrow stromal cells” is the proper term inology for this collection of cells. We 
oppose that they are referred to as stem cells unless proper attem pts have been made to 
isolate a homogenous subpopulation o f clonally related cells that express known ‘sternness' 
genes such as Nanog, Oct-4, and Myc. Moreover, we concur with Parker and co-workers321, that 
stem cells in general are best defined operationally. Thus, the term ‘stem cell' can only be 
applied when the cells are m ultipotent, able to populate a developing area or repopulate an 
ablated or degenerated area with appropriate cell types, able to be serially transplanted, and 
able to self-renew. For a more in-depth discussion on this operational definition for stem cells 
we refer to a previous publication321.
HARVEST A ND CULTURING O F BMSC
Although some sm all variations exist, BM SCs are harvested according to largely sim ilar 
protocols am ong the m any groups studying these cells for their potential in a variety of 
therapeutic approaches. Bone marrow cells are removed from usually long bones such as the 
femurs and tibiae by flushing with cold phosphate-buffered saline with low percentage o f fetal 
bovine serum. These cells are washed and cultured in Dulbecco's Modified Eagle's M edium or 
Iscove's Modified Dulbecco's M edium  with 1 0 -2 0 %  fetal bovine and /o r horse serum. After 3-5 
days in culture, non-adherent cells, m ainly red blood cells that have a short lifespan o f about 
72 h in these culture conditions, are removed, and the rem aining cells washed and further 
cultured in the sam e m edium. Usually within two weeks after in itiation, the cultures consist of 
spindle-shaped cells with some monocytes and macrophages present13, 247. The adherent cells 
are removed by trypsinization and then replated for further expansion or used experim entally. 
These particular cells, i.e., the plastic adherent cells, are considered to be ‘the BM SCs'. 
G enerally these cells are not further phenotypically characterized. However, several groups did 
analyze the presence o f a battery o f surface antigens and with great consistency 
demonstrated the presence on human BM SCs of M H C  class I, C D 13, CD 44, CD 63, CD 73, 
C D 29 , C D 9 0 , C D 105, and C D 16 6  and the absence of M H C  class II, C D 14 , CD45, and CD34.
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Several other surface antigens (i.e., SH 2, SH3, C D 71, C D i2 o a , and C D 124) have been 
described for rat BM SCs457.
With this in m ind we reviewed the literature on the use of BM SCs (harvested as described 
above) for repair of the spinal cord. We will focus prim arily on the application o f BM SCs and 
not only the stem cell fraction thereof. Nevertheless, through transdifferentiation the stem cell 
portion and possibly the precursors and progenitors after de-differentiation can give rise to 
cells from the neural lineage; neurons, astrocytes, and oligodendrocytes. Especially for sm aller 
focal traum atic and dem yelinating lesions it could be beneficial to acquire neural cells from 
BM SCs in vitro prior to transplantation into the spinal cord or m anipulate them in vivo such 
that they can replenish lost neural cells.
DIFFERENTIATION O F BMSC IN TO  NEURAL LINEAGE IN VITRO
To get a better understanding o f the true nature of BM SC-derived astrocytes, oligodendrocytes 
and neurons it is im perative to define criteria for each of them. Is it acceptable to merely 
assum e that cells that express markers specific for a particular neural cell will also have 
relevant functional properties or should it be a requirem ent to dem onrtrate this at least io 
vitro? The expression of certain molecules has been accepted as an ind icatio n of 
differentiation into a particular neural cell type. Asttocytes ex press g lial fibrillary acidic protein 
(GFAP) and oligodendrocytes express rat insulin promoter (RIP) and m yelin-basic protein 
(M BP). Neurons are identified by the prepence of (3 - 3  tubulin (immature neurons), neuronal 
marker N (NeuN), neuron-specific enolase (NSE), neurofilam ents (NF), and microtudule 
associated protein-2 (M AP-2). However, the expression o f cell-specific markers alone is not 
adequate and, except for astrocytes, morphologieal fharacterisfics that are in aoparent 
agreem ent with a specific cell type can be m isleading243,448a Indisputably, the dent criteria ior a 
BM SC-derived neural cell are its functional properties, which unfortunately is much easier to 
demonstrate in vitro than in vivo. Nevertheless, u nless BM SC-derived cells positive for RI P- or 
M BP m yelinate central axons in vitro their designation as oligodendrocytes should be taken 
with caution. Sim ilarly, unless BMSC-derived cells positive for n euronal markers have 
appropriate electrophysiological properties their designation as neurons should be carefully 
considered. In line with this, we propose to use the additive -lik e  for cells that express 
particular markers but have not been fijn ctio sa ily  characterized. We believe that this would 
better reflect the uncertainty of the true nature o f the paeticular cell.
Several groups have reported tCat BM SCs can differentiate into cells that; express 
neuronal markers or into cells that have a neuron-like morphology47, 270■272, 314, 370 371 387. Figure 1A 
dem onstrates rat BM SCs isolated and cultured according to earlier described methods13. When 
brain-derived neurotrophic factor (BDN F) is added to the culture, the presence o f neuronal-like 
cells can be observed (Fig. 1B). To benefit most from the ability o f BM SCs to give rise to neural
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cell;;, it is im perative to investigate and optim ize the culture conditions that are necessary for 
this transdiffeeentiation. Padovon and co-workers3’4 demonstrated that human BM SCs 
proliferated beet and expreeted the highest percentage of7(33-tubulin (about 2 7 %  of the total 
population) when cultured in the presence o f 2 0 %  fetal bovine strum  and 1 on g /m l basic 
fibroblast growth faetor (bFGF or FGF-2). With fibronectin as a grcwth stbstrate this 
percentage was further incteased to approx. 4 8 %  3’4. B D N f rrr feuro tro p fin-3  (NT-3) eliciaed 
the e x p ^ ^ o n  o f (33-tubulin up to ovor 4 0 %  oUthe cellst whicU could not f t  further increasef 
by com bining them with FG F-2 (’4. Witlf these culture conditionst tlfe cells; did not expreet 
NeuN. In the stm e m edium  but without serum, about ’ 0 %  o f the cells differentiated into 
GFAP-positive astrocytes^4. Unfortunately;, the iautkroirs did n ot further combine these different 
cdture conditions to postibly enhance the induction of BM SCs tee differentiate into neuronal­
like c oIIs ,
AlthoabO thu study of Padovan and colleagubs04 may suggest that serum is necesaary for 
neural induction, nestin-positive neural precursor ce1 Is were found i n serem-free cuiture 
conditions444. These nestin-positive cells differentinted into GFAP-positive ashrocytes atsa:se;cd 
on morphology; approx. 4 0 %  o f the populatiun) cor N euN - positive ne u ro n a li ike cellr fa p>prox. 
’ 9 % )  ufter 5 days in co-cu l °ure with uerelaell ar granule ceHs445. Tha grcfupr men tioned above 
reported elegant and co m pteliersive stud ies. U n fo rtu n a te ! a general consensus for culture 
cenditions fot neura1 induction of BM SCa has notyet been esstablished.
B
Fig. 1. Panel A depicts undifferentiated rat BMSCs 7 days in culture expressing green fluorescent protein (GFP). The cells 
were isolated and cultured according to a previously described protocol and infected with lentiviral vectors encoding 
GFP. Addition olbcain-derived neurotropiic factor- pushes the BMSCa info neurai-like cells as can bn seen in panel B.
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A number of studies have s hown that BM SCs can be induced to become neural-like cells in 
vitro by a dding g rowth factorst ,89, 273 280 3583 4° 5, cJibju'tyiry'l crAC M/1 P100 or c hemical a gents as - 
p-m ercaptohthanol an d dimhtfyluulfoxide i n coml;)in;a^io n w itf butylatnd fyic^i'oxyianiuol 34 44iii449, 
Using thess various induction fjro^ocols, 2 -7 6 %  of the cells became neural-like cells. Thess 
results may indicate that depending on the growth factor the sam e intracellular pathway 
resulting i n neural l nduction gets differentiaily activated. However, more I ikely i s that the 
different growth factors exert their activity through different intracellular pathways that result 
in different degrees uf neural induction.
Padovan and colleagues34 investigated whether am ong BM SCs there is a subpopulation 
that can more nasily differentiate i nto the neural I ineage. They compared unsorted BM SCs 
and a population o f BM SCs sorted on the pressnce of CD 133 on their m em brane and 
demonstrated that it higher percentage of7the latter was able to express neural markera. Thi;; 
phenom enon wns n lao demonstnated by com paring gene expression paUerns of7the different 
ssbpopulations o f BM SCs cells4’’ 045. Although thi:> particular population of7 CD i33-po sitive cells. 
or cells derived thereof, were not further d e ln e d  dunctionally, thess results make it c l ia r  that 
the BM SC population wWen obtained as described above is n aeterogeneous cell population.
Interestingly, and stuonglg em phasizing that more complete criteria are im perative to 
d e ln e  BM SC-derived neuronal c^lls^ Lu and coworkerst43 demonstnated that the neuron-like 
cells derived from BM SCs by adding p -mercaptoethanol to the culture m edium 32 448 14/49 are 
actually dying cells! Tim e-lapse microscopy revealed that the cellular exXxnsions protruding 
from the cells are mereln a result of cellular shrinkage. Lu and colleagues.43 took thi:; 
investigation one level further and demonstnated that these morphological changes of the 
BM SCs wem actually due to cellular toxicity, They stowed that cells eeposed to several 
stuessors. sucO as d etnrgentSr chloride a nd exereme pH , exhibited the s ame morphological 
cOaracteristics. i.e., neuronal-like cells. as the BM SCs coltured in the presence of - 
m ercaptoethanol. Cleariy, neural cells obtained in vitro from BM SCs need to be functionally 
d iaracterized. In case o f BM SC-derived neurons, demonstnating appropriate 
electrophysiological behavior is cruci^i.
ELECTRO PHYSIO LO GICAL ACTIVITY O F NEURON-LIKE (CELLS
So far only n lew groups published in vitro evidence that BM SC-derived neuron-like cells have 
electrophysiological activity appropriate for neurons185, ,86, 2,3 445. Kohyama and co lleagues^ 
demonstnated that s uch cells exhibited a resting m em brane potential (Vrest) o f - 2 °  m V a nd - 
50 m V  a t , 4  a nd 2 8 d ays in vitro, respectively Thi;; was nhe l  - i t  study that id emonstnated 'that 
BM SC-derived neuron-like cells acquite a Vrest resti'ebling that o f neurons, w hidi i s 
approxim atele - 70 mV. Jiang and colleagues185, 186 cultured BM SC-derived neuron-like cells 
long-term with different m itogens a nd cytokines, then co-cultured them with fetal in- ouse brain
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astrocytes and demonstrated that the neuronal-like cells had a Vrest between -8.4 and -55.4 
mV. These authors also demonstrated that prolonged co-culture with the fetal astrocytes 
resulted in a further decrease o f the resting m em brane potentials. Moreover, these cells were 
then able to fire action potentials’85, ,86. Regrettably, this study did not investigate the potential 
of these cells to fire trains o f action potentials, a characteristic o f fully matured neurons62.
Electrophysiologically active cells derived from BM SCs were also described by W islet- 
Gendebien and colleagues445. They reported that after 4-6 days in culture some of the cells 
demonstrated sensitivity to the neurotransm itters, GABA, glycine, serotonin, and glutamate, 
possessed an outward K+ current but no inward Na+ current, and exhibited a Vrest of about -37 
mV. These characteristics correspond with those described for neurons in stage , o f their 
m aturation445. W islet-Gendebien and colleagues445 further showed that after 7-15 days in 
culture the cells were able to fire a single-spike action potential and had acquired Vrest o f -56 
m V (characteristics that corresponded to neurons in stage 2 of their m aturation62. These 
findings are exciting and dem onstrate that cells within the BM SC population can differentiate 
in m aturation stage 2 neurons when cultured under the appropriate conditions. It is 
unfortunate that W islet-Gendebien and co-workers445 could not demonstrate the presence of 
fully mature neurons (stage 3)62, which are able to fire trains of spikes and exhibit a normal 
Vrest o f -70  mV. The results from the studies mentioned above indicate that in vitro the BM SC- 
derived neuronal-like cells acquire a more negative Vrest in tim e. Perhaps they could have 
succeeded in creating fully matured neurons if they had cultured their cells for longer than ,5 
days. The differentiation o f BM SCs into fully mature neurons in vitro rem ains one o f the more 
intriguing challenges in the field of stem cells and C N S repair.
DIFFERENTIATION O F BMSC IN TO  NEURAL LINEAGE IN VIVO
The first study that provided evidence that BM SCs can differentiate into neural-like cells in vivo 
was from M ezey and Chandross270. Using a m ice model, they transplanted m ale bone marrow 
cells into the peritoneal cavity o f female recipients. The grafted bone marrow cell preparation 
did not contain neuron- or glia-like cells at the tim e o f transplantation, although it should be 
noted that about , 8 %  of the cells expressed the neural precursor cell marker, nestin when 
cultured for several weeks. Using in situ hybridization techniques, Y-chromosome containing 
neurons were located in the brain o f the host, suggesting that the grafted BM SCs had crossed 
the blood-brain-barrier and formed neurons within the CN S.
Interestingly, Cogle and colleagues87 also demonstrated Y-chromosome containing 
neurons that were nicely integrated in the hippocam pus of three fem ale hum ans that had 
received transplants of male bone marrow cells up to 6 years earlier. It should be mentioned 
that a fusion between a grafted BM SC and a host cell could result in false-positive results. In 
several studies it has been reported that BM SCs can spontaneously fuse with other cells in
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vitro4'5’ 458. W hereas this is a real possibility, Cogle and co-workers87 used fluorescence in situ 
hybridization techniques to reveal the presence of only one X  chromosome, concluding that in 
their study the neurons could not have been the result o f cell fusion. The Y-chromosome- 
containing, transgender cells accounted for approxim ately ' %  o f all neurons and ' - 2 %  of all 
astrocytes and microglial cells in the hippocam pus. These studies provide exciting evidence 
that BM SCs can migrate across the blood-brain-barrier and differentiate into neural cells in 
the mature CN S, which is prom ising for the use o f BM SCs in C N S reparative approaches.
BMSC FOR SPINAL CO RD REPAIR
Spinal cord injury results in cell death, axonal damage, progressive loss of tissue, and 
im paired motor and sensory functions. Some restoration o f function has been reported 
resulting from endogenous self-repair processes or from applied interventions. At present, 
due to the lack of repair approaches that cause m eaningful functional restoration, spinal cord 
injury results in a w heelchair bound life. In general it is thought that functional recovery can be 
achieved by addressing several key areas; prevention of injury-induced cell death 
(neuroprotection) close and away from the injury, promoting axonal regeneration by 
decreasing the inhibitory nature of the environm ent at the injury site or by increasing the 
intrinsic ability o f injured neurons to grow their axon, and promoting m yelination of 
regenerated axons and dem yelinated intact axons. It appears that a com bination of these 
approaches followed by intensive rehabilitation to develop and stabilize new axonal circuits 
will be necessary. Moreover, the interventions need to be applied sim ultaneously and/or 
successively thereby creating optim al conditions for morphological and functional repair.
A typical feature o f the injured cord is the progressive loss o f the central gray and 
peripheral white m atter creating large fluid-filled cysts. To provide axons with a substrate to 
grow across these cavities transplantation o f cells has been widely explored. M any cell types, 
alone or in com bination, have been investigated over the last decades55, 354. Over the last years, 
the potential beneficial use of BM SCs in restorative approaches of the spinal cord has 
attracted am ple attention. Table ' provides an overview of studies in which BM SCs were 
applied into the damaged spinal cord and the results that were obtained. Clearly, among 
these studies some results are confusing and in disagreem ent with each other. For 
optim ization o f BM SC transplantation paradigm s for application in clinical trials several 
crucial questions regarding cell survival, migration, neuroprotection, axonal regeneration and 
functional recovery need to be addressed.
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Cell survival
An essential aspect for successful cell transplantation approaches is survival o f the grafted 
cells. In vitro, BM SCs are cultured in m edium  containing 1 0 -2 0 %  serum. Factors other than 
present in serum are not essential for their survival and proliferation. In fact, addition of 
growth factors such as B D N F , FGF-2, or neurotrophin-3 (NT-3) instigates differentiation o f the 
BM SCs into neural-like cells rather than affect survival314. In vivo, in a rat contusion injury 
model, Hofstetter and colleagues170 showed that more BM SCs survived when transplanted one 
week after injury compared to im m ediately after injury. The surviving cells were located within 
trabeculae that span the injury site8’  17°. However, with the one week delay only 1 %  o f the cells 
(about 3000 total) survived at 4  weeks after grafting and although this is an increase over the 
percentage o f cells that survived im m ediate transplantation (< 0 .15 % ) the total number of 
surviving cells was very low170.
It has been proposed that one o f the m echanism s underlying death o f cells transplanted 
into the spinal cord is injury-induced inflam m ation409, 455. The cellular and molecular 
com ponents o f the inflam m atory response could initiate cell death28, which would also explain 
improved survival with delayed grafting paradigm s. If this were the case, grafting into a 
chronically injured cord would further improve cell survival. Unfortunately, so far there have 
been no conclusive results on their survival rate in the chronically injured spinal cord. In one 
study, BM SCs grafted into a contusion site at 3 months after injury reportedly survived an 
additional 4  weeks but actual numbers were not provided472. From the data so far, it has 
become clear that the survival of the BM SCs is compromised after transplantation into the 
injured spinal cord.
Several recent publications have reported that in vitro BM SCs produce and secrete a 
variety of growth factors such as glial cell line-derived neurotrophic factor (G D N F )143, 457, nerve 
growth factor (N G F)143, 219, 247, B D N F 74, 219, 247 and, albeit in sm aller amounts, FG F-2 247. These 
factors may have pronounced effects on repair-related processes such as neuroprotection and 
axonal outgrowth, but they may also affect BM SC survival and /o r proliferation in vivo through 
an autocrine action457. If this is the case why then do BM SCs survive poorly within the injured 
spinal cord? It is possible that the grafted BM SCs sim ply do not secrete enough of the 
necessary growth factors to positively effect their own survival within an extremely harsh injury 
m ilieu with m any cells and factors that negatively influence survival. Also, there m ay be batch- 
to-batch differences in the ability to produce growth factors, which was demonstrated for 
human BM SCs291 and that could result in highly variable results m asking the true potential of 
BM SCs to survive the spinal injury m ilieu.
Clearly, for the developm ent o f safe and effective clinical application the survival of 
BM SCs after transplantation into an injury has to be improved. Especially when the cells also 
function to deliver factors that are most likely necessary to optim ize the neuroprotective and 
axonal regeneration response. Future research should concentrate on decreasing death of
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BM SCs within the lesion area, possibly by elevating local levels o f growth factors essential for 
survival or by preventing the up regulation o f apoptotic molecules or promoting the 
expression of anti-apoptotic molecules.
Publication Source In vitro  
mod ified
Injury m odel N u m b er o f  
cells
M ain results A d d itio n al results
Chopp 
et a l, 2000
rat no Contusion at T 9 level. Cells 
grafted 7 dp i. Survival 5 weeks.
250,000 Significantly improved 
m otor outcom e at 2 wks.
Upregulation o f nestin in ependymal 
and associated cell layers.
Hofstetter 
et a l, 2002
rat no Contusion at T 9 level. Cells 
grafted im m ediate o r 7 dp i, 2 
mm rostral and caudal. 
Survival 5 weeks.
300,000 Transplanted BM SCs 
form guiding strands at 
the injury site.
Better BM SC survival with delayed 
grafting (7 d p i). Motor outcome 
improved at 5 weeks.
Akiyama 
et a l, 2 0 0 2 b
mice no EB-X lesion# T 10  level. Cells 
grafted 3 dp i. Rats were 
im m unosuppressed. 
Survival 3 w eeks.
5,000 Remyelination of 
demyelinated axons after 
BM SCs transplantation .
Corti 
et a l, 2002
mice no Cells injected in tail vein after 
X-irradiation. Survival 3 m onths
10 ,000,000 System ically infused 
BM SCs migrate towards 
sp inal cord.
Inoue 
et a l, 2003
rat no EB-X lesion lum bar spinal cord. 
Cells grafted 3 dp i, system ic or 
focal. Survival 3 weeks.
10 0,000  - 
10 ,000,000
Remyelination of 
demyelinated axons after 
BM SCs transplantation .
More myelinated axons with focal 
in jection. Focal application more 
efficient.
Lee
et a l, 2003
mice no Contusion at T 11 level. Cells 
grafted 7 dpi in and 2 mm 
rostrally to in jury. Survival 4 
weeks.
3,000 Neural differentiation: 
BM SCs differentiate into 
neurons in the brain and 
astrocytes in the cord.
03
1 4
et
rat no Contusion in jury T 9 level. Cells 
grafted im m ediately. Survival 
i , 2 ,3,4 weeks.
1 ,000,000 Neuroprotective: 
signifient reduction of 
cavity volum e.
BM SCs survival decreased in tim e 
up to 3 weeks. Motor outcom e 
significantly improved up to 14  dpi.
Ohta 
et a l, 2004
rat no Contusion injury T 9 level. 
Im m ediate cell grafting in CSF 
(4th ventric le). Survival 5 
weeks.
5,000,000 Neuroprotective: 
reduction o f cavity 
volum e w ith 47% .
Significant im provem ent o f motor 
outcom e after 5 weeks. BM SCs 
migrated to cord.
Ankeny 
et a l, 2004
rat no Contusion injury T 9 level. 2 dpi 
transplantation o f cells into 
lesion cavity. Survival 8 weeks.
60,000 Neuroprotective: BM SCs 
reduce cavity volum e. 
Increased spared tissue 
volum e and white m atter.
No significant im provem ent in 
m otor outcom e after 8 weeks.
Lu
et a l, 2004
rat no BM SC s-N T3 into lesioned 
dorsal colum n 5 days after 
cA M P in L4 DRG and N T3 
im m ediate rostral to graft.
Survival 3 m onths.
200,000 Axonal regeneration: 
cA M P and N T -3 
combined promoted 
axonal growth o f sensory 
axons.
Satake et a l, 2004 Rat No Contusion T 9-10  level. 3,5,7 dpi 
cell injection lum bar 
subarachnoid space.
1 ,000,000 Hom ing o f transplanted 
cells towards lesion area.
Some BM SCs differentiated into 
nestin-positive im m ature neurons 
or glial cells.
Zurita 
et a l, 2004
rat no Contusion at T 7 level. Cells 
grafted 3 mo post injury at 
lesion site. Survival 4 weeks.
1 ,000,000 Significant im provem ent 
in motor outcom e (B BB ) 
after 2 weeks in the 
chronically injured rat.
BM SCs survive and form bridges in 
the cavity.
Sigurjonsson et al, 
2005
human no In ovo surgery and cell 
im plantation in chicken embryo 
(stage 15-16 ) .  Suvival 4-9  days.
20,000 Grafted cells 
indistinguishable from 
neurons ch ick and also 
electrophys. active.
During differentiation loss o f C D 34 
expression by BM SCs.
Lu
et a l, 2005
rat Yes§ Dorsal co lum n lesion C 3. 
Survival up to 3 m onths.
100,000 Neural induced cells in 
vitro do not express 
neural m arkers in v ivo .
BD N F secreting BM SCs led to 
higher axon density . No change in 
motor outcom e at 3 m onths.
§ BMSCs were neurally induced following the procedure described by Woodbury et al., 2002 and modified to express 
BDNF.
# EB-X lesion=Ethylbromide injection with X-irradiation to create a demyelinating injury
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Cell migration
Are BM SCs able to migrate towards or away from the site of in jury/transp lantatio n? In vitro 
studies have shown that BM SCs express CXCR4, the receptor for the chemokine, C X C L 12  (also 
known as stromal derived factor-1, SD F-1 12. C X C L 12  has been im plicated in cell migration 
possibly through the extracellular signal-regulated kinase (ERK) and Akt phosphorylation 
pathways39, 134. Interestingly, under some pathological conditions reactive astrocytes produce 
C X C L 12  39, 274 It is possible that following spinal cord damage upregulation of the level of 
C X C L 12  attract CXCR4-positive BM SC towards the injury site. This could be the m echanism  at 
the basis of the hom ing of BM SCs into spinal cord injury sites. However, at this tim e it is not 
known whether this particular chemokine is present within the injured spinal cord.
In vivo, system ically adm inistered BM SCs have been reported to migrate towards injury 
sites in the brain222 240 28°, but the results regarding hom ing towards the injured spinal cord 
have been conflicting. Recently, 111In-oxine-labeled BM SCs were shown to migrate poorly 
towards the injured spinal cord following intravenous adm inistration96. On the other hand, 
BM SCs labeled with iron-oxide microbeads were detected using m agnetic resonance im aging 
within a spinal cord com pression injury after intravenous adm inistration406. Satake and co­
workers373 demonstrated that BM SCs grafted into the lum bar subarachnoid space aggregated 
onto the cord near a thoracic contusion injury site and that a few migrated into the contusion 
injury. Possibly, the m eninges may have prevented more BM SCs to migrate into the spinal 
cord parenchyma. Obviously, if  BM SCs are able to migrate towards an injury site in the adult 
spinal cord, it would allow for systemic delivery of the cells thereby avoiding invasive 
transplantation strategies.
M igration of transplanted BM SCs away from an injury site in the spinal cord might be 
beneficial for outgrowth o f regenerating axons. It was reported that such m igration did not 
occur in a contusion in jury model96. However, at present, the question whether BM SCs are 
truly capable of migration within the injured spinal cord has not explicitly been answered. 
Future research should focus on these questions because the outcome is crucial for the design 
of BM SC transplantation paradigm s for clinical application to repair the injured spinal cord.
Neuroprotection
Although grafting of cells into the injured spinal cord is typically applied to generate a growth 
response, a neuroprotection effect can usually also be observed408. Repeatedly, it has been 
demonstrated that cellular grafts lim it the loss of nervous tissue in the injured cord338, 4° 8. In 
fact, in anim al models o f spinal cord injury and repair im provem ents in motor performance 
seen after cell transplantation are often contributed to neuroprotection rather than axonal 
regeneration. Grafting BM SCs into the contused adult spinal cord also promotes tissue 
sparing, which was evidenced by sm aller cavities and preserved host white m atter5, 10 3° 4.
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It is likely that the m echanism  underlying the neuroprotective effect o f BM SC transplants 
is related to the ability of the cells to produce and secrete factors that either arrest and/or 
prevent the onset of cell destructive events. BM SCs are known to produce and secrete factor 
(G D N F )’43, 457, nerve growth factor (N G F)’43, 2’9, 247, B D N F 74, 2’9, 247 and, albeit in sm aller amounts, 
FG F-2 247. These factors have all been im plicated in neuroprotective effects. N G F and B D N F 
increase survival’50 4,8 and decrease apoptotic death o f neurons and oligodendrocytes39’. B D N F 
also increases oligodendrocyte proliferation267. G D N F  has been im plicated in the rescue of 
motor neurons25, 78 possibly by activating M AP kinase and Bcl-2, an anti-apoptotic regulator78. 
FG F-2 is known to positively effect tissue sparing’87, ,88, 269 and promote neuronal survival and 
angiogenesis269 following spinal cord injury. Another molecule produced by BM SCs that could 
positively influence tissue sparing is V EG F, a potent angiogenic factor’58.
Axonal regeneration
In a few studies the axonal regeneration promoting abilities of BM SCs have been addressed. 
Lu and co-workers244 demonstrated that transplantation of native BM SCs into the contused 
spinal cord promoted modest sensory and motor axon regeneration, whereas grafting of 
neurally-induced BM SCs did not result in axon growth. O ne explanation for the failure of the 
neurally-induced BM SCs to promote axonal regeneration in the injured spinal cord is that 
these cells die soon after transplantation. The neural induction of the BM SCs was performed 
according to an earlier described method32 448, 449, which, as had been already recognized by Lu 
and colleagues245, causes BM SCs to die rather than become neuron-like cells.
An alternative explanation for the lower axonal growth response observed by Lu et al244 is 
that neurally induced BM SCs are less effective in eliciting such a response than 
undifferentiated BM SCs, for instance because they produce and secrete less growth-promoting 
factors. At present it is known that BM SCs produce and secrete several growth factors. 
However, it is unknown whether neurally induced BM SCs actually produce growth factors or 
whether they do so but in lower amounts than undifferentiated BM SCs. Indirect evidence that 
the neurally induced BM SCs do not produce enough growth factors to stim ulate axonal 
regeneration was provided in two studies dem onstrating that transplantation of neurally 
induced BM SCs genetically modified to produce and secrete B D N F did improve the axonal 
growth response244, 248. In another study, a multifaceted and intriguing spinal cord 
injury/regeneration model was used to investigate the regeneration-prom oting capacity of 
BM SCs244. BM SCs modified to secrete NT-3 were transplanted in a transection injury of the 
m id-thoracic dorsal colum ns one week after adm inistration o f cA M P into the L4 dorsal root 
ganglion as a preconditioning stim ulus for the sensory neurons. This was then combined with 
injection o f NT-3 after injury/grafting within and beyond the injury site244. The com bination of 
all interventions resulted in regeneration of ascending sensory axons into and from the BM SC 
graft. Either cA M P or NT-3 adm inistration alone did not result in such an axonal response.
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These results suggested that a cam binatorial approach that stim ulates both the neural soma 
and axon m ight effectively increase the axonal regeneration. Surprisingly, in the study of Lu 
and colleagues244 application of cAM P alone at the level o f the sensoty neurons did not result 
in improved sensory grow/th wUile it had been im plicated in such a response earlier292 as well 
as in other types of axonal regeneration responses329. Clearly, as with m any other prom ising 
cell types for transplantation in to th e injured spinal cord, more extensive studies need to be 
performed before BM SCs can be used effecti vely in rep air strat egies.
Functional recovery
It has been reported that BM SC results in significant im provem ent of hindlim b locomotor 
performance when transplanted in the acutely45’, sub-ocutely8’ anti chrnninally472 contused 
spinal cord. In all three studies hindlim b function was evaluated using the open-field IBB-rent, 
which scores for jo int movements, paw flacem en t, weight suppnrt, and fore/hindlim b 
coordination23. Although a valid way to test hindlim b function, the BBB test has lim itations; the 
scoring is subjective and difficult for fore/hindlim b coordination. This affects the proper 
assessm ent o f hindlim b motor performance. Othur sensorim otor tests ruch as foot print, grip - 
and beam walking, and analysis o f gait uoiug the CatW aln® provide a morn complete 
m easurem ent of hindlim b function. In addition, it wns anfortunafe that these particular 
studies8’  45’  472 did not investigate; wUethor tWe im p ro vrm e n ti in brhanio r vasre associa ted with 
an axonal regeneration respanse. Considering that in these atudius th a oUservei functional 
im provem ents appeared relatively noon after injury and transplantation, it seems than 
neuroprotective m echanism s3, r ° t54, possibly through secretion op growth fattoas, rather than 
axonal regeneration responses242'244 were at th f basis of the im provum ents.
So far studies on behaoioral effects following intrasninal transplpntaiiun  o f BM SCs have 
used a variety of models in differ ent species. In mice or rat different numbers o f BM SCs were 
grafted acutely into the cervical244 or thoracic spinal cord’0 ’70, 45’, or sub-acutely8’ or 
chronically472 in the thoracic spinal cord. M ost models involved a contusion injury’0 8’  ’7°  45’, 
others a partial transection model244. The servival p erio t after transplantation as well as thn 
studied end points varied am ong fhese sta lie s . (Hi ven the m ajor differences betwuen th ese 
approaches, it is difficult to compare the respective results and thus to proporly value the 
effects of BM SCs on functional recovery and axonal regeneration in the injured spinal cord so 
far.
This brings up the question whether there should be one particular model that should be 
used uniformly by groups that study the use o f BM SCs in spinal cord repair. Is there a best 
model? We do not support the idea o f only one model. In hum ans, the morphological and 
functional outcome following spinal cord injury is highly variable. Nervous tissue loss, axonal 
dieback, neuronal death, and scar formation depend largely on factors such as the site and 
degree o f injury and the post-injury care. A pplying one particular model will ultim ately only
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benefit a percentage of spinal cord injured patients. However, one particular in vivo model 
can be superior to another to answer a particular aspect of spinal cord injury and repair. For 
instance, neuroprotective effects of BM SC transplants can best be addressed in contusion 
injuries, whereas their effect on axonal regeneration is most reliably assessed in complete 
transection injuries.
The highly variable outcome after human spinal cord injury requires testing o f BM SC 
transplantation (and of other approaches) in a variety of in vivo injury models. This would 
allow proper judgm ent whether following a certain injury BM SC grafting or an alternative 
intervention would be best. For understanding the potential o f BM SCs for spinal cord repair it 
would be better to have certain studies independently repeated to confirm the results, which if 
that would be the case may establish BM SC grafting as the type of intervention best suited for 
a particular type of injury.
CLIN ICA L APPLICATION O F BMSC
There is considerable experience with the harvesting o f BM SCs from the iliac crests of 
patients206. In the clinic, following chemotherapy and /o r radiation therapy, the bone marrow 
m icroenvironm ent is damaged resulting in dim inished or delayed hem atopoiesis’09, 266. 
A llogeneic marrow transplants have been explored for reconstitution of the damaged marrow 
stroma, although at present it seem s that recipients o f such transplants have only host-type 
marrow stromal cells after transplantatio n390 402. Also, BM SCs are more increasingly used for 
surgical approaches for spinal fusion or for degenerated disc disease275 , 434.
BM SCs have several features that make them appealing candidates for transplantation 
after spinal cord injury in the human which include the facts that (a) they can be relatively 
easily isolated under local anesthetic206, (b) human BM SCs can be rapidly and extensively 
expanded in cell culture’3, 47, (c) there is no evidence that they produce tumors in vivo, even 
after im m ortalization to ensure an unlim ited source o f self-renewal ex vivo'’ " 5, (d) they have 
demonstrated capacity for tissue repair3, 244, and (e) they secrete growth factors in vivo that can 
enhance regeneration/repair73, 74. Clearly, BM SCs may be a good candidate for transplantation 
into the injured spinal cord. However, a concern is that a considerable variation exists among 
donors290 29’. M any factors that are difficult to control can influence the variations between 
donors, such as gender, genetic background, and general health. Therefore, we agree with 
Neuhuber and colleagues290 29’ that specific param eters need to be found that allow rapid and 
reliable selection o f BM SCs with therapeutic potential.
Based on the above-mentioned features of BM SCs, there is much excitement about the 
potential use o f these cells for spinal cord repair. However, it is also clear that BM SC are not 
the so-called “silver bullet”, the one therapy that will promote regeneration and restore 
function in the injured spinal cord. In fact, it is generally accepted in the field of spinal cord
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injury and repair that such a “silver bullet” does not exist. Spinal cord injury is particularly 
complex and involves a variety of histopathological destructive and som etim es constructive 
events. A  treatm ent for spinal cord injury aimed at repair of function needs to deal with all of 
these events in a tim ely, most likely sequential, fashion.
There have already been several clinical trials that have used intravenous adm inistration 
of BM SCs for specific diseases such as patients with m align ancies237, but also efficacy trials in 
osteogenesis imperfecta68, ,72, 298, Hurler's syndrome and m etachrom atic leukodystrophy210. Each 
of these trials has had various degrees of success depending on the measured end-points. A 
positive outcome from all of these trials is that only one o f the 68 patients that entered in the 
studies m entioned has suffered any side effects (i.e., mild urticaria as a reaction to the fetal 
bovine serum album in in which the cells were grown), indicating that BM SCs can be used 
safely in clinical settings.
There is considerable debate as to which patients with a spinal cord injury would be the 
ideal candidates for testing cell types (including BM SCs) that have shown potential for clinical 
applications. Hum an trials approved by the United States Food and Drug Adm inistration 
(FDA) require safety data prior to efficacy data. Consequently, most cellular transplantation 
strategies tested in clinical trials in the United States have focused on patients with 
functionally complete spinal cord injuries (ASIA A; Am erican Spinal Cord Injury Association). 
However, for proper evaluation o f the efficacy o f transplantation strategies regarding 
functional im provem ents patients with incom plete lesions (represented by A SIA  B-D) may be 
more beneficiary. C lin ical trials transplanting BM SCs after spinal cord injury are ongoing in 
several countries including Korea, Mexico, Colum bia and Brazil. Other than a Korean study318 
results from these trials have not been published yet. In this particular study, six functionally 
complete spinal cord injured (ASIA A) patients received a BM SC transplant combined with 
the adm inistration of granulocyte macrophage-colony stim ulating factor (GM -CSF). All 
patients were operated on in the first two weeks after injury and a total of 1.8 ml with a 
density o f 1.1 x 106 B M S C s/ I was injected at the epicenter of a contusion lesion at 5 mm 
below the dorsal surface. In 5 out of 6 patients motor and sensory function improved, with 4 
patients o f them switching from the A SIA  A  to the A SIA  C level. Follow-up evaluations up to 18 
months after transplantation revealed no serious com plications. Although these results are 
very prom ising, detailed information concerning neurological exam ination is lacking. Further 
studies in this arena will need to focus on reproducibility, safety and finally efficacy.
CO N C LU D IN G  REMARKS
Studies on the ability o f BM SCs to transdifferentiate in vitro into the neural lineage often use 
different protocols370, 448, 449. This leads to a great deal of confusion on the true capacity o f these 
cells and thus their therapeutic potential. There clearly is a need for a consensus on how to
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induce BM SCs into the neural lineage in vitro. Moreover, this procedure and in particular 
alternative ones that claim  a higher efficiency need to be repeated independently. Also, there 
is a need for standardized criteria (operational definition)32’ that will result in the proper 
designation o f BMSC-derived cells as neurons or oligodendrocytes. O n ly  then it will be 
possible to optim ally benefit from the therapeutic potential of BM SCs for spinal cord repair.
In vivo, the use o f BM SCs in spinal cord injury models is still relatively new (see Table ’ ) 
and m any questions remain unanswered. Some o f these questions are: To what extent do 
BM SCs survive when grafted into the contused spinal cord and does tim e o f transplantation 
make a difference? Do BM SCs migrate towards and away from the transplantation site and if 
so where to? To what extent do BM SCs differentiate when transplanted into the injured cord? 
Can grafted BM SCs support spinal cord repair and if  so what m echanism s underlie the 
biological effects? Based on the reported differences between in vitro and in vivo results, it is 
clear that the influence of the m ilieu of the injured spinal cord on BM SCs is not fully 
understood. This is a complicated issue because of the abundance and variety o f factors in 
injured nervous tissue all with different effects on BM SC survival, migration, and 
differentiation.
For transplantation purposes, it appears that differentiation of BM SCs prior to grafting 
would be best for effective repair for sm aller, focal lesions o f the spinal cord or for specific 
aspects in larger, more routinely seen, injuries. For instance, BM SC-derived oligodendrocytes 
could be used to address specifically a dem yelinating disease such as m ultiple sclerosis or the 
effects o f rem yelination on functional restoration o f the spinal cord after injury. Differentiation 
into neurons would allow addressing a motor neuron disease such as amyotrophic lateral 
sclerosis. However, is ex vivo differentiation o f BM SCs prior to grafting in the spinal cord 
necessary. In theory, the C N S  environm ent m ay induce the cell to develop into the required 
cell type. Im plantation paradigm s using undifferentiated BM SCs in vivo have shown prom ise 
in the laboratory and clinical trials are ongoing.
46
3
Gene expression pattern and suitability of bone marrow stromal cells.
Early passage Bone Marrow Stromal C s lls  express genes involved in nervous system 
developm ent supporting their relevance for neural repair.
Submitted Restorative Neurology (2010)
R.D.S. Nandoe Tewarie 
K. Bossers
B. Blits 
J.A. Grotenhuis 
J. Verhaagen 
M. Oudega
Chapter 3
INTRO DUCTIO N
The application o f mesodermal bone marrow stromal cells (BM SC) for nervous system repair 
has been explored extensively’65, 323. BM SC may promote repair through their ability to 
differentiate into neural cells’7, 47, 76, 370 and/or the secretion of growth-promoting m olecules’43, 
2’9, 454, 457. The true potential of BM SC to repair nervous tissue is still under investigation.
A more com prehensive understanding o f the neural repair potential o f BM SC and possibly of 
the underlying m olecular m echanism s may be obtained by gene expression profiling. BM SC 
express genes common to cells from the mesodermal lineage such as bone, cartilage, and 
adipose cells’6, ’37, 223. On the other hand, they also express genes that are typical for epithelial, 
endothelial, and neural cells’85, 38°, which may point at their proposed ability to differentiate 
across lineages.
Few groups have studied genes involved in nervous system developm ent expressed by 
BM SC. It was shown that 3’ 2 genes including neural progenitor genes are co-expressed in 
human-derived hippocam pal neural stem cells and undifferentiated B M SC 56. Genes encoding 
for the neurotrophins nerve growth factor and brain-derived neurotrophic factor are expressed 
in undifferentiated BM SC and in neurally-induced BM SC, with reduced expression in the 
latter453, 454.
The expression of genes encoding for neurotrophins and proteins characteristic o f neural 
progenitors in cultured BM SC may indicate their ability to support repair after transplantation 
into nervous tissue. To further evaluate the overall repair potential we profiled gene 
expression of BM SC from passage (P) 3, which are typically used for transplantation studies in 
our laboratory, using 44k whole genom e rat microarrays. We also compared the gene profiles 
of P3 and P’ 4 BM SC to investigate effects o f long-term culturing on gene expression.
MATERIAL A N D  M ETHODS  
BM SC isolation and culture
BM SC were isolated from Sprague-Daw ley rats (8-’ °  weeks, 2 ° ° - 2 5 ° g ;  H arlan, Indianapolis, 
IN, USA) as described previously’3. Briefly, rats were deeply anaesthetized and decapitated 
and their femurs and tibias im m ediately removed. The marrow from these bones was 
aspirated with a syringe, plated on plastic culture dishes, and cultured for 48-72 h in 
Dulbecco's m inim al essential m edium  (Invitrogen, Carlsbad, CA, USA) with ’ ° %  fetal bovine 
serum (Hyclone, Logan, UT, USA) and ’ %  penicillin-streptom ycin (Invitrogen) at 37°C  /  5 %  
C O 2. Next, non-adherent cells were removed through washing with Hank's buffered salt 
solution (Invitrogen) and fresh culture medium  was added to the adherent cells. These were 
grown to confluency and then harvested using ° . 2 5 %  trypsin, diluted ’ :2 in m edium , plated, 
and cultured at 3 7 °C /5 %  C O 2. BM SC were obtained from 3 rats and cultured in 4  different 
batches to ensure the availability o f biological replicates for microarray analysis.
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RNA isolation and amplification
From P3 and P14 BM SC, total RNA was isolated using Trizol-based and RNeasy M ini Kit RNA 
isolation methods. Cells were first hom ogenized in ice-cold Trizol (Life Technologies, Grand 
Island, New York). After phase separation by addition of chloroform, the aqueous, RNA- 
containing, phase was transferred to a new RNAse-free 1.5ml tube and mixed with an equal 
volume o f 7 0 %  RNAse-free ethanol. Next, an RNeasy M ini column (Qiagen, V alencia, 
California) was used to isolate RNA according to the manufacturers' guidelines. RNA yields 
and purity were determined using a N anoD rop N D -10 0 0  spectrophotometer (Nanodrop 
Technologies, W ilm ington, Delaw are). RNA integrity was determined by the RNA Integrity 
Number (RIN) as measured by the A gilent 2 10 0  bioanalyzer (Agilent Technologies, Palo Alto, 
California). RNA was am plified and a total o f 500 ng cRN A  labelled with Cy3 or Cy5 using the 
A gilent Low RNA Input Fluorescent Linear Am plification kit (Agilent Technologies) according 
to the m anufacturers' guidelines.
Microarray design and hybridization
For the m icroarray experim ents we used 44K whole genom e rat m icroarrays (Agilent 
Technologies) and a design consisting o f direct com parisons between P3 and P14 BM SC (3 
biological replicates each). Fragm entation and hybridization was performed according to the 
manufacturer's guidelines (Agilent Technologies) using A gilent solutions and buffers. Briefly, 
target solution was prepared co ntaining Cy3 and Cy5 labelled cRN A sam ples (500 ng in total). 
The cRN A was hydrolyzed for 30 m inutes at 60 °C, followed by hybridization in hybridization 
buffer on the m icroarray probes for 17 h in a rotating chamber at 6 0 °C . After hybridization, the 
slides were washed in wash solution 1 (6x SSPE, 0 .0 0 5 %  N-Lauroylsarcosine) for 5 min and 
then in solution 2 (0.06x SSPE, 0 .0 0 5 %  N-Lauroylsarcosine) for 1 m in. The m icroarrays were 
then transferred to acetonitrile solution for 1 m in and dried under pressurized nitrogen gas.
Data analysis
M icroarrays were scanned with an A gilent m icroarray scanner. Red (Cy3) and blue (Cy5) 
intensity was acquired using Feature Extraction software V7.5.1 (Agilent Technologies). Arrays 
were norm alized based on quantile norm alization. Differential gene expression was 
determined by fitting a linear model to the norm alized data. N ine m icroarrays were used for 
com parisons between P3 and P14 BM SC. Expression of a particular gene was accepted with 
an intensity o f A >6 ,6 , to exclude outliers based on background staining. Oversaturated genes 
were also removed from our analyzed set o f genes. In the subset of genes, we looked for the 
presence of a clear neural relation in the nam e o f the gene and for this we searched for neur*, 
glia*, oligo*, nerv* am ongst others. Furthermore, we searched online in the present gene 
database for a known function in any neural processes.
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Gene Ontology overrepresentation
Overrepresented Gene Ontology (GO)-classes were indentified using the web-based 
application G O stat (http://gostat.w ehi.edu.au)26. We first determ ined the number of genes 
that were expressed in P3 a well as in P14 BM SC (cut-off: >2 x background intensity) and these 
served as a reference for the fraction o f differentially expressed genes. For each top-level G O - 
term (e.g., biological process, cellular com ponent, m olecular function), we determ ined the 
overrepresented GO -classes. The overrepresentation o f a G O -class within a set of differentially 
expressed genes m eans that this G O -class is statistically higher represented than would be 
expected by chance26. Statistical inference was calculated with Fisher's Exact Test. The 
Benjam ini and Hochberg False Discovery Rate model was used to correct for m ultiple testing. 
The m inim al length of considered G O -paths was 3. Significance was set at P < 0.01.
RESULTS
BM SC have emerged as candidate cells for repair o f the brain167, 273, spinal cord6’  324, and 
peripheral nerves17, 356. Profiling gene expression of BM SC may present information on their 
repair potential. Here we determ ined the gene expression profile of P3 BM SC, which we 
typically em ploy in our transplantation studies. Im portantly, we have focused on genes 
associated with neural cells/events (searches for neur*, glia*, oligo*, nerve* in their name) 
and on genes with a neural function as indicated in the gene database. In this study we have 
also compared gene expression of P3 and P14 BM SC to assess the effects o f long-term 
culturing.
Gene expression profile in P3 BM SC
100 highest expressed genes
Am ong the 100 highest expressed genes, 55 genes encode for ribosomal proteins, 20 for 
proteins involved in protein binding processes, 6 for proteins involved in cell differentiation 
and proliferation, 4 for proteins involved in apoptosis, and 3 for proteins involved in enzym e 
activity (Fig. 1). The Notchy, Tubb2, and G ja i  genes were am ong the top 100 highest expressed 
genes. These genes are im plicated in central nervous system development. Notchy (Notch 
homolog 3) is involved in Notch signalling in cell differentiation1’  183, 194, forebrain 
developm ent18’  256, and neuronal fate com m itm ent193, 256. Tubb2 is a member of the tubulin 
superfam ily which is im plicated in nervous system developm ent8, 3 236. Gja 1 (gap junction 
protein 1) is involved in protein and receptor binding in several processes including neuron 
m igration and neurite m orphogenesis120 162.
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other
Fig. 1 . Schematic representation o f the top 100 genes with 
the highest level o f expression in bone marrow stromal cells 
at passage 3 . The numbers in the graph indicate how many 
genes out of the top 100  encode for proteins known to be 
involved in the indicated respective processes.
Nervous system development
The genes expressed in P3 BM SC were studied for their involvem ent in nervous system 
developm ent in general (Table 1A), oligodendroglial developm ent and m yelination (Table 1B), 
astroglial differentiation (Table 1C), and neuronal processes (Table 1D ). These genes may be 
indicative of the potential of BM SC to become neural cells, and may thus be im portant for 
their potential to contribute to neural repair. Am ong those involved in nervous tissue 
developm ent (Table 1A) were the genes that encode for nestin (Nes)147, 226, insulin-like growth 
factor 1 (Igf 1)4°  79, and neural proliferation, differentiation, and control (Npdc 1)117, 396. Genes 
im plicated in oligodendroglial developm ent and m yelination (Table 1B) were Cog1, Erbb2, 
Mobp and Plp2 97, 171 328, 375. P3 BM SC expressed genes involved in gliagenesis (Table 1C) such as 
Igf1, Pdgfra, and Erbb2 77, 230 328 and in glia m igration such as Cspg4 461 462. Am ong those involved 
in neuronal processes (Table 1D) were genes im plicated in cell proliferation and neurite 
developm ent (glial cell line-derived neurotrophic factor, Gdnf)124 and synaptic plasticity (Ras 
homolog enriched in brain, Rheb)456.
Cell cycle and developmental processes
There were several genes involved in cell cycle and developm ental processes expressed in P3 
BM SC (Table 2; not including nervous system developm ent genes as they are listed in Table 
1). Am ong these were genes for stem cell factor KL-2 receptor binding (Kitl), which is 
im portant for proliferation o f myeloid and lymphoid hem atopoietic progenitors4, 352, insulin-like 
growth factor 1 (Igf 1) 40 79, transform ing growth factor beta (Tgfb 3) 43, 268, vascular endothelial 
growth factor C (Vegfc)48, 289, and growth arrest and DN A-dam age-inducible 45 gamma 
(Gadd45g)468. We also identified the gene for adipose differentiation-related protein (ADRP) 
which is indicative for the mesodermal origin of BM SC3°2 376.
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Growth factors and growth factor signalling
P3 BM SC expressed several genes encoding for growth factors or for proteins involved in 
growth factor s ignalling (Table 3). These may play a role in cell growth, differentiation and 
maturation and are thus potentially im portant for repair. Am ong those encoding for growth 
factors were the genes for vascular endothelial growth factor C (Vegfc)48, 289, glial cell line- 
derived neurotrophic factor (Gdnf)'24, 38’, and platelet-derived growth factor alpha (Pdgfa). 
Genes involved in growth factor signalling  were the gene for fibroblast growth factor receptor­
like 1 (F g fri)398 and for neurotrophin receptor associated death domain (Nradd).
Cell death
We found several genes in the P3 BM SC that are involved in cell death (Table 4). These are of 
interest as they may be targets for im proving BM SC survival after transplantation in the 
injured nervous system. Some of these genes are for members of the tumor necrosis factor 
superfamily, which is involved in cell death113, 411, and others are im plicated in the caspase 
pathway (Casp2, Caspy, Casp6, Caspii), which is involved in apoptotic m echanism s50 203.
Comparison between Gene expression profiles o f P3 and P14 BM SC
We found that 6687 genes are expressed in P3 as well as in P14 BM SC. O f  these genes, 159 
were more than 1.5-fold higher expressed in P3 BM SC and 43 were more than 1.5-fold higher 
expressed in P14 BM SC. Thus, o f the genes expressed in both P3 and P14 BM SC, 20 2 genes 
(3%) were differentially expressed and these genes were considered biologically relevant.
We found that from the 43 genes that were higher expressed in P14 than in P3 BM SC, 6 genes 
were over 3 tim es higher expressed (Table 5A). Am ong these were genes involved in cell death 
regulation (clusterin; Clu, and growth arrest-specific protein 2; Gas2)22h 384 and cell differentiation 
and proliferation (clusterin; Clu, and odd-skipped related 2 protein; Osr2)'96, 384, 423.
From the 159 genes that were higher expressed in P3 than P14 BM SC, 12 genes were over 3 
tim es higher expressed (Table 5B). Am ong these were genes involved in cell death (gremlin 1 
homolog, Grem i)296, 474, brain developm ent, motor axon guidance, and neuron migration 
(stromal cell-derived factor-1 gamma, SD F-1)K’ 229, 303, and in cell survival (chemokine (C -C  motif) 
ligand 2, Ccl2) 125.
We used G O stat (http://gostat.w ehi.edu.au) to perform functional data m in in g  by G O -an alysis 
on the 20 2 differentially expressed genes to identify overrepresented G O -classes (Table 6). 
The group o f 6687 genes expressed in both P3 and P14 BM SC was used as a reference. From 
the 159 genes that were higher expressed in P3 than P14 BM SC, 85 (53%) were annotated in 
the G O  database. We found a total of 43 G O -classes that were overrepresented including 29 in 
cellular m etabolic processes and 9 in developm ental processes and cell proliferation 
(G O :0048513/ G O :0 0  0 7 275 / G O :0 0 4 8 731/ G O :0 0 325 0 2/ G O :004 8856 / GO :0035 2 95/ 
G O :0 0 0 15 6 8 / G O :0 0 0 19 4 4 / G O :0 0  08283). From the 43 genes that were lower expressed in
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P3 than P14 BM SC, 22 genes (5 1% ) were annotated in the G O  database. Two GO -classes were 
overrepresented and these were involved in organ developm ent (GO: 0048513) and response 
to m echanical stim ulus (GO: 0 0 0 9 6 12).
DISCUSSION
We found that P3 and P14 BM SC express numerous genes encoding for proteins involved in 
oligodendroglial developm ent and m yelination, astroglial differentiation, and neuronal 
proliferation and neurite formation. Other genes expressed by these cells play a role in 
nervous system developm ent in addition to their functioning in other pathways. These 
findings may reflect the described ability of BM SC to differentiate across lineages and become 
neural cells. If BM SC possess such an ability it would greatly benefit their use in nervous tissue 
repair as grafted BM SC could replace lost and /o r damaged neural cells. It was reported that 
BM SC can differentiate into neural cells in vivo2'5 or be induced to become one in vitro'00 371 445, 
but the evidence is controversial66, 243, 291.
We found that BM SC express genes that encode for proteins involved in the 
developm ent o f tissue in general and in growth factor signalling. The expression o f these 
genes may indicate the potential o f BM SC for cell-based repair as the gene products could 
promote tissue formation and functioning372 427. We also found that BM SC express genes 
involved in cell death m echanism s. This could be benefited from as these genes can be 
targeted to improve survival o f BM SC transplanted into the injured nervous tissue. It has been 
demonstrated that survival of BM SC is low after transplantation in for instance the damaged 
spinal cord170, 285. Improved survival could enhance the overall repair efficacy o f a BM SC 
transplant322 324, 472.
Our functional data m in ing revealed that 9 overrepresented G O -classes in P3 BM SC 
(compared to P14 BM SC) were involved in developm ental processes and cell proliferation. On 
the other hand, 1 overrepresented G O -class in P14 (compared to P3 BM SC) was involved in 
organ developm ent and m echanical stim ulus. Together, these findings suggest a dim inished 
plasticity of BM SC after long-term culturing. Th is idea is corroborated by the finding that the 
expression level of the SD F-1  gene was more than 3 tim es higher in P3 than P14 BM SC. S D F-1 
gene encodes for a protein involved in brain developm ent, motor axon guidance, and neuron 
m igration86, 89, 229, 303 and may be indicative of the overrepresentation of developmental 
processes in P3 compared to P14 BM SC. Also supporting the idea is that no genes involved in 
neural developm ent were higher expressed in P 14  BM SC than in P3 BM SC.
In the present study, the gene expression profiles of BM SC that were cultured for a shorter 
and longer period were compared to exam ine possible effects after long-term culturing. To our 
knowledge the effect of long-term culturing on gene expression in BM SC has not been 
investigated previously. In 3 %  of the genes that were expressed in P3 and in P14 BM SC,
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expression levels had significantly changed after long-term culturing. Previously, it was shown 
that, after a sciatic nerve crush, the expression level o f 5 %  of the genes in neurons that had 
their axon damaged changed significantly’88. This resulted in a crucial phenotypic change as 
this group of genes were involved in regenerative events in the damaged neurons’88. Franssen 
and colleagues’39 showed that 7 %  of the genes that were differentially expressed between 
cultured Schwann cells and cultured olfactory ensheathing glial cells were expressed with more 
than 3 tim es difference. Further studies will be necessary to elucidate the relevance of the 3 %  
of genes differentially expressed between P3 and P’ 4 BM SC.
O ur data showed that both P3 and P ’ 4 BM SC express genes involved in developm ental and 
differentiation pathways in general, and in nervous system development, m yelination and 
gliagenesis in particular. The overrepresentation o f differently expressed genes involved in 
these pathways alters significantly between P3 and P ’ 4 and pointed at a decrease in plasticity 
in long-term cultured BM SC.
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APPENDIX
Table 1. Genes expressed in P3 BM SC involved in nervous system pathways.
A: Nervous system development
Gene Name Exp Gene Description Ontology
N M _o i2987 7 3 1 Nes Nestin CNS development
XM_239373 7 ,69 Cog1 Predicted: component of oligomeric 
golg i complex 1
CNS development, myelin 
formation
N M _o i9i 39 11,69 Gdnf Glial cell line derived neurotrophic 
factor
anti-apoptosis, cell proliferation, 
CNS/PNS, neurite development
L15011 7,56 Ctxn N eu ron-specific cortexin CNS development
NM_031357 6,89 Cln2 Ceroid-lipofuscinosis, neuronal 2 CNS. development
NM _178866 6,9:2 lgf1 insulin-like growth factor 1 CNS development
NM_017003 915 Erbb2 V-erb-b2 erythroblastic leukemia 
viral oncogene horn 2
CNS development
NM_ 1003401 7,74 Enc1 Ectodermal-neural cortex 1 CNS development
N M _100 .4:231 10,32 Npdc1 neural prol / diff and control, 1 neural proliferation and 
differentiation
NM_012529 7J5 Ckb creatine kinase, brain CNS development
B: OUgodendroglial development
Gene Name Exp Gene Description Ontology
XM_239373 7,69 Cog1 Predicted: component of oligomeric 
golg i complex 1
-structural component olf myelin 
sheath
NM_017003 9^47 Erbb2 V-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2
myelination
NM_012720 7 >697 Mobp Myelin-associated oligodendrocyte 
basic protein
myelin formation
NM_207601 1:2,61 Plp2 Proteolipid protein 2 myelin protein
C: Astroglial differentiation
Gene Name Exp Gene Description Ontology
NML031022 9,65 Cspg-4 Chondroitin sulfate proteoglycan 4 glial cell migration, neuron fate 
commitment:, remodelling, etc
NML178866 6,9:2 lgf1 Insulin-like growth factor" 1 glial cell differentiation
XM L214030 9>72 Pdgfra Predicted: platelet derived growth 
factor" receptor alpha polypeptide
gliagenesis
NM_017003 9.15 Erbb2 V-erb-b2 erythroblasticleukemia 
viral oncogene homolog 2
glirl d ll diffe^entiftitn
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D: neuronal processes
Gene Name Exp Gene Description Ontology
NIVL019139 11,69 Gdnf Glial cell line derived neurotrophic 
factor
anti-apoptosis, cell proliferation, 
CNS/PNS, neurite development
NIVL013216 9,43 Rheb Ras homolog enriched in brain regulation of neuronal synaptic 
plasticity
N M_ 0 12922 7,65 Casp3 Caspase 3 neuron apoptosis, cell fate 
commitment
NM_031022 9,64 Cspg4 Chondroitin sulfate proteoglycan glial cell migration, neuron fate 
commitment, remodelling, etc
NM_012987 7,31 Nes Nestin neuron differentiation, CNS 
development
NM_130740 7,63 Pacsin2 Protein kinase C and casein kinase 
substrate in neurons 2
NM_053389 7,09 Sip1 Survival of motor neuron protein 
interacting protein 1
NM_1025400 7,01 Smndc1 Predicted: survival motor neuron 
domain containing 1
XM_233798 10,76 Crim1 Predicted: cysteine-rich motor 
neuron 1
NM_031357 6,89 Cln2 Ceroid-lipofuscinosis, neuronal 2 CNS development
L15011 7,55 Ctxn Neuron-specific cortexin CNS development
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Table 2. Expression of genes involved in cell cycle and developm ental processes in P3 BM SC.
Gene Name Exp Gene Description Ontology
NM_178866 6,92 Igf1 Insulin-like growth factor 1 growth factor activity, anti- 
apoptosis, cell development
NM_013174 9.51 Tgfb3 Transforming growth factor, beta 3 protein binding, cell growth, 
embryonic development
XM_237999 11 ,51 Gadd45g Predicted: growth arrest and DNA- 
damage-inducible 45 gamma
protein binding, cell differentiation, 
apoptosis, regulation of cell cycle
NM_053 653 8,68 Vegfc Vascular endothelial growth factor
C
growth factor activity, cell 
proliferation, angiogenesis
NM_031022
VO9, Cspg4 Chondroitin sulfate proteoglycan 4 
(Cspg4)
cell differentiation, cell proliferation, 
angiogenesis
XM_215993 8,74 Edf1 Predicted: endothelial 
differentiation-related factor 1
transcription, cell differentiation
XM_341934 7,56 Tgfb1i1 Predicted: transforming growth 
factor beta 1 induced transcript 1
protein binding, cell differentiation, 
cell fate commitment
AB105879 9,03 Scf mRNA for stem cell factor KL- 
2 , complete cds]
stem cell factor receptor, regulation 
of apoptosis
XM_345649 7,53 Similar to development- and 
differentiation-enhancing factor 2 ; 
PYK2
XM_216438 7,43 ADRP Adipose differentiation-related 
protein (ADRP)
XM_224733 7,01 Gdfi Predicted: growth differentiation 
factor 1
growth factor activity
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Table 3. Expression o f genes encoding for growth factors or proteins involved in growth 
pathways in P3 BM SC.
Gene Name Exp Gene Description Ontology
N M _o i9i 39 11,68 Gdnf Glial cell line derived neurotrophic 
factor
anti-apoptosis, cell proliferation, 
CNS/PNS, neurite development
NWL139259 7,83 Nradd Neurotrophin receptor associated 
death domain
signal transduction, neurotrophin 
p75 binding
N M_053401 9,64 Ngfrap1 Nerve growth factor receptor 
associated protein 1
induction of apoptosis
NM_053 653 8,68 Vegfc Vascular endothelial growth factor
C
growth factor activity, cell 
proliferation, angiogenesis
N M _o i28oi 8,59 Pdgfa Platelet derived growth factor, 
alpha
growth factor activity, cell 
proliferation, cell migration
N M _ io ii92 i 10,35 Pdgfrl Platelet-derived growth factor 
receptor-like
cell surface protein
XM_214030 9,72 Pdgfra Predicted: platelet derived growth 
factor receptor, alpha polypeptide
gliagenesis, positive regulation of 
cell proliferation and cell migration
NM_031525 9,14 Pdgfra Platelet derived growth factor 
receptor, beta polypeptid
anti-apoptosis, positive regulation 
of cell proliferation
NM_199114 8,25 Fgfrl1 Fibroblast growth factor receptor­
like 1
negative regulation of cell 
proliferation
N M_0221 82 9,23 Fgf7 Fibroblast growth factor 7 growth factor activity, positive 
regulation of cell proliferation
NM_178866 6,92 Igf1 Insulin-like growth factor 1 anti-apoptosis, cell development, 
glial cell differentiation
NM_1004274 10,41 Igfbp4 Insulin-like growth factor binding 
protein 4
regulation of cell growth
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Table 4. Expression of genes involved in cell death m echanism s in P3 BM SC.
Gene Name Exp Gene Description Ontology
XM_226833 8,29 C1qtnf3 Predicted: C1q and tumor necrosis 
factor related protein 3
NM_139194 8,07 Tnfrsf6 Tumor necrosis factor receptor 
superfamily, member 6
induction of apoptosis
NM_013049 7,87 Tnfrsf4 Tumor necrosis factor receptor 
superfamily, member 4
induction of apoptosis
N M _oioo6952 7,76 Trap1 Tumor necrosis factor type 1 
receptor associated protein
XM_222503 7,23 Tnfrsfn
a
Predicted: Tumor necrosis factor 
receptor superfamily, memna
NM_01010945 7,11 Similar to transm protein induced by 
tumor necrosis factor alpha
N M _i8io 86 10,33 Tnfrsf12
a
Tumor necrosis factor receptor 
superfamily, member 12a
cell death
NM_013091 9,96 Tnfrsf1a Tumor necrosis factor receptor 
superfamily, member 1a
positive regulation of angiogenesis
NM_01012123 9,61 C1qtnf5 Predicted: C1q and tumor necrosis 
factor related protein 5
cell death
XM_226833 9,49 C1qtnf3 Predicted: C1q and tumor necrosis 
factor related protein 3
NM_030836 9,48 Arts1 Type 1 tnf receptor shedding 
aminopeptidase regulator
positive regulation of angiogenesis
N M _i8io 86 8,47 Tnfrsf12
a
Tumor necrosis factor receptor 
superfamily, member 12a
cell death
BC061751 7,96 Androgen receptor-related 
apoptosis-assoc protein CBL27
XM_342470 9,91 APi5 Predicted: apoptosis inhibitor 5 anti-apoptosis
XM _2 i 6650 9,14 Predicted: similar to apoptosis rel 
protein APR-3 ; p18 protein
NM_0535i6 9,09 N0I3 Nucleolar protein 3 (apoptosis 
repressor with CARD domain)
regulation of apoptosis
XM_342137 8,45 Amid Predicted: apoptosis-inducing factor 
(AIF)-like mitochondrion-associated 
inducer of death
regulation of apoptosis
XM _23566i 8,34 Predicted: similar to TGF-beta 
induced apoptosis protein 12
induction of apoptosis
NM_053736 8,77 Casp11 Caspase 11 regulation of apoptosis, 
inflammatory response
NM_022522 7,69 Casp2 Caspase 2 regulation of apoptosis, 
inflammatory response
NM_012922 7,65 CasP3 Caspase 3 regulation of apoptosis, neuron 
apoptosis, cell fate commitment
NM_031775 7,291 Casp6 Caspase 6 regulation of apoptosis, 
inflammatory response
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NM_139259 7,827 Nradd Neurotrophin receptor associated 
death domain
signal transduction, apoptosis
NM_019139 11,69 Gdnf Glial cell line derived neurotrophic 
factor
anti-apoptosis, cell proliferation
NM_199270 7,79 Bre Brain and reproductive organ- 
expressed protein
apoptosis
NM_053401 9,64 Ngfrap1 Nerve growth factor receptor 
(TNFRSF16) associated protein 1
induction of apoptosis
NM_133546 6,87 Mydn6 Myeloid differentiation primary 
response gene 116
apoptosis, response to stress
NM_012588 8,52 Igfbp3 Insulin-like growth factor binding 
protein 3
positive regulation of apoptosis
NM_01012154 7,179 Tbrg4 Predicted: Transforming growth 
factor beta regulated gene 4
apoptosis
XM_216265 6,842 Ing4 Predicted: Inhibitor of growth family, 
member 4
apoptosis, cell cycle arrest, neg 
regulation of cell proliferation
XM_237999 1 1 ,51 Gadd45
g
Predicted: Growth arrest and DNA- 
damage-inducible 45 gamma
apoptosis, regulation of cell cycle
NM_133544 11,04 Usmg5 Upregulated during skeletal muscle 
growth 5
apoptosis, regulation of cell cycle
NM_012756 10,76 Igf2 r Insulin-like growth factor 2 receptor regulation of apoptosis
NM_013174 9,51 T gfb3 Transforming growth factor, beta 3 regulation of apoptosis, cell growth, 
regulation of cell cycle
NM_031525 9,14 Pdgfrb Platelet derived growth factor 
receptor, beta polypeptide
anti-apoptosis, positive regulation of 
cell proliferation
NM_017003 9,15 Erbb2 V-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2
anti apoptosis, positive regulation of 
cell proliferation
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Table 5. Differentially expressed genes between P3 and P14 BM SC with A > 3 fold difference.
A: Upregulated at P14
Gene Name Exp Gene Description Ontology
NM_053021 3,96 Clu Clusterin (Clu) protein binding, apoptosis, cell 
differentiation /proliferation, etc
U87983 3,66 receptor for hyaluronan-mediated 
motility
N M _o i2862 3,39 Mgp Matrix Gla protein regulation of bone mineralisation
XM_574454 3,09 LOC49
9156
Predicted: similar to growth arrest- 
specific protein 2 - mouse
cell cycle arrest
NM_00101211
8
3,08 Osr2 Predicted: odd-skipped related 2 
(Drosophila)
positive regulation of cell 
proliferation
NM 0010118 
89
3,04 Cldn9 Predicted: claudin 9 cell adhesion molecule
B: Upregulated at P3
Gene Name Exp Gene Description Ontology
NM_012893 2,99 Actg2 Actin, gamma 2 protein binding, cytoskeleton
N M_080886 3,19 Sc4mol Sterol-C4 -methyl oxidase-like oxidation reduction
XM_231258 3,25 E-FABP similar to Fatty acid-binding protein, 
epidermal
NM_031776 3,27 Gda Guanine deaminase indiinbiniotaletm
XM_233037 3,30 Pappa Predicted: pregnancy-associated 
plasma protein A
Ppptidase activity, response to 
glucocorticoid stimulus
XM_214778 3,45 TSP -2 Thrombospondin 2 angiogenesis, positive regulation of 
synaptogenesis
XM_573502 3,78 similar to Fc gamma (IgG) receptor 
II alpha precursor
AF217564 3,79 SDF-1 Stromal cell-derived factor-1 gamma brain development, motor axon 
guidance, neuron migration, etc
N M _i0076 i 2 ,83, Ccl7 Chemokine (C-C motif) ligand 7 chemokine activity, immune 
response
N M_030834 4 ,40 Slci 6a3 Monocarboxylate transporter transporter activity
NM_031530 4 ,44 Ccl2 Chemokine (C-C motif) ligand 2 anti-apoptosis, immune response, 
chemokine activity
NM_019282 5,09 Gremi Gremlin 1 homolog, cysteine knot 
superfamily (Xenopus laevis)
apoptosis, cell-cell signalling
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Table 6. Overrepresented G O -classes in significantly different expressed genes between P3 
and P14 BM SC (A > 1,5 fold difference) compared to total subset of expressed genes.
GO CLASS GENE ONTOLOGY GROUP Total P-value
UPREGULATED AT P3
Biological process
00:0048513 organ development 25 252 3,45e- ° 6
GO:ooo6o66 alcoholic metabolic process 15 75 4 ,10E -06
G0 :0 0 0 8 20 2 steroid metabolic process 11 37 4 ,1°E-o6
GO:ooo6694 steroid biosynthetic process 9 23 4,84E-o6
G O :oo i6i 25 sterol metabol ic process 8 19 5-0
L.Ù3,3
G0:0032501 multicellular organismal process 38 554 6 ,82E- °5
GO:ooo7275 multicellular organismal development 31 4°9 6,82E- °5
G0:0008203 cholesterol metabolic process 7 17 6 ,82E- °5
G O :oo i6i 26 sterol biosynthetic process 6 12 1,°5E-°4
GO:oo4873i system development 27 345 1 ,67E- ° 4
GO:ooo86io lipid biosynthetic process 11 62 3,77E-°4
G0:0032502 developmental process 38 601 6,29E- ° 4
GO:ooo6oo7 glucose catabolic process 7 27 0,001
GO:oo46 i 64 alcohol catabolic process 7 28 0,001
00:0046365 monosaccharide catabolic process 7 28 0,001
G0 :0 0 19 320 hexose catabolic process 7 28 0,001
00:0048856 anatomical structure development 28 4°9 0,002
G0:0009605 response to external stimulus 14 123 0,002
G0:0006096 glycolysis 6 21 0,002
G0:0044275 cellular carbohydrate catabolic process 7 31 0,002
GO :0 0 i 6052 carbohydrate catabolic process 7 31 0,002
G0:0035295 tube development 7 31 0,002
G0:0065008 regulation of biological quality 17 201 0,003
G0:0006936 muscle contraction 6 25 50
00,
G0 :0 0 0 30 12 muscle system process 6 25 0,005
G0:0006695 cholesterol biosynthetic process 4 9 0,005
G0:0009058 biosynthetic process 23 325 50
00,
00:00 4 24 4 6 hormone biosynthetic process 3 4 0,005
G0:0030199 collagen fibril organization 3 4 0,005
G0:0044255 cellular lipid metabolic process 13 122 0,005
00:0048878 chemical homeostasis 9 62 50
00,
G0:0006935 chemotaxis 5 17 0,005
62
Gene expression pattern and suitability of bone marrow stromal cells
GO :0042330 taxis 5 17 0,005
G O :ooo i568 blood vessel development 8 50 0,006
G O :ooo i944 vasculature development 8 51 0,007
GO:ooo6oo6 glucose metabolic process 7 39 0,007
GO :0007267 cell-cell signaling 11 95 0,007
GO :0055082 cellular chemical homeostasis 8 52 0,007
GO:ooo6873 cellular ion homeostasis 8 52 0,007
GO :0030005 cellular di-, trivalent inorganication homeostasis 7 40 0,007
GO :0055066 di-, tri-valent inorganic cation homeostasis 7 40 0,007
GO:ooo8283 cell proliferation 15 182 0,008
GO:oo5o8oi ion homeostasis 8 55 0,009
Cellular component
GO :0044421 extracellular region part 28 306 3,45E-° 6
GO:ooo56i 5 extracellular space 25 286 3,69e-05
GO:ooo5578 proteinaceous extracellular matrix 9 59 0,005
Molecular function
GO :0008201 heparin binding 5 17 0,005
GO :0005125 cytokine activity 6 29 0,008
GO :oo42379 chemokine receptor binding 3 5 0,008
GO:ooo8oo9 chemokine activity 3 5 0,008
G O :ooo i871 pattern binding 5 20 0,009
GO:ooo5539 glycosaminoglycan binding 5 20 0,009
GO :0030247 polysaccharide binding 5 20 0,009
UPREGULATED AT P14
Biological process
GO :0048513 organ development 10 252 0,005
GO:ooo96i 2 response to mechanical stimulus 3 9 0,008
Cellular component
GO :0005578 proteinaceous extracellular matrix 6 59 0,004
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INTRO DUCTIO N
A contusion o f the adult spinal cord causes acute death of neural cells at the lesion epicenter 
and sets off a series of events resulting in additional tissue loss and the formation of cystic 
cavities’55, 3° 5. Transplantatio n o f growth-promoting cells is considered a prom ising approach 
for repair of the contused spinal cord3’3 3’3.
Bone marrow stromal cells (BMSC) are am ong the candidates for cell-based spinal cord 
repair strategies285. These m esenchym al cells secrete growth factors that could support 
repair’43, 247. Their potential was confirmed by the finding that transplantation o f BM SC into 
the contused adult rat spinal cord resulted in functional recovery’70 3° 4, 45^  473 473. The 
m echanism s underlying these functional im provem ents observed after BM SC transplantation 
are incom pletely understood.
A BM SC graft could contribute to repair by sparing spinal cord nervous tissue at the site of 
transplantation. It is known that BM SC secrete brain-derived neurotrophic factor (B D N F)247, 
which has been im plicated in lim iting spinal cord tissue loss after injury364. At present, the 
evidence for BM SC grafts to elicit tissue sparing in the injured spinal cord is still am biguous304,
45’, 464.
Following an insult to the spinal cord, a cytotoxic environm ent develops at the injury 
epicenter to d im inish  in strength in tim e’55. M ost likely these circum stances decrease the 
survival of cells transplanted into the lesion and consequently their effects on sp inal cord 
repair. At present, quantitative evidence o f the survival and neuroprotective effects of BM SC 
transplanted into a spinal cord contusion is sparse, which obscures their spinal cord repair 
potential. We transplanted BM SC into a moderately contused adult rat spinal cord at ’ 5 min 
(acutely) and at 3, 7 and 2 ’ days (delayed) post-injury and determined tissue sparing and 
BM SC survival up to 4  weeks post-transplantation.
MATERIAL A N D  M ETHODS
Timeline of the experiment
Rats received a moderate contusion o f the T9 sp inal cord. Some of these rats received a BM SC 
injection into the injury epicenter at ’ 5 min, 3, 7, or 2 ’ days post-contusion. These BM SC- 
transplanted rats were euthanized at ’ 5 m in, 3, 7, and 28 days post-injection. Other contused 
rats did not receive the BM SC injection (control rats) and, to match survival tim es of the 
BM SC-transplanted rats, were euthanized at ’ 5 min, and 3, 7, ’ 0, ’ 4, 2 ’ , 24, 28, 3’ , 35, and 49 
days post-injury. Their spinal cords were removed and prepared for histology to enable 
analysis o f tissue sparing and BM SC numbers. D etails on the used techniques are described 
below.
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Animals
Adult female Sprague-Daw ley rats (n =  121), 16 0 -18 0  g; H arlan, Indianapolis, IN, USA) were 
used in these experim ents. All an im als were housed according to the guidelines by the 
National Institutes of Health and the United States D epartm ent of Agriculture. The 
institutional A nim al Care and Use Com m ittees of the University o f M iam i and Johns Hopkins 
University approved all surgical procedures.
Culture and lentiviral transduction of BM SC
BM SC were obtained from the marrow o f femurs and tibias o f adult fem ale Sprague-Daw ley 
rats (n =  8) according to a previously published protocol13. Passage 0 cells were infected with 
lentiviral vectors (LV) encoding for green fluorescent protein (GFP) at an M OI of 150. The 
vectors were generated using the ViraPow er Lentiviral Expression System (Invitrogen)36. 
Expression was under control o f the human cytomegalovirus promoter and the Woodstuck 
hepatitis virus Post-transcriptional Regulatory Elem ent284. The titer o f the lentiviral stocks 
varied from 1-3 x 10 9 T U /m l. O n ly passage 3 cultures with a transduction rate of about 9 5 %  
were used for transplantation.
With enzym e-linked im m une sorbent assays (ELISA) we determ ined whether the BM SC 
secreted B D N F and glial cell-derived neurotrophic factor (G D N F). For this, medium of nearly 
confluent passage 3 cultures (with an average of 2 x 10 6 cells) was refreshed, removed 24 h 
later, and used for B D N F ELISA (B D N F Emax Im m unoAssay System; Promega Corporation, 
M adison, WI) and G D N F  ELISA (G D N F Emax Im m unoAssay System; Promega) according to 
the m anufacturer's instructions. Standard curves of the ELISA kits were linear between 7.8 and 
500 p g/m l for B D N F and 15.6 and 10 0 0  pg/m l for G D N F . ELISAs were analyzed with a 
microplate reader (SpectraM ax M5, M olecular Devices, Sunnyvale, CA). The cells in culture 
secreted 14.1 p g /m l/2 4  h of B D N F. The am ount of G D N F  was below the reliability level o f the 
ELISA.
Contusion injury
Rats (n =  108) were anesthetized with 1 - 2 %  isoflurane in oxygen and their backs were shaved 
and cleaned with Betadine and 7 0 %  alcohol. Lacrilube ophthalm ic ointm ent (Allergen 
Pharm aceuticals, Irvine, CA, USA) was applied to the eyes and gentam icin (1.2 mg in 0.03 ml; 
Abbott Laboratories, North Chicago, IL, USA) was injected intram uscularly. During surgery, 
rats were kept on a heating pad to m aintain their body tem perature at 37 ± 0.5 °C . A 
lam inectom y was performed at the eighth thoracic vertebra to expose the ninth thoracic spinal 
cord segment, which was subsequently m oderately contused (NYU impactor; 10 g, 12.5 mm.; 
Gruner 1992). To ensure consistency between contused rats, the contusion im pact velocity 
and com pression were monitored and all rats with more than 5 %  error in these 
m easurem ents were removed from the study. Rats that rem ained in the study displayed
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h in d lim b  p a ra lysis  and scored less than 3 at 1 d ay and  less than 7 at 3 days p o st-in ju ry  on the 
B a sso -B e a ttie -B re sn a h a n  (BBB) scale23, 24. Im p le m e n ta tio n  o f these criteria  ensured 
a p p ro p ria te n e ss  o f the co ntusio n in ju ry  and co n siste n cy  a m o n g  the e x p e rim e n ta l a n im a ls . All 
la m in e cto m ie s  and inj uries w ere perform ed by th e sam e  investigator. After in jury, overlying 
mu scles w ere sutured in leyers and the al<in w as closad with m etal w ound c lip s. Th e  rats 
received Ringee’s solution (10  m < suecutaneoua) and g e n ta m ic in  (1.2  m g, in tra m u scu la r). The 
rats w ere kept in a sm a ll a n im r l ie su b a te r at 3< ° C  un til full recovery and then returned to 
their cages with ad Ubhum access to w ater and food. D u rin g  the first w eek p o st-in ju ry  
g e n trm ic in  ( i.e  mg; Abbott L a b o ra to rie s  IMorth Ch icago, 11_, USA; in tram u scu lar) was 
a d m in i stored daHy. T h e  a n al gedic, bup ren orp h 1 ne (Bu ferencx®; 0 .0 0  6 m g; Reckitt Benckiser, 
Rich m ond, V A , U SA; sub cutaneaus) w as rd  m in  istered im m e d ia te  l y after surgery and once for 
t_e next; three days. Tine thadders were exprhssecJ m a n u a lly  tw ice a day un til reflex bladder 
function retu rned. U rin _ ry  tract i n frctio  n did not occur in auy o f  tne groups.
BM SC transportation
C o ntu sed  tats wern cn a e sth a tize d  with an in tra m u scu la r in je ctio n  o f  25.7 m g /k g  ketam in e, 
5 .14  m g /k c  x y la z in e , and ce85 r u g m  acep rom  a e in e  and tli e ir co ntused sp in a l cord was 
exposedi A total oC 1 x sd>s B M S C  in s jxi D M e M vrais; injectod into the contusion e p ice n te r 
usin g  tech n iq ues d ts c r iged p revio usly’75. B M S C  in je ctio n s  w ere m ad e at 15 m in , 3, 7, and 21 
d a y / po st-co ntu sio n. In the 15 m in  eroup, the rett re m a in e d  eedated with the co ntused sp in a l 
cord tdvered with a sal in e -m o ista  n ga nze u nti l B M S C  in je ctio n . A ll tra ns p la n ta tio n s  were 
perform ed ey the cam e investigator. After in je ctio n , m uscles w ere sutured in layers and the 
skin closed with m etal w ound c lip s . gost-surgery caret w as r s  dexcribed above.
Assessment o f BM SC viability during nho injection proteVrred
Th e effeete o f t t a  in je ctio n  procedures o r  the n u m b e r c r B M S C  were d eterm in ed  in vitro usin g  
the sam e  tools and m ethods a r used So’  aceuai trc n s p la n ta t io n . First, we assessed  the v ia b ility  
o f 1 x 1 o 6 B M S C  in s (el D M E M  in an e p e e n d o rf  tube after 5 h on ice (the typ ica l length o f a 
trd n sp lu n te  tion se ssio e  ti A  sa m p lu  oS tli ese cel Is w es str ined  w it i  trypan blue (1:1; S igm a) 
and t°ie  .  urce ntage o f lie ing (un stain ed) B M S C  cal culated u s in g  a h em acytom ote r. Second, we 
a sse rse d  taMdSCZ v ia b ility  iafter in je ctio n . B M S C  in D M E M  w ere kept on ice for 5 h and then 
in jected  into an e p p e n d o rf tube (1 x i r 6 B M t C  in 5 ml D M E M  pen tube) n sin g  the sam e  pulled 
g lass injeceion n eed le  a tta c le d  to a H a m ilto  n syri ngn as used for tra n sp la n  tatio  n into the rat 
sjuinal cord. Th e se  cells  w ere then kept at 3 1  ° C / 5 %  C O 2 for 1, 3, and 5 h (n =  c for each tim e 
p o iat). B M S C  tha_ w ere not passed  through the g lass n fe d le  and  kept in the incubator for the 
se m c timet perioda served as controlc (n =  3 eon each tim e p oint). Ait the celected tim e s, and 
im m ed  iately  after pecsi n |  tli rouut the h la rs  needle (tim e p o in t 0), ce lls  w ere stain ed  with 
trypan blue (11:1; S igm e) and the p e rcrn (a g e  o f liv in g  (un stain ed) B M S C  calculated  u sin g  a
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hf;m^cytome:^ei'. The effect o l  passing throughi thè glass aendle wes determ ined by thè 
differenee i n hhe paraentax as o f Ii\/ingj BM SC betwean control asci Itim e paint o celi s. ’SX/1'iethier 
the ii'i(^ ub)ohl(^ n conditions Cad aliTect^sJ dM SC dnath ln tim e wes cjalsulotesd Oroia the differenee 
in \zisiSiililty b etwenn contrmi cells a ad ceCs tdet were passed tOron^la tbe glass n endlh a t 1 , 3 , 
and s Ir. TNird, we determ iaed Iiow m cnd </«sli^  passes tdirongla the needle. A  sassipile m l1 x io 6 
BM SC in 5 mI D M SM  thet were injected into a s ^ppanCerlT^uge usine a pallsd glass needle 
attached e H am ilton tnringe wes otnised v/ithi tri^p>aa blus (1:1; SiCiaie) to calnulste the total 
nem der of lihing ^unc1;Esi^ed) BM dC u :singf a SemolytometelP
Histolngical MroceOures
At 15 m in, 3, 3, a isd 28 de^s cfter dM SC injeuèion, rats wern nncosthetized as aSiond (ncte thet 
tho in m in d i^cus» remhmed anensthstized nnSil fìnatidn). Costm i rats thet were contused bet 
did noS seeeive a BM SC thantcltsst were sin;as;sdOntizzd 15 m in, and a, 7, 10, 4  21 , C8, 28, 31, 
355, nnd so  dco'd p ast-m isa r Thhcm timo naiste ooi'r^sf3(3nC with the murvinal tim es efthe BM SC- 
trantelwnfnd satc. After deap sehetion wes condrmed, thu heart wes expaced und 0.1 ml 
H aporine (500 IU; l-lan s; Sabein, IVInlvllle, N'Y', l_lSA) injedted into /hie l^ft \^ €5Sìdricle5. Next, 3 0 ,  
mi caline follownd do 50ic:> ml icn-mold 4 %  paraformeldehyde in paoupaate buffer (PB; 0.1 IM, 
pH n-4 ) vsea pjurtipi^d theongd ithie vasculsr system. Thn sp insi ccnrd wes removed and kept 
occrnigat in the eame fìoctlve nt 4  °C . TO m , a 15 m ni long segm ent Cif the sptincl cord 
centeted at sbe contusion wes diesectod mut, liispct in paeipaTte-duffnred t ^ <^  sunnaue 0 0  M, 
p a  7.4) fai' no 0 , esd Nrooen w itirn  Sìliiini^on M  Em eodding Mictrix (Theumo Electron 
Tc^rp>or;ation, Pistsbergh, fssii, O dA r Frorn thnse blonks, :?o (jrnn-thick eoriodntcl nections were 
o it  ori a cryostat, sn^nnt^d onto glans elide/, and stored ct -2-8 °C.
Frons innse antr n ln e cd  groug, a 1 maa tliicd section wes takan dromo t in  epicenter csf 'thie 
Icsion for im paratis>n olsnns^t;lEÌn plcsUic seetions fci> Iì^1i 1> minrassopy. The j m ei tdieb tissun 
Iti I o le  were ta p i ih 2 <:8S oluta raldellyde n^ i'tl-e s%  sunrosc in f3 t  for at le ast eoi Ir £it 4 °C . In ( %  
osmiuns tetraooirJe in e B for S2-16 li, .ehydsatxd, and ^m^edOs!^ io [if j^ n -^ rii1!:!!^ «; (Udectron 
|bc^ Trou::^f:)  ^ Sieroinh^, s or1t '^aclcisiJt^on, I^B,. C^nT:-m tliia1  tsnnsvinrsb e^i:tiont 'Nere cot ssn a 
Reid1eo1:-Juno uitra-microtome, utniceed vsi'thi a 1 %  toluidino (ili/a :^SX  ^ m^thj/len^ Silun-:1^  noliem  
Siorat^ uolution assi asad ^o anai;y;se g5ane)ai hlietoloji4: of7 the sp in a 1 cord aind trarnspìlant £md 
df;^ei'l55id^ ^i^san lous ct tàe iaijur^dtr^istp:>lhsst s^ fmi^ n^te^ r'.
Measdrdmem o f apmol nord tiszue a»a ring
^Co rics g of7 sptincl eors( ti^eu^ vs^s temesse0 in a olin<^ec( foshiien in horioontal (sr^syil isic^ e^ t- 
sthicesJ cryoutct ss^c^ion^ Lisiing e (Sovalicri ect;im^^oi> ^anctican of^^tl;rno Incfcstis;at^r®> (i^SV  
Bioucience, ^^llisto n , ^T"). (!ili m^asnrens^n^s wese take!n Io). ^h^ aamn ionnrtigator> F: rom ^^ch 
^ n i^ e l, ever}! ^en.h croou^nt; s^c^1© ' (orcionim ivtezvals) lites es^cJ tn dsi^n^m^si^ tne mccium  ^ a 
;. mm Ir^ ng1 e^g^m^nt c:en^erf5c( at; t;he contu^ionftrEmtpilantation epi^^nt^r and thet of7apared
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tissue within this segment. Tissue was considered spared if7 it lacked cavities, areas with high 
density of7 in tltratin g  sm all cells, resem bling nsutropails and lympaocytes, and nturons with 
darkly-stained cytnnlasm ic Nissl bodies409. The volsm e of spared tissue was expressed as a 
percentage o f tha average volume of a co mp arable uninjured spinal cond segmdnt.
Measurement o f - he number o f BM SC  wWCoo the conSurep spinal cord
From each rat transplantdd witli E3 INd:^ C, every tunth cryoctat section weis coveued with a glass 
slip with Vectashield with D A P 1 (4'-6-diam iding-:^ -p l^'^a;by' i^sictole  ^ Vector Laboratories, inc.) and 
used to dielte;rmine tl-v«; number o f l r F^ ^p>oci i^ve n M SC in t h i  contu siopia In t l i  se sections, in a 
blinded fashion, tlm consusion areo with G FP-cocitive  celln was outlined uncJ^r a 2.5 x 
objective. T h in , ijncd^r t 63 n objpctive (oil im m ersion), gride of 250 by 250 | m  (coueting iTramv 
area, 6 3 p nm  2) we re placed ovsr 'tO/6; outline d ares and each GFP-uor:i^ive ceil with a 
secognizdbie n u n le d  w st countdd using / h i  o ^ ic a l fractionator 'T^ ncr'tion o f Stereo 
Investigaton® (Kit S I1 B icscience, W illiston, V T, UOA). T h i  sam plin g interval was: x =  25 o mm , y 
aa ^50(sm . A ) m easurem erts wero ta)en bo the sam e inveFtinarsr. "Thii^  ^euulrtii j^ej nunrtjirii^  ^
wade us ed to c;sl'^ulsit:e; t S i  tota l num ber c f  GFP-pocitihe BM SC within t lo  ^ontusiioni These 
totel numbere w /te  1; i^ n x p r e o t e d  as a f^ercei^tai^^ o f the totri numbes fomnch Ft 15 m in poct- 
injection,
Assessment e f  BM SC migeaaion
We hound tin^t traesplanted BM SC h id  migrated cway from t in  injection ¡¡it;«;. Their numbee 
location, s n t  distance from shy contu^ic^n epicenter were cSe^erminird in one serips ofcryostst 
«^j'c'ticsns; oS each oC h^nen transplanted rats. Because it is peonsible t h it  BM SC lind migrated 
eeyond 8 mire w hicf wei;:; tfe  I'oximsite; dis^tanc:t; from tine; in"ury epicentat to ihe e d is  of 
tine; section in rosCral an d cau d d  direction, we also sectioned and oxemined the contiguous 10 ­
mm long eoctral and crsiurl l^ spinal cord segment. A ) GFP-pocitive CMUC outsida of7 t h i 
contu nioc were c:ounted m anually unden a 4 o x  oUjective.
Statisti'car analysiv
We uned Sigm srtat® (Systat Software, inc., San Jore, CA) U55/X) ■fo>r t h i rtatistical analyses. T h i 
t-Sest was uned to determ ine differences betw/een groups which; were accepted at po 0.05. T h i  
relationship tetw een tissue sparing and BM SC number was diteri'nined by the Pearson 
correlation coefficient (n).
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RESULTS
B M SC  transplants in the contused spinal cord
W ith all tra n sp la n ta tio n  p a ra d ig m s, G F P -p o s it iv e  B M S C  w ere found w ith in the co ntusio n at 15 
m in  after the in je ctio n  (Figs. lA -C ) . Th e  nu m b er o f B M S C  w ithin the co ntusio n w as noticeably 
decreased at 7 days (Figs. lD -F )  and 28 days (Figs. i G - 1) after in je ctio n .
T i m e  o f  I n j e c t i o n  
1 5  m in  ( a c u t e )  7  d  d e l a y e d  2 1  d  d e l a y e d
Fig. l .  BM SC transplants within a moderate contusion in the adult rat thoracic spinal cord decrease in size during 28 
days post-injection. The transplant is shown at 15  min ( A -C ) ,  7  days (D-F) and 2 8  days ( G - l )  after an injection at 15  min 
(acute), 7  days and 2 1  days, respectively, post-injury. A ll microphotographs are from horizontal cryostat sections. Bar in 
A  represents 600 jmin in ( A -1) .
Spared tissue in the contused adult rat spinal cord
W e q u alita tive ly  assessed  the contused  sp in a l cord seg m e n t o f  adult rats w ithout (controls) 
and with a B M S C  tra n s p la n t  u sin g  to lu id in e  b lu e-sta in ed  tra n sverse  sem ith in  p la st ic  sections 
o f the co ntusio n e p ice n te r and cresyl v io le t-sta in e d  ho rizo ntal cryostat sectio n s o f  the 
contused sp in a l cord seg m e n t (Fig. 2). In tran sve rse  p la stic  sectio ns, a loosely o rganized  
t ra n s p la n t  that filled up the co ntusio n w as found at 3 days after an acute in je ctio n  (Fig. 2A ). A t
28 days after a B M S C  in je ctio n  into the 2 1 -d a y  old contusion the sp in a l cord w as not only  
decreased in s ize  but a lso  co n tain ed  one or m ore large cavities (Fig. 2B ). O n  horizontal 
sectio ns, after an acute in je ctio n , cavities w ere not p re se n t at 3 days (Fig. 2C) but could be
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found at 28 days (Fig. 2D ). With a 7 day delayed injection, sm all cavities were found at 3 days 
(Fig. 2E) and much larger ones at 28 days (Fig. 2F) post-injection.
Fig. 2. Spared tissue in the contused aduIt- rat spinal coI'd after BMSC transplantation. (A) Loosely organized tissue in 
contusion euicenter at a days after sin acute BM SC injection. (B) Cavities presen t in the contusion epicenter at 28 days 
aCtrr a 21 day delayed transplaetation of BMSC. Note that the spinal cord has also decreased in size. (C) At 3 days after 
ncute BMSC injection, damaged tissue but not cavities was observed. (D) At 28 days after acute injection, large cavities 
were found in the contused segment. (E) WitO a 7 day delayed BM SC injection, damaged tissue and few small cavities 
were found at 3 days post-trnnsplantation. (F) /At s 8 days after BMSf injection into the 7-day old contusion, large 
cavities were found in the centusfd segmfnt. Images in A and O are from toleidine blue-stained transverse semithin 
plastic sections . Images in C-O are from cresyl violet-stainod horizontal cryostat sections (rostral to the left). Bar in A 
represents 150 jjLrn in (A-B). Bar in C hepresents 600 |jJin in (C-F).
Using Stereo I n v e s t ig a to (  software (M BF Bioscience) we determ ined that the volume of 
spared tissue in the contused spinal tord segm ent gradually decreased to 10.1 ± 1.7 m m 3 at 49 
days post-injury in control ra ts and to 11.5 ± 0.9 m m 3 at 49 days post-injury in BM SC 
trainsplanted rats (Tabln 1). Because narrow ing o f the contused segm ent occurs, we 
determined tht aolume o f spared tissue relative to th at o f a com parable segm ent from 
u nii-s jured an d u u tre ated s ft ina 1 co rd (21.9 ± 3.4 m m 3i SD , n =¡5; Fig. 3A). We found that with 
BM SC injected at 15 m in, 3, or 7 days after injury the; volume o f spared tissue was significantly 
higher in tranuplantee ratr than in control rats at the respective endpoints (i.e., 28, 31, and 35 
days post-inj ury).
We then determ ined the relative change in spared tissue volume in transplanted and 
control rats between the sam e tim e periods after contusion (Fig. 3B). Importantly, in BM SC
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t r a n s p la n te d  rats the vo lu m e  o f  sp a re d  t i s su e  a t  15 m in after  in jection w a s  s im ilar  to that 
found in control rats o f  m a tch in g  survival t im es .  T h e  results  sh ow  th at t i s su e  s p a r in g  during 
the 28-days  that B M S C  w e re  p r e s e n t  w a s  in crea sed  with acute  and  3-days delayed  but not with 
7 and  2 1 -d a y s  d e layed  B M S C  t r a n sp la n ta t io n  c o m p a r e d  to the loss that occurs in control rats  
within the s a m e  t im e  per iods.
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Fig. 3. BM SC transplantation elicits tissue sparing in the contused adult rat spinal cord. (A) Bar graph showing the 
volumes of spared tissue in the contused spinal cord segment in rats without (control, open bars) and with (closed bars) 
BMSC transplants. Spared tissue volume is expressed as a percentage of the volume of a comparable uninjured spinal 
cord segment. Time points of the x-axis refer to control rats. The survival times of BMSC-transplanted rats that matched 
these time points were 15 m/15  m, 15 m/3 d, 15 m/7 d, 3 d/7 d, 7 d/7  d, 21 d/15  m, 21 d/3 d, 15 m/28 d, 3 d/28  d, 7 d/28 
d, and 21 d/28 d (see also Table 1 ). Asterisks indicate a significant difference control and BMSC transplanted rats (* = 
p<0 .05 ; **  = p<0 .0 3 ; * * *  = p<0 .0 1 ) . (B) In this graph the decrease in spared tissue volume occurring during the 28 day 
time period is shown. The volume at the endpoint is expressed as a percentage of the volume at the starting point. The 
time periods refer to control rats. The matching time points of transplanted rats are listed above.
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Loss o f  B M SC  transplanted into the moderately contused rat spinal cord
W e found that 9 5 %  o f  B M S C  survived a per iod o f  5 h on ice and  9 2 %  survived w h en  p a ss e d  
through a pulled g la ss  needle .  Thus, our m e th o d s  could have resulted in a m a x im u m  o f  1 3 %  
death  a m o n g  B M S C  injected into the c on tu s io n .  From  the in te n d e d  1 mill ion cells ,  6 .7  x  1 0 5 
B M S C  p a s s e d  through the n e e d le  al ive. T ak ing  th e  g r e a te s t  p o ss ib le  p e r c e n t a g e  o f  death  due 
to t r a n s p la n ta t io n  into account,  this  im plies  th at  8 x  1 0 5 B M S C  w e re  in jected into the 
contusion  o f  which 1 .3  x  1 0 5 cells  ( 13%) w e re  dead .  To correct for variabili ty du e  to our 
proced ures ,  B M S C  nu m b e rs  w e re  e x p re s s e d  a s  a p e r c e n t a g e  o f  th e  n u m b e r  found a t  15 min 
post-in ject ion .
W e found at 15 min post-in ject ion th at  35% , 2 5% ,  58% , and  3 2 %  o f  the ca lcu lated  a v e ra g e  
o f  6 .7  x  1 0 5 (live) B M S C  w e re  p r e s e n t  and  al ive in th e  con tu s ion  with the in jection m a d e  a t  15 
min, 3, 7 and  2 1 -d a y s  post-injury, resp ect ive ly .  T h ere  w a s  no direct re la t io n sh ip  b e tw e e n  the 
p e r c e n t a g e s  an d  the t im in g  o f  the in jection; cell loss during the first 15 m in post-in ject ion w a s  
3 5 %  with acu te  and  3 8 %  with d e layed  p a ra d ig m s .
The a v e r a g e  n u m b e rs  o f  B M S C  and c o r re sp o n d in g  p e r c e n t a g e s  (relative to the n u m b e r  at 
15 m in post-in ject ion) are  listed in T a b le  2 (also  Fig. 4A) and  reveal th at the n u m b e r  o f  B M S C  
at  7 days  post-in ject ion w a s  s ign if icantly  higher after  a cu te  (p < 0 .0 1 )  and  3-days d e layed  (p <
0 .0 0 5 )  in jections  co m p a re d  to 7-days and  2 1-d a ys  d e layed  in ject ions ;  3 2 %  and  5 2 %  vs. 9 %  and 
9 % ,  resp ect ive ly  (Fig. 4B).  The  n u m b e r  o f  B M S C  in the con tu s ion  a t  28  d ays  post-in ject ion w a s  
c lo se  to 0  in all g rou ps ,  ind icating  re jection o f  the t r a n s p la n te d  cells .
Tissue sparing and B M SC  survival are strongly associated
The re la t io nsh ip  b e tw e e n  t is su e  s p a r in g  and  B M S C  survival w a s  a s s e s s e d  using  the 
P e a rso n  correlat ion coefficient. W e found that with an acute  and  3-days de layed  in jection, the 
posit ive  correlat ion w a s  la rge  with r =  1 . 0  a t  3, 7, and  28  days  post-in ject ion . With a 7-days 
delayed  in jection, the posit ive  correlat ion w a s  la rge  with r =  0 .7 9  at 3 days  and  with r =  1 . 0  at
7 and  28  days  post-in ject ion . With a 2 1 -d a ys  de layed  injection, th ere  w a s  no correlation 
b e tw e e n  B M S C  nu m b e r  and  s p a r e d  t i s su e  vo lum e.  Thus, in g ro u p s  th at  rece ived  the B M S C  
t r a n s p la n t  during the first w e e k  post-contusion , w e  found a s tron g  posit ive  assoc ia t ion  
b e tw e e n  t i s su e  s p a r in g  and B M S C  survival with r v a lu es  b e tw e e n  0 .7 9  and  1 .0 .
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Fig. 4. BM SC survivat in a moderate contusion in the 
adult rat thoracic spinal cord ts /oio. (A) The number of 
BMSC transplanted acutely (15 min post-injury) or 
delayed (3 , 7 , and 21 days post-injury) into a moderate 
condusion decreases over 28 days post-injection. The 
numbers are oxpressed as a percentago of the numbers 
Boundat 15 min post-injection. (B) de:ath veithiin the
moderate contusion at 7 days post-injection is ¡significantly 
lower abter ac ute and 3-day delayed injocti ons thnn with 7 - 
and 21 j day delayed injection's. Percentages are relative to 
the number at 15 min post-transplantation. Bars represent 
standard error of the mean. * = p<0 .0 1 ; * *  = p<0 .0 0 5 .
Migration o f  B M SC  into adjacent spinal nervous tissue
The n u m b e r  o f  B M S C  in the t r a n s p la n t  site could d e c r e a s e  a s  B M S C  m ig rate  a w a y  from  the 
injection site. W e  found th at  a fe w  days  after in jection B M S C  started  to m ig rate  a w a y  m a in ly  
from the rostral and  caudal a s p e c t s  o f  the t r a n s p la n t  (Figs. 5A). O n e  w e e k  after  injection, 
B M S C  w e re  found in th e  dorsal anai ventral co lu m n s  s o m e  a s  far  a s  7 m m  a w a y  from  the 
contusion  ep icentee .  M o s t  of1"these c s l ls  w e re  sp ind le -eh a ped  with a sm all  n u c leas  and  several 
ex tenn io n s  (Fig. e B). With a 3 d ay  f ost-injury injection, a total of72 , 1 0 0  ± <349 B M S C  at  7 days 
and  8 2 0  ± 9c) a t  28 d ays  p o s t - t ra n sp la n ta t io n  had m igrated  a w a y  from  the t r a n s p la n t  sita 
(Fig. 5C). S ign if icantly  (p < 0 . 0 0 1 )  m o re  B M S C  w e re  fe u a d  rostra! (80 ± 14 % )  th tn  ca a d a l  ( f o  
±  9% )  to the tran sp laata t ; io n  site.  T he total n u m b e r  of7 m igrated  B M S C  r e p r e s e a t e d  1 . 2 %  of7 
the n u m b e r  o e B M j C in the c o n tu s io r  f t  15 m in p o s t .n j e c t io n  an d 2 . 4 %  o f  the n u m b e r  a t 7 
days  p o s C in ject ioe .  A t  28 daye post- in ject foa ,  a l m o s t  twico as  m a n y  B M S C  w e re  found o u t f id r  
o f  the con tu s ion  c o m p a r e d  to within. Thus, B M S C  tlrat had m ^ r a t e d  aw/ay from  the injection 
site into the a d ja c e n t  sp ina l  cord t i s su e  a p p e a r e d  to be p rotected  c o m p a r e d  to th o se  that 
re m erned with.n th e  c o n tu s io r .
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Fig- 5- BMSC transplanted into the moderately contused adult 
rat spinal cord contusion migrate into spinal cord white 
matter. (A) GFP-positive BMSC (arrow) ‘leaving’ the 
transplant (T) at its rostral edge. (B) Several GFP-positive 
BMSC that have migrated approximately 5 mm into the rostral 
lateral white matter (WM). (C) Bar graph showing the 
number of BMSC that migrated out of a transplant at 7 and 
28 days post injection. BMSC were injected at 3 days post­
injury. All microphotographs confocal images from horizontal 
20  jjm thick cryostat sections. Bar in A represents 15 jjm in 
panels A and B.
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Survival o f  B M S C  t r a n sp la n te d  acu te ly  (15 min post-injury) or de layed  (3, 7, and  2 1  days  post­
injury) into a m o d e ra t e ly  con tu sed  adult rat sp ina l  cord is low with fe w  or n o n e  o f  the cells  left 
a t  28 days  post-in ject ion . B M S C  loss a t  the 7 -day post-in ject ion t im e  p o int  w a s  6 8 %  with 
acute  and  4 8 %  with 3-days de layed  in ject ions  which w a s  s ignif icantly  lower than with 7- and 
2 1 -d a ys  ( 9 1 %  both) delayed  in jections .  This indicated th at  the contusion  e n v i ro n m e n t  is m ore  
d e le ter iou s  to t r a n sp la n te d  B M S C  during  the se co n d  and  fourth w e e k  after  im p a c t  than during 
the first w e e k  after  im p act .  In control rats, the a m o u n t  o f  sp a re d  t i s su e  gradual ly  d e c r e a s e d  in 
t im e  until 4 6 %  o f  that in a c o m p a r a b le  u nin jured  sp inal  cord s e g m e n t  a t  4 9  days  post-injury.  
The  p r e s e n c e  o f  B M S C  resulted in in c re a se d  a m o u n ts  o f  sp a re d  t i s su e  c o m p a r e d  to controls .  
A cute  and  3-days de layed ,  but not  7- and  2 1 -d a y s  de layed ,  injection o f  B M S C  sign ificantly  
im pro ved  t i s su e  sp a r in g .  T h ere  w a s  a la rge  posit ive  correlat ion b e tw e e n  sp a re d  t is su e  vo lum e 
and  B M S C  n u m b e r  with in jec t io ns  during the first w e e k  post-contusion .
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Effects o f  B M S C  on t is su e  s p a r in g  w e re  a s s e s s e d  by d e te r m in in g  the vo lu m e  o f  spared  
(intact) t i s su e 409 within th e  con tu sed  sp inal  cord s e g m e n t .  This revea led  an in c re a se d  vo lum e 
o f  sp a re d  t i s su e  a t  7 and  28  d ays  post-in jury with an acute  B M S C  injection and a t  6, 10 ,  an d  31 
days  post-in jury with a 3-day d e layed  B M S C  in jection. This  part icu lar  a p p r o a c h  o f  m e a su r in g  
sp a re d  t i s su e  is e m p lo y e d  regularly but it d o e s  not  take  into a c co u n t  n a rro w in g  o f  th e  sp inal  
cord, which typica lly  occurs  after  a contusion .  Therefore ,  w e  a lso  d e t e rm in e  th e  v o lu m e  o f  
sp a re d  t i s su e  relative to that o f  a c o m p a r a b le  s e g m e n t  from  uninjured and  untrea ted  spinal 
cord409. This  revea led  an in c re a se d  v o lu m e  o f  sp a re d  t is su e  a t  the a b o v e m e n t io n e d  t im e  
po ints  but a lso  at 35 days  post-in jury with a 7-days de layed  B M S C  injection.
O ur results  d e m o n s tr a te d  that acu te ly  t r a n s p la n te d  B M S C  contributed to s p a r in g  o f  
n e rvou s  t i s su e  fo l low ing a m o d e r a te  contusion  o f  the thoracic  rat sp in a l  cord better  than 
delayed  t r a n s p la n te d  B M S C .  The  reduced loss  o f  the acute ly  t r a n s p la n te d  B M S C  during the 
first w e e k  after  in jection correlated c losely  with the in c re a se d  v o lu m es  o f  t issue  sp ar ing .  
Previously, it w a s  reported  that acutely  t r a n s p la n t e d  B M S C  reduced the s ize  o f  cavit ies  at 3 
w e e k s  after  an injection into the c o n tu s io n 451 and  a t  5 w e e k s  after  an injection into the 4th 
ventr ic le304. In the p r e s e n t  study, w e  h ave  a s s e s s e d  sp a re d  t is su e  vo lum e re lat ive  to that o f  a 
c o m p a r a b le  s e g m e n t  from  an unin jured and  untrea ted  sp inal  cord to acco u n t  for the norm ally  
occurring shrinkage . D e s p i te  this d ifference in a p p ro a c h ,  our results are  in a g r e e m e n t  as  they 
indicated th at  acute ly  t r a n s p la n te d  B M S C  exert  ne uro protect ive  a c t io ns  on the ne rvou s  t i s su e  
within the con tu sed  s e g m e n t .  T h e  effects o f  th ese  ne uro protect ive  a c t io ns  re m a in  v is ible  until 
28  d ays  p o s t- t ra n sp la n ta t io n .  Y o sh ih a ra  a n d  co l laborators463, 464 d e m o n s tr a te d  that 
t r a n sp la n ta t io n  o f  B M S C  into a 9-day old m o d e ra te  con tu s ion  did not  resu lt  in 
neuro protect io n  within th e  con tu se d  s e g m e n t  which is in con cu rren ce  with our f ind ings  that 
delayed  t r a n s p la n te d  B M S C  fail to exert  ne uro protect ive  act ions .  O n e  po ten tia l  m e c h a n is m  
by which t r a n sp la n te d  B M S C  result in ne uro protect io n  m a y  be by s e c re t in g  B D N F 326, 364 W e 
used ELISA to confirm  th at  th e  B M S C  used for t r a n sp la n ta t io n  in our study produced and 
secrete d  B D N F .  Future studies  in which the production o f  B D N F  by B M S C  or th e  a c t io ns  o f  
B D N F  are  blocked will help  to e luc idate  th e  role o f  BM SC -derived  B D N F  on neuroprotect ion .
O ur data  sh ow ed  th at 0 . 0 2 %  o f  acutely  t r a n s p la n te d  B M S C  had survived up to 28  days  in a 
m o d e ra te  sp inal  cord con tus ion .  In a p rev ious  study, it w a s  shown th at  0 . 1 7 %  o f  B M S C  acutely  
in jected into and  n e a r  a m o d e ra te -s e v e re  contusion  (25 m m , N Y U  im pactor)  in the rat sp ina l  
cord had survived a t  5 w e e k s  p ost- in jury/ in ject ion 170. W hen B M S C  w e re  grafted into a 7-day old 
con tu s ion ,  6 t im e s  m o re  cells  (0 .9 9 % )  had survived a t  5 w e e k s  post-in jury (i.e., 4  w e e k s  post­
injection).  In our study w e  used a le ss  se ve re  contusion  injury but found a lower B M S C  survival 
a t  t im e  points  th at w e re  c lo se  (acute  injection -  28 days  survival here  vs.  35 days  survival170) or 
exact ly  m a tch in g  (7 d ays  d e layed  injection -  28  d ays  survival here  vs.  35 days  survival170), 
n a m e ly  0 . 0 2  vs.  0 . 1 7  an d  0  vs.  0 .9 9 ,  resp ect ive ly .  A  po ss ib le  e x p la n a t io n  for this d isc re p a n c y  
is that in H ofstetter  e t  a l . 17° the B M S C  w e re  in jected  2 m m  rostral and  caudal as  well  a s  into
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the con tu s ion  les ion . It w a s  not  studied w h e th e r  the surviving B M S C  w e re  in fact  th ose  
in jected n e a r  rather than in the contusion  as  has  b een  d escribed  for a s im ilar  p a ra d ig m  in a 7- 
day  old m o u se  sp ina l  cord contusion  m o d e l222. O thers  have repo rted  survival o f  B M S C  in sp inal  
cord les ion s  but w ith ou t qu an t i f ica t ion ’0' 3°4, 84, 85 96472' 473.
H ofstetter  e t  a l . ’7° in jected  B M S C  into the c o n tu se d  sp inal  cord acutely  or o n e -w e e k  
delayed  and e x a m in e d  during the e n s u in g  w e e k s  locom otor  function o f  th e  hind limbs. Both 
g ro u p s  w e re  not  directly  c o m p a r e d  and  tes ted  for s ign if icance ,  but th e  data  from  this study 
indicated that im p ro ved  B M S C  survival w a s  a s so c ia te d  with im proved  locom otor  fu n ct io n ’70. In 
g e n e ra l ,  this a g r e e s  with our data  th at  im pro ved  survival o f  t r a n sp la n te d  B M S C  elicits posit ive 
effects on sp ina l  cord repair.  S tud ies  that in v e st ig a te  th e  correlat ion b e tw e e n  B M S C  survival 
and  m o to r  and  s e n so ry  function a re  in p ro g ress .
Survival o f  grafted B M S C  during the first w e e k  post-in ject ion w a s  s ign if icantly  lower w h en  
the cells  w e r e  grafted 7 an d  2 ’ d ays  post-in jury c o m p a r e d  to ’ 5 m in and  3 d ays  post-injury.  
N orm ally ,  im m u n e  cells  invade  c o n tu se d  t is su e  rapidly  to be fo llowed by in f la m m a to ry  cells  
inc luding m a c r o p h a g e s .  The  pe a k  in m a c r o p h a g e  p r e s e n c e  is around 7 days  post-injury, to 
reced e  th e re a f te r34, ’ 92 34’ . W e found that B M S C  survived b est  w h en  in jected im m e d ia te ly  or 3 
days  after  injury, which is w h en  the n u m b e r  o f  in f la m m a to ry  cells  is still in c re a s in g  in the 
contusion  lesion . Possibly , m a c r o p h a g e s  are  directly  involved in t r a n sp la n te d  B M S C  loss 
which would exp la in  the g r e a te r  loss  at in jection t im e s  w h e n  m o re  m a c r o p h a g e s  can be found 
in the con tu s io n .  T h e  re la t io nsh ip  b e tw e e n  m a c r o p h a g e s  and  t r a n s p la n te d  B M S C  within the 
injured sp ina l  cord is still poorly understood.
W e ob se rv e d  th at  s o m e  o f  the t r a n s p la n t e d  B M S C  m igrated  from  the contusion  into the 
rostral and  caudal w hite  m atter .  To our know ledge ,  this is the first e v id e n c e  th at  B M S C  
t r a n s p la n te d  into a contusion  site in the adult rat  th orac ic  sp inal  cord m igrate  into the 
a d ja c e n t  ne rvou s  t issue.  N eu h ub e r  and  c o l le a g u e s 29’ described th at h u m an  B M S C  grafted in a 
hem isect ion  in the adult  rat cervical sp ina l  cord m ig rated  into the n e a rb y  sp inal  t issue .  O ur 
data  s u g g e s te d  th at  the condit ions  at and  n e a rb y  the 3-day old sp ina l  cord contusion  
perm itted  m igrat ion  o f  the in jected B M S C .  In the injured adult centra l  ne rvou s  sys tem , 
ch em o tac t ic  factors  and  cytokines such as  m a c r o p h a g e  in f la m m a to ry  pro te in- ’ , m o n o cyte  
c h e m o a tt ra c ta n t  pro te in - ’ , and  interleukin-8 have b een  im p l icated  in B M S C  m igrat ion433.
In sum , w e  have gath e re d  ev id ence  that B M S C  t r a n sp la n te d  im m e d ia te ly  and  3 days  after 
a con tu s ion  survive better  within th e  lesion e n v i ro n m e n t  during the first w e e k  after  injection 
c o m p a r e d  to B M S C  t r a n s p la n te d  a t  7 an d  2 ’ d ays  post-injury. T h e  im p ro ved  survival is 
t r a n s ie n t  but th e  B M S C  t r a n s p la n t  elicited ne uro p rotect ive  effects th at  resu lted in im. proved 
t is su e  s p a r in g  up to 28 days  after  injection.
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Chapter 5
INTRODUCTION
A  con tu s ive  sp ina l  cord injury c a u se s  im m e d ia te  dea th  o f  neural cells  and  d isruption o f  axon 
circuits ’55. T h e  n u m b e r  o f  m a c r o p h a g e s  in th e  injury site rap id ly  in c re a se s  over  the e n su in g  
days  and  contribute  to further destruction o f  local ne rvou s  t i s su e 34. T here  is no th erap y  
ava i lab le  th at  effectively im p ro ve s  function after  sp inal  cord injury.
T r a n s p la n ta t io n  o f  m e s e n ch y m a l  b o n e  m a r r o w  strom al cells  (BM SC ) has b een  exp lored  
for sp inal  cord repa ir285. In different m odel sy s te m s ,  B M S C  t r a n sp la n ta t io n  resu lted in t i s su e  
sp a r in g  and, in s o m e  c a se s ,  m otor  fu n ct io n ’70 , 286, 291 351 473. T h e se  resu lts  w a rr a n t  further 
invest igat ion  o f  B M S C  for nervous  sys tem  repair .
Survival o f  a l lo g e n e ic  B M S C  t r a n sp la n te d  into the d a m a g e d  sp inal  cord is low ’70, 286, 403. Several 
studies  have  po in te d  at a role o f  m a c r o p h a g e s  in th e  loss  o f  B M S C  after  in jection into the 
injured nervous  s y s t e m 9’, 403. So  far, qu an tita t ive  ev id e n c e  that w ould s u p p o rt  such a role is 
sp arse .
C y c losp o r in e  A  (CsA), m inocyc line  (MC), an d  m e t h y lp re d n iso lo n e  (M P) t r e a t m e n t  
d e c r e a s e s  m a c r o p h a g e  infi ltration into a sp inal  cord les ion22 ’77, 265, 3’ ’  399, 403. T h e  p r e s e n t  s tudy 
fo cuses  on th e  eff icacy o f  th e se  th ree  drugs to reduce m a c r o p h a g e  infi ltration and  w h e th e r  this 
w ould  result in in c re a se d  survival o f  su b seq u en t ly  t r a n sp la n te d  B M S C .
MATERIAL A N D  M ETHODS
Spinal cord contusion and post-surgery care
Adult fe m a le  S p ra g u e - D a w le y  rats  ( n = 7 6 ,  2 0 0 - 2 3 0 g ;  H arlan ,  In d ian ap o l is ,  IN, USA) w e re  
a n a e s th e t iz e d  with an in t ra p e r i to n e a l  injection o f  6 0  m g / k g  o f  K e ta m in e  HCl (Phoenix  
P h arm ace ut ica ls ,  St. Jo s e p h ,  M D , USA) and  0 .4  m g /k g  m e d ito m id in e  (D om itor ,  an alpha-2- 
a d re n e rg ic  agon is t ;  Orion C orporat ion ,  E spoo, Fin land).  The  1 0 th th orac ic  sp inal  cord s e g m e n t  
w a s  e x p o s e d  and  c on tu sed  using  th e  Infin ite  H orizon Im p a c to r  a t  a force  o f  2 0 0  kDyn (Fig. 
’ A). C o n s is te n c y  b e tw e e n  a n im a ls  w a s  g u a ra n t e e d  by reg is te r ing  the im p a c t  force  and  spinal 
cord d i s p la ce m e n t .  T h e  w o u n d  w a s  c losed and  th e  rats  w e re  given  a n t i se d a n  (a t ip a m e z o le  
hydrochloride;  ’ .25 m g/kg, intram uscular) ,  an a lp h a  2 -a d re n e rg ic  a n ta g o n is t  th at  re verses  
sed at ive  and  a n a lg e s i c  effects o f  m ed ito m id ine .  All surgical pro ced ures  w e re  p er fo rm ed  by the 
s a m e  invest igator .  Post-surgery m a i n t e n a n c e  w a s  as  described previously286.
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Fig. i . Schematic representation o f  the experiments and 
BMSC harvest and transduction, (a) Rats were contused at 
the 10 th thoracic spinal cord segment and then divided into 4  
groups that received CsA, MC, M P or saline, (b) BMSC were 
harvested, transduced to express GFP using lentiviral vectors, 
and grown in DMEM. (c) GFP-expressing BMSC in a passage 
3 culture which were used for transplantation into the 
epicenter o f the 3-day old contusion. Abbreviations: BMSC, 
bone marrow stromal cells; CsA, cyclosporine A; ip, 
intraperitoneal; MC, minocylcine; MP, methylprednisolone; 
sc, subcutaneous. Bar in C represents 10  fxm.
Drug administration
C o n tu se d  rats  w e re  divided into 4  grou ps  th at  rece ived  CsA, MC, M P, or  sa l ine  ( n = i 8  each; 
Fig. lA) s tar t in g  5 m in after  the con tu s ion .  All in jec t io ns  w e re  p e r fo rm e d  by the s a m e  
invest igator .  C sA  (Bedford Labs, Bedford, O H , USA) w a s  a d m in is te re d  sub cu ta n e o u s ly  o n c e  
p e r  day  at a d o s e  o f  3 0  m g / k g  for the first three days  and  15 m g /k g  for the next seve n  d a ys4“3. 
M C  (Sigma-Aldrich, St. Louis, M O , USA) w a s  a d m in is te re d  in t ra p e r i to n e a l ly  at a d o s e  o f  50 
m g / k g  tw ice  a day  for the first two d a y s399. M P  (Sigma-Aldrich) w a s  a d m in istere d  
in t ra p e r i to n e a l ly  o n c e  a t  a d o s e  3 0  m g / k g 22. S a l in e  w a s  given to contro ls  fo llowing th e  s a m e  
re g im e  as  for MP.
B M SC  culture and lentiviral transduction
B M S C  w e re  o b ta in ed  from fem urs  o f  adult fe m a le  S p ra g u e - D a w le y  rats  (n =4) as  previously  
d escr ib ed '3,286 (Fig. lB ) .  B M S C  at  p a s s a g e  o  w e re  t ran sd u ced  o vern ig h t  u s in g  lentiviral vectors  
e n c o d in g  for g reen  f lu o re sc e n t  protein  (GFP) a t  an M OI o f  1 5 0  '75, 286 (Fig. lB ) .  T ransdu ced  
B M S C  w e re  cultured in D - 10  m e d iu m  at  37 °C/5 %  C 0 2. B M S C  from the third p a s s a g e  (Fig. 1C) 
w e re  used for th e  t r a n sp la n ta t io n  e x p e r im e n ts .  T h e  tran sd u ct ion  rate o f  the B M S C  w a s  
d e te rm in e d  using  a F A C Sca n /F A C S orte r  (Becton Dickinson Im m u n o c y to m e try  S y s t e m s  (BDIS) 
B io sc iences ,  S a n  Jo s e ,  CA). The n u m b e r  o f  v iable  (GFP-positive) cells  relat ive to the total 
n u m b e r  o f  cells  w a s  d e t e rm in e d  re ve a l in g  a t ransduct ion  rate  o f  63 % .
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Transplantation o f  BM SC
A t three days  after  injury, 2 4  rats  (6 rats  from  each  group) w e re  a n a e s th e t iz e d  with 
in t ra p e r i to n e a l  in ject ions  o f  6 0  m g /k g  o f  Kedam ine HCl (Phoenix  Pd arm aceu tica ls)  and  0 .4  
m g / k g  o Sm n d ito  mid ine (D om itor;  Orion C orpora  t ion). The  1 0 th th orac ic  sp inal  cord s e g m e n t  
w a s  e x p o s e d  and 5 ml D M E M  with 1 x  1 0 6 B M S C  (Fig. 1A) w a s  in jected into the contusion  
e p ic e n t e r 13. Four extra con tu se d  rats w e re  s imilarly  in jected  and  perfused with fixatide (sad 
below) 15 m in latnr. Thns d rats  w e re  used  to dnrnrm ine th e  n u m b e r  o f  B M S C  in th e  contusion  
a t  15 min post-in jnction. All B M S C  in ject ions  w e re  p er fo rm ed  by the s a m e  invest igator .  A ftsr  
the injectionn, the rats  w e re  m a in ta in e b  a s  Sescribnd previously286.
General histology
Three days  (n=24)  and  ten  d ays  (n=48) after  injury, rats  w e re  a n a e s th e t iz e d  with an 
in t iap b ri to n eo l  in ject icn  o f  9 0  m g/kn  o f  K s ta m in e  HCl (Ph oed ix  P h a r m a c e u t i t a l f  and 0 .6  
m g / k g  of7 m ed ito m id in e  (Orion C orporat ion ).  After  d e e p  sedntinn w a s  oon firm ed , 0 . 1  rrH 
H n f a r i n e  (50 0  IU; H e n ry  Sghein , Melvil le ,  N's'  ^ USA) w a s  rnjncted inter the left v entric le  o f  the 
heart.  Then , 5013 ml sa l ine  fo llowed by 5 0 0  ml ice-cold 4 %  p a raeorm aldehyde in p h o s p h a te  
buffer (PB; 0 . 1  M, pH 7.4) w a s  p u m p e d  through the va scu la r  syntem. S p in t l  cords  w e re  
rem oved  w i th su t  d a m a g in g  thd a n a to m ica l  idtegrity , post-fixad for 2 4  h is  the s a m f  fixative, 
and  tran sferred  to 3 0  %  tu cro se  in phesp h ata -b u ffered  sa l in e  (PBS; o .i  M, pH 7 . f )  'foi^  48  h. A  
1 2  m m  long sp ina l  cord s e g m e n t  cen tero d  a t  th e  con tu s ion  w a s  cut into ;>o juui^  thick 
horizontal c ryosta t  se ct io n s  whlclr w e  re m o u n te d  on g la s s  slides.
Immunocytochemicnl pronedures
For character izati  on o f  fd d B M S C ,  8 -w et  ch am b n r  g la r s  s lider  (BD Falcon; B D  B iosc ian ces ,  
Bedford, MA) w e re  coatdd with 1 0 0  (jil/ml poly-D-lysine For 1 li at room  t s m p e r a tu r e .  Atter 
w a sh in g  2 x 5  m ic  w i t l  doufle -disti l led  w a te ^  3 0 0 0  B M S C  in 2 5 0  jjlI D - 10  m e d io m  w e re  p lated  
p e r  well .  After  two days a t  3 s  °C/5 %  C O 2 the cokureu w srn  w a sh e d  3 x 5  min with P B S  and 
fixed with 4  %  p a ra fo rm a ld e h y d e  in P B ( 10  m in , roo m t e m p e  ratu re. N e x t 1 the cultu res w e re  
w a sh e d  5 x 5  min with PBS,  incubated with 5 %  norm al g o t s sdrum  (NGS) in P B S  for 30  m in u 
and  then in c u b t te d  overn ig h t  a t  4  sC with antiloodies Bgainst: C D 9 0  (i: icxo; I m m s n o t e c h, 
Brusse ls ,  Be lg ium ), C D 1 0 5  (r : 'd0 0 ;  N ^ ,  B e a fo e  D icken son ),  C D 3 4  (1 : i 0 0 i 8 G 1  2 cl nnn IgC^^ 
Becton  D ic l< a i s to ) ,  C D 4 5  (1:10)0;  H 1 3 0  c lo ne  Ig G 1, Becton  D ickenson),  and  HU'l-DR ( 1 : 1 0 0 ;  
Dako, G lostrup , D en m ark )  diluted in PB with 5 %  N G S .  S o m e  cultures w a re  incubated  with PB 
with 5 %  N G S  only. and served  a s  n e g a t iv e  (no pr im ary  antibody) contro ls  to exc lude a fa lse- 
posit ive  outcom e° IMext, culturen w e re  w a sh e d  3 x 5 min with PB and  then in tub ated  with goat- 
a n t i -m o u se  IgG -Altxa  5 9 s  ( 1 : 5 0 0  io PB; M o k c u ^  P ro b ts ,  C arlsbad , CA) for 2  h a t  room 
te m p e r a tu r e .  A fterw a rd s ,  cultures  w e re  w a s h e d  3 x  5 min with PB and  covered with a g la s s  slip
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with V ectash ie ld  and  DAPI (Vector Laboratories ,  Inc., B ur l ing am  e, CA). The  slide;;; w e re  
e x a m in e d  and  im a L e s  w e re  taken with an  O ly m p u s  Fluoeiew F V 1 0 0 0  confocal m icroscope .
For im m u n o s ta in in g  of7 activated m a c r o p e a g e s ,  every 1 0 th c ryosta t  sect ion  w a s  pre ­
incubated a t  room  te m p e r a tu r e  for 30  min in 5 %  N G S  and 0 . 3 %  Triton X - 1 0 0  in 0 .0 1  M P B S  
(pH 7.4) and  th tn  incubated  with an t ib od ie s  a g a in s t  ED1 ( s :2 0 0 ;  Sero tec ,  Raleigh, NC) in 5 %  
N G S  for 2  h at room  tem  pe ra tu re  fo llowed by overn igh t  incubation a t  4  °C. Afteh w a sh in  g  3 x  5 
min with PBS,  sect io n s  w e re  incuh ated with goah an ti-m o u so  Alexa  ,9 4  anti  bodi es  ( 1 :2 0 0 ;  
M olecu la r  P r o f t s )  in P B S  (0 .0 1  M; pH 7.4) a t  room  t r m p t F a t u r e  for 2  Is. The  s e c t iu s s  w e re  
then w a sh e d  r n d  covered with f  g la ss  slips in V ectash ie ld  with DAPI (Vectur Labosatories ,  
Inc.). T S e  coversl ips  w e re  s to le d  w t h  nail polish. All seca ions w e re  stored at - 2 0  °C  until 
e n c ly s is .
Qeantitative acsesacreats
For a n a ly s is  obG FP-posih iee  B M S C ,  eyery  1 0 th c a^ci^tat a ecr i on w a s  covered  with a g la s s  slip 
with V ectash i  eld m o u n t in g  m e d id m  with D A P I (Vectoe Laboradoriee, In c) . S te re o in v e s t ig a t o r  
(MicroBrightFie ld  Inc., Colchester ,  VA, USA) w a s  used  to d e te r m in e  th e  nu m b e  rs o f  surviving 
B M S C  in th e  c o n tu s io n 168. The  wect ionr  w e re  2 0  0 m m  a p a r t  s p a n n i n g  tha width o f  the sp inal  
cord. In e v ery  rect ion  c o n ta in in g  G S P  posit ive cells ,  the dra n s p la n t e d  area  w a s  outlined 
m a n u a l ly  a t  4 X  m a g n i f t a a io n  an d  covered  hy a 215c) x  2 5 0  fom grid. A t  6 0 X  m adnifihation with 
oil i ro m ers icn ,  G F b -po s it ive  ceils  with a d isce rn a b le  D A PI-posit ive  nucieuw wern m arked  using 
the optical f ract iona(or  witM a 6 0  x  6 0  fim c^ourrtinsih Urcmh. N um beut w e se  corresSeW for the 63 
%  tra nsd uction note ob the tf l\/l Î2C wi th i_^-Cf |tPi For eacV o i  the g rou ps ,  BM  SC  survival w a s  
cnlculated as  the n u m b e r  o f  B M S C  relative to the n u m b e r  oh B M S C  at 15 m in after  
t ra n sp la n ta t i  on (wh icF w a s  1 a 8 t 5 9  ± n r  9; SEM  , n c 4 )  , Td e effect  e f  t re a tm  e n t on B M S C  
survivai w a s  a c n e sn e f  by e x e r e t a in g  B M S C  uurvival f"oa eiachi g roup  as  a p e r c e n t a g e  of7that in 
controls.  For a n r l s s i s  o f  m a c ro fh w g n s  w e  e m p lo y e d  a m eth o d  previousln e m p lo y e d  Hayashi 
and  oolleaguhtin3i This m y th o d  uses  'thn-eie se ct io n s  p er  rat 'for e x a m in a t io n :  o n a  sect ion 
tCroueL the; c e n te r  c f  thw c o n tu n io n / tr a n s p ia e t  (vui'tt t i e  d o n s e s t  ce l le la  2 s ta in in g),  and 
suctions  2 0 0  mm cinsisinl and  ventral to tFn ccn ter .  T h r  a rea  fractio at o 2 stai n in g  in th e se  
sact ion s  w a s  h o term inen  u s in g  Sii^d eEFciol< 4 . i ; 0 . i a  henthllloent I m a g in g  I n n rv a t io n s ,  Inc, 
S a n ta  f i o n i c a ,  CA, USA) and  nx d 'cnaed  as  a p ^ rc:u;ii t^£ijge o f  th at  in control a n im a ls .
Statistica/ aoalysis
S ig m a n ta t ®  (Systat Scftwarn , Inc., S a n  Jo se ,  CA, U s a ) w a e  used tor statistical a n a ly s e s  using 
o n e -w a y  A N  O V A  and the Bonferroni povt-hoc /est.  D iftetences  w e re  a c c e p te d  at p < 0 .0 5 .
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Ethics and surgical approval
All rats used in this study w e re  housed accord ing  to the gu id e lines  o f  the N a t io n a l  Institute  o f  
Health  and  U nited S t a te s  D e p a r t m e n t  o f  Agriculture. The  described  an im a l  p ro ced ures  w e re  
a p p r o v e d  by the Institutional A n im a l  C a re  and U se  C o m m itt e e  at the J o h n s  H opkins  
University .
RESULTS
Characterization o f  B M SC  in vitro
Cultured G FP-p os it ive  cells  e x p re s s e d  C D 9 0  (Fig. 2A) and  C D 1 0 5  (Fig. 2B). T h e s e  two 
extrace l lu lar  m o lecu les  are  both well-known B M S C  m ark ers38,98. N o n e  o f  the cells  e x p re sse d  
the blood cell m arkers ,  C D 3 4  (Oig. 2C) and  C D 4 5  or the im m u n e  cell marker,  HLA-DR. No 
s ta in in g  w a s  v is ible  i f  the pr im ary  an t ib od y  w a s  om itted .  The  data  c h aracter ize  th e  cells  used 
for t r a n sp la n ta t io n  a s  B M S C .
( a )  — ( b ) - ' ( c )
Fig. 2 . Characterization o f in vitro. Cultured cells expressed the BMSC markers, CD90  (a) and CD105  (b), but 
n ot the blood cell marker, CD34 (c) . Scale lia r=io |xm.
CsA, MC, and M P reduces macrophage infiltration into the spinal cord contusion
Mi oroscopie  a na lys is  o f  m a c ro p h a g e  p i e s e n c e  in the con tu s ion  revea led  high n u m b e rs  in 
contro ls  (Fig. 3a) c o m p a ie d  to tre a te d  rats; (Fig. 3b) a t  3 d ays  after  injury. T h e  nu m b e rs  
a p p e a r e d  in c re a se d  in tre a te d  rats  at 1 0  d ays  (Fig. 3c) c o m p a r e d  to 3 days  (Fig. 3b) after 
con tu s ion .  Q uan t i ta t ive  a n a ly s is  d e m o n s tra te d  th at  a t  th ree  days post-injury, relative to 
c o n trols, m a  c ro p h a g  e inSltret  ion w e  s 4 6  ± 1 0  %  with CtA-, 47  ± 3 %  with MC-, and  63 ± 3 %  
with M P - t r e a tm e n t  SFig. 3dS. A N O V A  revea led  that the nu m b e r  for each  o f  the t r e a t m e n t  
g ro u p s  w a s  s ign if icantly  sm a l le r  ( p < o .0 0 1 )  hhan th at  for contro ls.  Thus t reatm en t- ind u ced  
reducti an  w a s  54  %  wrth CsA, 513 %  with MC, and  37 %  with M P  c o m p a r e d  to controls .
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T re a tm e n t- in d u ce d  reduction w a s  not  s ign if icantly  different from  contro ls  a t  ten d a ys  post­
injury (Fig. 3d). T h e se  results  sh ow ed  th at all th ree drugs w h en  a d m in is te re d  fo l low ing the 
t r e a t m e n t  r e g im e  described  a b o ve  reduced m a c r o p h a g e  infi ltration into the adult  rat sp inal  
cord contusion  at th ree d ays  post-injury.
BM SC  survival in contusion is not affected by CsA, MC, or M P treatment
B M S C  w e re  p r e s e n t  in th e  contusion  at seve n  days  post-in ject ion (Fig. 4a).  Q u an t i ta t ive  
a n a ly s is  revea led  th at  B M S C  survival in th e  con tu s ion  at seve n  days  post-in ject ion w a s  2 7  ±  4  
%  with CsA, 2 4  ±  4  %  with MC, and  33 ±  2  %  with M P  tre a te d  rats. In sa l ine- in jec ted  control 
rats , B M S C  survival w a s  2 1  ±  7 % .  To a s s e s s  the effects  o f  t re a tm e n t ,  w e  e x p re s s e d  B M S C  
survival in each  t r e a t m e n t  g rou p  relat ive  to th at  in th e  control g rou p  (Fig. 4b). W e found that 
B M S C  survival w a s  1 2 6  ±  17  %  with CsA, 1 1 1  ±  19  %  with M C, and  155 ±  1 2  %  with M P  treated  
rats re lat ive  to control rats (Fig. 4b). A N O V A  revea led  no difference  in B M S C  survival b e tw e e n  
t r e a t m e n t  an d  control g ro u p s  ( p = 0 . 16 ) .
Fig. 3 . Cyclosporine A (CsA), minocycline (MC), and 
methylprednisolone (MP) treatment reduced macrophage 
infiltration into the contusion. Photomicrographs of ED-1 - 
positive cells in control rats (a) and CsA-treated rats (b) at 
3 days postcontusion and in CsA-treated rats at 10  days 
postcontusion (b). In panel (c) the more intense staining 
was found associated with cellular debris. (d) Bar graph 
shows that at 3 days postinjury (open bars) relative to 
controls (Con), macrophages infiltration in the contusion 
was decreased significantly with CsA, MC, and MP 
treatment. At 10  days postinjury (solid bars), the decrease 
in macrophage presence in the contusion of treated rats 
was not statistically different from that in Con. ^Significant 
difference between treated and Con groups at 3 days 
postinjury with P<0 .0 0 1 .
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(a)
Fig. 4 . Cyclosporine A (CsA), minocycline (MC), and methylprednisolone (MP) treatment did not improve bone 
marrow stromal cell (BMSC) survival. (a) Photomicrograph of green fluorescent protein-positive cells within the 
contusion at 7 days postinjection. (b) Bar graph showing BMSC survival relative to controls (Con). The differences 
were not statistically different, although there was a trend towards higher numbers in CsA-treated rats.
BM SC  presence initiates macrophage infiltration into the spinal cord contusion.
W e a s s e s s e d  the effect o f  a B M S C  t r a n s p la n t  on m a c r o p h a g e  p r e s e n c e  in th e  con tu s ion  a t  ten 
days  post-in jury relat ive to th at  a t  three d ays  post-injury. With a B M S C  tra n sp la n t ,  
m a c r o p h a g e  infi ltration re lat ive  to contro ls  w a s  2 .4  fold in CsA- and  M P-treated  rats , and  6.9 
fold in M C -trea ted  rats. T h e se  d i fferences  w e re  s tat is t ically  s ign if ican t  ( p < o . o o i ) .  In the 
a b s e n c e  o f  a B M S C  tra n sp la n t ,  m a c r o p h a g e  p r e s e n c e  in treated  rats  re lat ive  to contro ls  w a s  
un ch a n g e d .  Our data  d e m o n s tr a te d  th at  the p r e s e n c e  o f  a B M S C  t r a n s p la n t  s ign if icantly  
in c re a se d  m a c r o p h a g e  infi ltration into the con tu sed  adult rat sp ina l  cord.
D ISCU SSIO N
Q u an ti ta t ive  in v e st ig a t io n s  have d e m o n s tra te d  th at  survival o f  B M S C  t r a n sp la n te d  into the 
c on tu sed  adult  rat s p in a l  cord is low ’70' 286. Previously, it w a s  p ro p o se d  th at  m a c r o p h a g e s  which 
are  natura lly  p r e s e n t  within an injury site are  involved in th e  loss  o f  B M S C  t r a n sp la n te d  into 
the centra l  ne rvou s  s y s t e m 9’ . O u r  p r e s e n t  resu lts  show ed that a d e c re a s e d  p r e s e n c e  o f  
activated m a c r o p h a g e s  at th e  t im e  o f  B M S C  injection (three days  post-injury)  do e s  not 
in c re a se  survival o f  grafted B M S C .  It is po ss ib le  th at  our t r e a t m e n t  r e g im e n s  fa iled to lower 
m a c r o p h a g e  infi ltration to a level w h e re  B M S C  survival w ould  have b een  im proved .  The  
m a x im u m  reduction which w a s  ach ieved  here  w a s  54% . B e c a u s e  m a c r o p h a g e  invas ion  into a 
sp inal  cord injury site  is typ ica l ly  la rge34, ’ 55, 3’ ’ th is  reduction m a y  still lea ve  m a n y  m a c r o p h a g e s  
th at  could poten tia l ly  contribute  to B M S C  loss.  An additional o bservat ion  is th at  th e  t r e a t m e n t  
effect which w a s  p r e s e n t  a t  th ree days  post-in jury w a s  not  s ign if ican t  at ten  days  post-injury.
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Although w e  used  t r e a t m e n t  protocols  known to effectively  reduce  the p r e s e n c e  o f  
m a c r o p h a g e s 22' ’77, 3" '  399, 403 th ey  m ig h t  not  have  b een  effect ive e n o u g h  for sufficient and 
pro lo n g ed  reduction o f  m a c r o p h a g e s .
An a l te rn a t iv e  e x p la n a t io n  for  the ob se rv e d  lack o f  im proved B M S C  survival w ould  be that 
a n y  t r e a tm e n t- in d u ce d  reduction in m a c r o p h a g e  p r e s e n c e  w a s  m a sk ed  by a su b se q u e n t  
in c re a se  in m a c r o p h a g e  infi ltration d u e  to the introduction o f  B M S C  into the e n v iro n m e n t .  
This notion is s u p p o rte d  by our data  b e c a u se  in a n im a ls  with a B M S C  t r a n s p la n t  w e  found 
th at  m a c r o p h a g e  infi ltration w a s  drastically  in crea sed .  It is likely th at  th e se  extra 
m a c r o p h a g e s  have e x a ce rb a te d  the loss o f  B M S C ’40. It is im p o r ta n t  to k e e p  in m ind  that other  
factors  than invaded  m a c r o p h a g e s  are  m o s t  likely a lso  involved in t r a n s p la n te d  B M S C  loss 
such as  the lack o f  oxygen a n d / o r  nutrients  within the d a m a g e d  t i s su e 470.
Previously, it w a s  reported  th at  B M S C  are  h y po - im m u n o g en ic ;  th ey  s u p p r e s s  the 
proliferation and  function o f  T-cells,  B-cells, natural killer cells ,  and dendritic  cells208' 424. 
H ow ever,  th e se  pub lications  did not in v e st ig a te  po ss ib le  effects o f  B M S C  on m a c r o p h a g e  
invas ion . It is poss ib le  that the im m u n o s u p p r e s s iv e  p ro p e r t ie s  o f  B M S C  af fect only  the 
a d a p t iv e  im m u n ity  du e  to the low  e x p re ss io n  level o f  h u m an  leukocyte a n t ig e n  (HLA) m ajor  
h istocom patib il ity  (M H C) c lass  I and  the a b s e n c e  o f  co-st im ulatory m o le c u le s208, 469. This  would 
exp la in  w h y  the recru itm en t o f  m a c r o p h a g e s  (acquired immunity) would not  be affected by 
B M S C .
L ow er in g  the n u m b e r  o f  m a c r o p h a g e s  in th e  injured sp ina l  cord n e e d s  to be a d d ressed  
with caution . It is well  known th at  m a c r o p h a g e s  can s u p p o rt  sp ina l  cord repa ir  by p ro m o tin g  
axon re g e n e ra t io n  and  m y e l inat io n  which m a y  be a c c o m p a n ie d  by im p ro ved  fu n ct io n ’46, 35°. 
T h e se  constructive  effects  occur while  m a c r o p h a g e s  a lso  exert  destructive  effects such as 
neural cell d e a th 400. B e c a u s e  o f  this dual role, d e c r e a s in g  th e  nu m b e r  o f  m a c r o p h a g e s  within a 
sp inal  cord injury could lead s im u lta n e o u s ly  to beneficial  and  d etr im e nta l  e f fects350. Thus it is 
im p o r ta n t  to aim  for a reduction in m a c r o p h a g e s  th at w ould not j e o p a r d iz e  their  posit ive  
contr ibutions  to sp ina l  cord repair .
CONCLUSION
W e h y po th es ized  that a d e c re a s e d  m a c r o p h a g e  p r e s e n c e  in an  adult  rat sp ina l  cord contusion  
would su p p o rt  survival o f  a B M S C  tra n sp la n t .  With CsA, M C, and  M P  t r e a t m e n t  w e  
successfu lly  lowered m a c r o p h a g e  infi ltration; however,  this reduction, which w a s  m a x im u m  54 
% ,  did not im p ro ve  t r a n s p la n te d  B M S C  survival.  Surpris ingly ,  w e  found th at  B M S C  p r e s e n c e  
in th e  con tu s ion  in reality  in c re a se d  m a c r o p h a g e  p r e s e n c e  by a lm o s t  4-fold. B a se d  on our 
current kn o w le d g e  it is to be e x p e c te d  that m a c r o p h a g e s  are  involved in the loss  o f  B M S C  
after  in jection into the injured sp inal  cord. The  f ind ing  that a la rge  d e c r e a s e  in m a c r o p h a g e
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infi ltration failed to im pro ve  survival o f  su b seq u en t ly  in jected B M S C ,  po int  at key roles  o f  other 
injury-related eve n ts  in the loss  o f  an in t rasp in a l  B M S C  tra n sp la n t .
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Functional recovery after transplantation
Locom otor  and  s e n so ry  function recovery  after  au to lo g o u s  b o n e  marrow/ s trom al cell
t r a n sp la n ta t io n  in the con tu sed  adult rat s p in a l  cord.
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INTRODUCTION
C o ntus ive  injury to the adult  rat th orac ic  sp inal  cord c a u se s  im m e d ia te  lo com otor  and  s e n so ry  
im p a ir m e n ts  o f  the h ind lim bs2’3, 246, 4° 8. Locom otor  function gradual ly  im p ro v e s  until a p la tea u  
is reached  after 2-5 w e e k s  d e p e n d in g  on the im p a c t  severity24, 6°  2°7, 33°. S p o n t a n e o u s  
restorat ion  o f  s e n s o ry  function is m ostly  a b s e n t ’76, 459 but s o m e  recovery  w a s  reported to occur 
m o n th s  after  the im p a c t27.
T r a n s p la n ta t io n  o f  rep a ir -p ro m o tin g  cells  into the con tu se d  sp inal  cord has been 
e x te n s ive ly  exp lo red  a s  an in tervent ion  to restore  function over  w h a t  is s p o n t a n e o u s l y  
o b se rv e d 29, 122 3’3, 325, 338. O n e  o f  the c a n d id a te  cell ty p e s  for sp ina l  cord repa ir  is the b o n e  m a rro w  
strom al cell (BM SC ).  T h e se  cells  a re  rela t ively  e a s y  to obtain  via a b o n e  m a rro w  b iop sy  which 
w a rra n ts  their  given p r o m ise  for  clinical a p p l ic a t io n 285, 325, 43°.
Currently, the ability o f  B M S C  t r a n s p la n ts  to restore  function after  sp ina l  cord contusion  is 
deb a ted .  S o m e  in vest ig ato rs  reported  benefic ia l  effects on m o to r  fu n ct io n ’69, ’79, 472 473 but 
others  are  in d i s a g r e e m e n t ’^ 385, 463. S p in a l  cord t i s su e  s p a r in g  h a s  b een  p r o p o se d  as  a 
pro b ab le  m e c h a n is m  o f  B M S C -m e d ia te d  re p a ir286, 3°4. Effects o f  a B M S C  graft  on s e n s o ry  
function restorat ion  after  sp ina l  cord con tu s ion  has  not  b een  described .
MATERIAL AND METHODS
Ethics and surgical approval
All rats  used in this  study w e re  housed  pre- and post-surgery  accord ing  to the N ational  
Institutes  o f  H ealth  and  the United S t a te s  D e p a r t m e n t  o f  Agriculture g u id e lines .  Air in the 
c a g e s  w a s  con tinu ous ly  refreshed and  w a te r  a n d  food w e re  a va i lab le  ad libitum. A t  all t im e s  
during th e  e x p e r im e n t ,  rats  w e re  kept within a double-barrier  facility. All a n im a l  p roced ures  
w e re  a p p r o v e d  by the Institutional A n im a l  C are  and  U se  C o m m itte e  a t  th e  J o h n s  H opkins  
University .
BM SC  culture and lentiviral transduction
B M S C  w e re  h arvested  from  the m a rro w  o f  the fem urs  o f  adult f e m a le  S p ra g u e - D a w le y  rats  
(n=4, 2 ° ° - 2 3 ° g ;  H ar lan ,  In d ia n a p o l is ,  IN, USA) accord ing  to prev iously  described  p ro to co ls ’3, 
359. Lentivira l vectors  e n co d in g  for g reen  f lu o rescen t  prote in  (GFP) w e re  p re p a re d  as  
prev iously  d e sc r ib e d ’75 and  used  a t  an M OI o f  ’ 5 °  to tra n s fe c t  B M S C  at  p a s s a g e  ° .  For 
t r a n sp la n ta t io n ,  B M S C  from  p a s s a g e  4  w e re  u sed  o f  which 6 3 %  e x p re s s e d  G F P  as  d e te rm in e d  
by F A C Sca n /F A C S orte r  (Becton Dickinson Im m u n o c yto m e try  S y s t e m s  B iosc iences ,  S a n  Jose ,  
CA, USA). Previously, w e  sh ow ed  that over  9 5 %  o f  the cells  w e  used for in trasp inal  injection 
e x p re s s e d  C D 9 °  and  C D ’ ° 5 ,  which are  typical B M S C  m arkers,  and  n o n e  o f  th em  e x p re s s e d  
C D 3 4  and  CD 4 5,  both blood cell m arkers ,  or HLA-DR, an im m u n e  cell m ark er359.
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Pre-surgery procedures
Adult fe m a le  S p ra g u e - D a w le y  rats (n = 4 0 ,  2 0 0 - 2 3 0 g ;  H adn n)  wi^re; sedatkd  with 
in t -a p e r i to n e a l  injec1;ions of7 6 0  m g / k g  K e ta m in e  HCl (Phoenix  Ohnrmoceutlcals ,  S 3. Jo s e c h ,  
M D , USA) and  0 .4  te g/kg  rr^ecJi1;ot^icdine (D o m ito s® ,  an a lp h a -2 -a d re n e rg ic  agon is t ;  Orion 
C o roorat ion ,  E spoo, F in land).  After d e e p  aedction  w a s  verified, the back o f  the; rats  w a s  ohaved 
and c le a n e d  with Beeadine  and  7 0 %  alcohol,  Lacrilube B in tm e n t  :s npplied  to tli e e ) e s ,  and 
0 m g / k g  g e n ta m ic in  (Abbot L a b o ra to r ie s  Nosta (ilhiicEjjjio, IL, USA) w a s  a d m in istere d  
intram uscularly .
Spinal cord contusion
The lower thoracic  (T) spinal c r lu m n  w a s  expooed , 1tloe lom ina  o f  the T 9  w a s  rem oved ,  and  the; 
e x p o s e d  underly ing  T 1 0  sp inal  eord o e g m e n t  c o n tu se d  using  th e  Infinite H orizon Im p a c to r  at 
a force o f  2 0 0  k D y n e 36, r77. C o e s ic te n c y  ne tw e en  rats w a s  guarnnSned usiir'igt th e  records  on tg h 
comn>j'e;s^ion rate  an d  velocity b f  tan im unctot;  rain from  wXieh 1;o ns;e va lu e  s Usviatrrd ovwr r %  
w e re  excluded from  the sltudy. TOe w o u n d  rite w a s  rinsmscJ with phosehate-bufpered sa l in e  (XBS) 
with 0 . 1 %  g e n ta m ic in  (Abbot Laboratories)  a n k  the m usclns  w e re  c losed  in l y^.'ei'ss us i ng 5 .0  
sutures.  T h e  skin w a s  c losed with Michel w o u n d  clips.
Cost-contusion procedures
After c losure od the w o u nd ,  the rats  rece ived  a s u b c u t r n r o u s  injection of7 1 .  m g /k g  
a t ip a m e z o le  hrdrochloride ( a n t i s e d a n ® ;  an a lp h a  2 -ad ren n rr ic  nn ta gon ie t ;  tKtzgo inc.,  N e w  
York, NY, USA), to reverse  th e  cedat ive  and  u n a lg e s ia  eObcts cC m ed ito m id inx .  T en  ml l ac ta  ted 
Ringur 'r  solution w a s  injucted sub ce to n e n u s ly  and  5^ i g^/ l^cjsr g e n ta m ic ie  (/ l^aijo'tt; Labotatories)  
iritramr-^culai'ly. T h e  rato w e r e  kept  in a sm all  a n im c l  in c e b a to t  a t  37 °C  untii 'full / e c o c e x  and 
wnre tkiern returned  tee their c a g e s i  Until thuE) se co n d  srur'j^ fesr;!) at th ree  days  post-contusion ,  the 
tats  received daily 5 ml R in g e r 's  solution (su bcutaneour) ,  (5 mebkb c e n ta m ic i  n (AOOca 
Laboratories ;  intram usculnrly),  an d 0 .0 5  m g / k g  Ouprnnorphin (Bu^|i'e;n(r^<r>; SecSitt  Xe nckirh) 
P h a rm a ce u t ie a js  Inc., R ichm ond, VA; su b cu tan eo us lyb  The b ladder  w a s  m o e u a l ly  empOied 
tw ica frier day.
CsA admicistration
S ta r t in g  5 min after  the contuaive  injury, c o n e u e e i  rats  received CeA (Bedford Labs; OeObord, 
O H , USA) sub cu tan eo ue ly  o n c e  p e r  d ay  a t  a Cose  oC 30  m g t k i  fit- 1; he Oirst thoee dnyt after 
contusion  injury and  15 m g /k g  for the fol lowin g  d ays  tn ro u o e su t  the survival p n do d  r°3.
Q f0 er eo nfereU  rafr  reeelveU sa i in e  injention s.
Chaptsr 6
BM SC  transplantation
A t three d ays  after  con tu s ion ,  rats  w e r e  se d a te d  with in t ra p e r i to n e a l  in jec t io ns  o f  6 0  m g / k g  
K e ta m in e  HCl (Phoenix  Ph arm ace ut ica ls )  a n f  0 . 4  m s / k g  m ed ito m id in e  (Orion C o r p o ra t io n )  
The  T 1 0  s f i n e l  cord s e / m e n t  w a a  re -exp osed  and  1 x  1 0 6 B M S C  in D M E M  se  D M E M  a lon e  
(total v o lu m t  w a s  5 / J  if1 both case s)  w a s  in jected into the conUusion e p ic e n t e r  u s in g  a 
H a m / lo n  syr inge  with a pulled g la s s  n e a d le  at tach ad  (tip d ia m e te r :  1 5 0  frm) fixed within a 
m ic ro m a n ip u  lator '75,4o8. After in jection, t S s  w o u n S  w a s  c losed  a s  dencribed above.
Post-injection procedures
After c losure o f  thn w o u nd ,  raSs wnre  /ullg recovered in a sm all  a n im a l  incubator  a t  3C°C b e ftae  
b e in g  re tv rn ed  tn their  c a g e s .  T h e  rats  rece ived  5 ml L actated  R in ger 'c  solution daily for 2  days  
(subcutaneously)  a n /  6 m g / k g  g e n fa m ic in  (AbOoUt Caboratories) daily for eeven days  cost-  
injection tin0r a 72uscularl)7). The  rats  wern  in jected  with 07.03 m g / k g  B apaen o rp h in  (Rackitt 
B enck iser  Phanm aceutica ls  Inc.; rubcutaneonsly)  daily for th e  first  3 days  post- in ject ioa .  
B lad ders  w e re  m a n u a l ly  e m p tie d  twice pier d ay  until reflex vo id ing  s ta i ted .  Throughout the 
re m a in d e r  o f  the e x p e s im e n t  th e  rats  w o re  m o nitored  daily. In c a s e  of7 c s i n  or d is tress  rats 
w e re  given  0 .0 3  m g /C g  e u o r e n s r p h i c  (RecCitt Bnnckixer Phanm aceutica ls  Inc.) su b cu tan eo us ly  
daily for 3 days.
Experimental groups
Rats with a T 1 0  con tu s icn  received e ither  B M S C / D M C M  or D M E M  only'’ and  w e re  teevted with 
C sA  c r  s a ! i r e .  Thus  th ere  w e re  e  e x p e r im e  ntal gr  oups:  B M S C / C s A  (n=9),  B M S C / s a l in e  (n=8), 
D M E M / C s A  ( n = i2 ) ,  and  D M E M / s a l i n e  ( n = i0 ) .
Testine o f  locomotor function
Ali rets  w e re  iecluded in lo com otor  fu n c t ir e  test ingi  A u to m a te d  h in d i im !  m o v a m e n ts  w e re  
a n a ly z e d  for eight w e e k s  p ost-contusion  rn in g  th e  B a se o -B e a t t ie -B re e n a h a n  ( fB B )  te s t23. Rats 
w e re  fa m il ia r ized  with the o p e n  field before injury. T h ree  days  a fter  th e  contusion ,  ju s t  before 
inj ection , rats  w e re  te s te d  and  th o se  with a score ab o ve  5 w e re  rem o ved  from  the study. Rats  
w e re  tes ted  o n c e  a w e e k  for e ight w e e k s  after  the injection into the contusion  e p ic e n t e r  over  a 
p e  riod o f  4  m in by two e x a m in e r s  oblivious o f  the t r e a tm e n ts .
Sp ecif ic  locom otion-re lated  fea tu re s  w e re  a s s e s s e d  u s in g  the B B B  sub-score220. Paw  
po sit ion (parallel  initially o r  at liftoff) and  to e  c le a r a n c e  (occasional ,  frequent,  or con sis ten t)  
for each  hind paw, and  the tail posit ion  (up, down) and  trunk stabili ty  (yes, no) w e re  
d e te rm in e d .  The  scores  o f  both limbs and  tail and  trunk w a s  s u m m e d  (m ax im u m  score 
po ss ib le  w a s  8).
The  pa ttern  o f  locom otion w a s  a s s e s s e d  u s in g  the footpr in t  a n a ly s is  which w a s  modified 
from that o f  D e M edina ce l i  and  c o l le a g u e s 99. H in d p a w s  w e re  inked and  footpr ints  w e re  m a d e
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on p a p e r  within a run w a y  o f  about 1 m len gth  and  7 cm  width. The; prints  w e re  used to 
m e a su r e  stride length , b a se  o f  sup port ,  nnd an g le  o f  paw/ rotation. A v e r a g e  v a lu e s  per  paw/ 
wene ca lcu lated  from  at  leas  t 5 sequ ent ia l  stepn. V alnee for both p a w s  w e re  a v e ra g e d .  Stride; 
length  w a s  def ined  h/ the d is ta n ce  b e tw e e n  the centra l  p a d s  o f  two con secu tive  prints  on 
each  side.  B a s e  o f  su p p o rt  w a s  d e t e rm in e d  by m e a su r in g  the core  to core d is ta n ce  o f  the hind 
p a w s  centra l  p a ds .  Limb) rotation was de f ined  by the a n g le  fo rm ed by the in tersect ion  o f  the 
line th rough the prin t o f  the third digit nn d the pr int  r e p r e s e n t in g  the m e t a n a rso p h a la n g e a l  
io int and  the line shrough th e centrai  pad  paral le l  to the walki ng direction. Footprint  te s t in g  
w a s  p er fo rm ed  a t  4  and  8 w e e k s  after  t r a n sp la n ta t io n  at which t im e s  all rats  exhibited w e ig h t  
support .
S e n s o r im o to r  function o f  the h indlim bs w a s  a s s e s s e d  a t  four and  eight w e e k s  post­
contusion  u s in g  the horizontal ladder  te s t218. W e used a 1 0 0  cm  long horizontal ladder  which 
the rats  crovsed th ree t fm es  each test.  The  pa s s a g e s  w e re  v id e o ta p e d  a nd later  p layed  back for 
accu rate  eva lu at ion .  O nly the m idd le  6 0  cm  o f  the la dd e  v w e s  used  for m e a s u r e m e n  ts. Sm all  
(foot: or pa rt  o .  foot),  m e d iu m  (foot and  pa rt  o f  lower leg), and  la rge (full leg) s lips  w e re  
counted  and  e x p re s s e d  as  a p e r c e n t a g e  o f  the total n u m b e r  o f  s teps .
Testing o f  sensory function
M e ch a n ica l  al lodynia w a s  d e te rm in e d  by m e a su r in g  foot w ithdrawal in r e s p o n s e  to a norm ally  
inn ocu ou s  m ech an ica l  s t im ulus  a p p l ie d  with an (electronic) von Frey a n e a s t h e s io m e t e r 69, 70. 
D uring  the test ,  rats  w e re  in a p lex ig las  box with an e le v a te d  m e sh  floor. The  rats  w e re  
acc l im ated  for 5 min before tes t in g .  T h e  von Frey tip w a s  a p p l ie d  p erpen d icu lar ly  to the mid- 
p la n ta r  a rea  o f  each  hind p a w  and d e p re s s e d  until p a w  withdrawal,  at which t im e  th e  p re ssu re  
(in g) w a s  recorded (3 t im e s  each  test).  The  v a lu es  for b o t t  p a w s  w e re  a v e ra g e d .
Withdrawal r e s p o n s e  to a no rm ally  inn ocu ou s  h eat  source,  a p p l ie d  u s in g  a H a rg re a v e '  s 
h eat  source, w a s  used to te s t  th erm al h y p e r a lg e s ia 160. T h e  rats w e re  kept  in a p lex ig las  box 
with an e le v a te d  m e sh  floor for 5 min to a cc l im ate .  The  rad ian t  h e a t  source  v^th c o n s t a n t  
in tens ity  w a s  a im ed  a t  th e  m id -p la n ta r  a rea  o f  each  hind pawn. T h e  t im e  Sin sec) from ¡nitial 
heat  source activation to p a w  withdrawal w a s  recorded. A  seco nd  und third m e a s u r e m e n t  wus 
per fo rm ed  5 and  1 0  min later. The  v a lu es  from  both p v w s  weve  evennged.
Statistical analysis
O n e -w a y  a n a ly s is  o f  v a r ia n ce  (ANOVA) followed by Fisher 's  proteofed  leust-s ign incant 
d ifference (PLSD ) te s t  w a s  used  to d e te r m in e  statistical pif ferences  b e tw e e n  grou p s .  In c a s e  
o f  unequal v a r ia n ce  (F test) ,  a n o n p a r a m e t r i c  a n a ly s is  (Kruskal-Wallis te s t  fo llowed by M a n n ­
W hitney  U-test) w a s  used. Statist ica l ly  s ign if ican t  d if fe re nces  w e r e  a c c e p te d  a t  P < 0 .0 5 .
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RESULTS
Surgery data
Forty-eight rats  w e re  included in th is  study. All rats  w e re  con tu se d  and  th ree days  later 
in jected with B M S C / D M E M  (n = 17 )  or  D M E M  only (n=22)  into the contusion  e p ic e n te r .  Two 
rats died prior to the t r a n sp la n ta t io n  surgery. S e v e n  rats  w e re  re m o ved  from  the study 
b e c a u se  their  B B B  score  w a s  higher than 5 a t  3 days post-contusion  (n=5) or  their  im p a c t  
p a r a m e te r s  w e re  over  5 %  o f f  from the in te n d e d  v a lu es  (n=2) .  N o n e  o f  the in jected rats  died 
during their  survival period.
BM SC  transplants did not improve open field locomotor ability
A u to m a te d  o p e n  field lo com otor  function w a s  eva luated  u s in g  th e  B B B  te s t23, 24 and  a n a ly z e d  
using  tw o-way A N O V A ,  which did not  sh ow  a n y  d i fferences  b e tw e e n  t r e a t m e n t  g ro u p s  and  the 
control group. The  a v e r a g e  B B B  score  o f  control ( D M E M /s a l in e )  rats w a s  1 1 . 0  ±  0 . 0  (SEM) at 
e ight w e e k s  after injection into the con tus ion .  T h e  o ther  g ro u p s  had sim ilar  scores;  1 1 . 4  ± 0 .2  
for the B M S C / s a l in e  group,  1 1 . 1  ± 0 . 1  for the D M E M / C s A  group, and  1 0 . 9  ± 0 . 1  for the 
B M S C / C s A  group (Fig. 1A). All rats reached  the p la te a u  score  o f  11  at 3-4 w e e k s  post- im pact ,  
which w a s  c o n s is te n t  with previously  published data  for rats  with a s im ilar  con tu s io n  o n ly60. 
The  score  o f  11  reflects the ability to su p p o rt  their  w e ig h t  on their  h indlim bs and  to m ak e  
frequently  to c o n s is te n t ly  p la n ta r  s t e p s  w ith ou t fo relim b-hindlim b coordination .
BM SC  transplants increased open field  locomotion-related features (BBB sub-score).
The sensit ivity  o f  the B B B  sca le  can be  in crea sed  by e v a lu at in g  individual character is t ics  o f  
lo com otor  function u s in g  the B B B  sub-scoring sca le 220. T wo-w ay A N O V A  show ed sign if icant 
d ifferences  ac ro ss  t r e a t m e n t  g ro u p s  (F (3,252) =  55.6; p < 0 . 0 0 0 1 ) .  For control rats  the B B B  sub­
score  w a s  1 . 4  ± 0 .3  (SEM) at e ight w e e k s  after  in jection. Rats  with a B M S C  t r a n s p la n t  
exhibited a score  o f  5.7 ± 0 .3  which reflected a s ign if ican t  4-fold in c re a se  c o m p a r e d  to contro ls  
The  difference  b e tw e e n  th e se  B M S C  treated  rats and  contro ls  b e c a m e  s ign if icantly  not iceab le  
s tart in g  th ree w e e k s  p o s t - t ra n sp la n ta t io n  (Fig 1B) .  B e tw e e n  th ree  and  six w e e k s  after 
t r a n sp la n ta t io n ,  C sA  treated  rats had higher sub-scores than contro ls  but this effect w a s  no 
long er  p r e s e n t  a t  seve n  or at e igh t  w e e k s .  The  scores  in rats with B M S C  and C sA  w e re  not 
d ifferent from  controls.
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Fig. i .  BMSC did not improve automated hind limb movements in the open field but enhanced locomotion-related 
features. Automated hind limb movements were assessed using the BBB scale and locomotion-related features were 
assessed using the BBB Sub-scoring scale. A. None of the groups demonstrated improved BBB scores over that of the 
controls. B. Rats witha BMSC transplant only (squares) reached significant higher scores than rats with controls with 
DMEM injections (circles), rats with DMEM injection and CsA treatment (quadrilaterals), and rats with BMSC 
transplants and CsA treatment (triangles). In both graphs the error bars indicate the standard deviation of the mean. 
Single asterisks: significant difference between BMSC/saline group and DMEM/saline (control) group (p<0.05  at 3 
and 4  weeks; p<o.oi at 5-8 weeks). Double asterisks: significant difference between BMSC/saline group and 
DMEM/CsA and BMSC/CsA grou p (p< 0.05  at 5 and 6 weeks; p<o.oi at 7 and 8 weeks). Number sign: significant 
d ifference between DMEM*/CsA group and DMEM/saline group) (p<0.05  at 4-8 weeks). Section sign: si gnificant 
difference between BMSC/CsA group and DMEM/saline group (p<o.oi a t4 -8 weeks).
BM SC  transplants improved some aspects o f  the pattern o f  locomotion
Footprint  a n a ly s is  w a s  used  to in v est ig ate  c h a n g e s  in stride length , b a s e  o f  sup port ,  and 
a n g le  o f  p a w  rotation which are fe a tu re s  o f  th e  p a ttern  o f  locom otion. .Ait e igh t  w e e k s  after 
injection into the con tu s ion ,  o n e - w a y  A N O V A  show ed no d ifferences  a m o n g  g ro u p s  in str ide 
length  (F (3.14) =  1 . 17 ;  p = o .3 5 ;  Fig. 2A) or in b a s e  o f  s u p p o rt  (F (3.17) =  1 .9 4 ;  p =  0 . 1 6 ,  Fig. 2B). 
O n e -w a y  A N O V A  did reveal d i fferences  in a n g le  o f  hind p a w  rotation (F (3,115) =  8 .29 ;  
p = 0 . 0 0 2 ,  Fig. 2C). Tukey post-h oc  c o m p a r is o n  sOowed th at  a B M S C  t r a n s p la n t  result;,  in a 
2 6 %  sm a lle r  a n g le  o f  rotation (M =  19 .7 ;  9 5 %  CI [18 .7, 20.7])  than (control an im alh  (M/I =  26 .5 ;  
9 5 %  CI [26 .0 ,  27.0] ;  Fig. 2C). Rats  th at  rece ived  ChA had a 1 9 %  sm a lle r  a n g le  o f  rotation (M =  
2 1 .5 ;  9 5 %  CI [20.5, 22.5]; Fig. 2C) c o m p a r e d  to contro ls  and rats that rece ived  the c om b in atio n  
o f  B M S C  and  C sA  show ed a 3 6 %  s m a lle r  a n g le  o f  rotation (M =  1 6 .9 ;  9 5 %  CI [15 .9, 17 .9 ] ;  Fig. 
2C).
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Fig. 2 . (left) BMSC transplants improved some aspects o f 
locomotion pattern. We applied the footprint analysis to assess 
specific characteristics of locomotion pattern. A. The average 
stride length was not different between groups. B. The average 
base of support was decreased at 4  and 8 weeks in rats that 
received a BMSC transplant compared to rats that rteceived a 
DMEM injection (asterisks, p<0 .05) . There were no differences 
between the other groups. C. The average angle of hind paw 
rotation was decreased at 4  and 8 weeks in the BMSC/saline 
(asterisks, p<0 .05) , DEME/CsA (number signs, p<0 .05) , and 
BMSC/CsA (section signs, p<0 .05) group. There were no 
differences among the groups that received BMSC and/or CsA 
treatment. In all three graphs the error bars indicate the 
standard deviation of the mean.
BM SC  transplants improved sensorimotor function.
After a con tu s ion  injury to the s p in a l  cord, rats exhibit im p a ire d  in tegra t ion  o f  s e n s o ry  and 
m o to r  inputs.  C h a n g e s  in s e n s o r im o to r  function w e re  te s te d  with a horizontal ladder2’8 by 
cou n t in g  th e  n u m b e r  o f  s lips  o f f  the rungs  by th e  rat 's  hind p a w  (small  slip), hind p a w  and 
pa rt  o f  leg (m edium  slip) or w h ole  hind leg ( large slip). T h e  n u m b e r  o f  slips  w e re  quantified 
and  e x p re s s e d  as  a p e r c e n t a g e  o f  the total n u m b e r  o f  s te p s .  The  a v e r a g e  n u m b e r  o f  s te p s  w a s  
’ 5 .0  ± 0 .3  a t  e ight w e e k s .  O n e -w a y  A N O V A  show ed s ig n i f ican ces  ac ro ss  g ro u p s  (F (3,23) =  
42 .7 ;  p <  0 . 0 0 0 ’ ). Control rats m a d e  s lips  in 7 0 .3  ± 4 .7  %  o f  their  s te p s  at e igh t  w e e k s  (Fig. 3), 
which w a s  s ign if icantly  different from  B M S C  treated  a n im a ls ,  w h o  show ed a 7 0  %
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im p r o v e m e n t  (IVI =  2 1 .4 ;  (ill [1 8.8, 24.0] ; (Fig. 3). Fiats with B M S C  and C sA  t r e a t m e n t  show ed a 
52 %  im p r o v e m e n t  Irons contro ls  (M =  33.8; CI [31.2, 3 6.4]) and  rats that rece ived  CsA 
t r e a t m e n t  only  sh ow ed  a 26 .  6 %  im p r o v e m e n t  from  contro ls  (M =  52.3;  CI [49 .6 ,5 5 .0 ^ .
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F'g. 3. Presence o f a BM SC transplant improved performance on the horizontal ladder. The number of small, medium, 
and large slips was assessed individually. These numbers were also added and expressed as a percentage of the total 
number of steps necessary to cross the horizontal ladder. The assessment was done at 8 weeks post-transplantation. 
Rats with a BMSC transplant (white bar) had a significant better performance (i.e., lower percentage of slips/steps) 
than control rats (black bars) (asterisks, p<0 .05) . This was also the case for rats with CsA treatment (dark gray bars) 
and rats with BMSC and CsA (light gray bars). The error bars indica te the standard deviation of the mean.
BM SC  transplants improved recovery from  mechanical ailodynia.
After a th orac ic  con tu s ive  sp ina l  cord injury rats  d e v e lo p  al lodynia  o f  the hind p a w s .  Ain 
(electronic) von Frey a n e a s t h e s io m e t e r 69, 70 w a s  used  to te s t  w h e th e r  a B M S C  t r a n s p la n t  
w ould be benefic ia l  for recovery from  m ech an ica l  (tactile) a l lo d y n ia . O n e -w a y  A N O V A  (F (3,23) 
= 2 4 .4 ;  p < o . o o o i )  and  Tukey 's  post-  hoc com pah ison s  show ed that a t  eigha w e e k s  p ost­
t r a n sp la n ta t io n ,  an im p r o v e m e n t  o f  2 1 %  in recovery from  m ech an ica l  al l tdy n ia  w a s  o b s e r v e t  
in rats  with a B M S C  t r a n s p la n ts  (M =  88.0 ;  CI [85.8 ,90.2]),  co m p a re d  to contro ls  (IV1 =. 58.2; CI 
[56.5, 59.9] ; Fig. 4A). T r e a tm e n t  with C sA  (M =  72.8 ; Cl [70.2,  75.4]) or  B M S C  a c  d C sA  
com b in ed  [ M = 7 0 .7 ;  CI [6 9 .6 ,  7 1.8]  did not c h a n g e  th e  w ithdrawal re sp o  n se  c o m p a r e d  to 
contro ls  (Fig. 4A).
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Fig. 4 . Presence o f a BMSC transplant decreases mechanical 
and thermal allodynia. Allodynia of the hind paws was 
assessed using a von Frey aneasthesiometer (A) and a 
Hargreave’s heat source (B) at 8 weeks post­
transplantation. A. Rats with a BMSC transplant but none of 
the other treatment groups had significantly higher response 
times (i.e., lowered (improved) hyper-sensitivity) to a 
mechanical (tactile) hind paw stimulus compared to the 
control rats (asterisks, p<0 .05) . B. The response times of 
rats with a BMSC transplant was significantly higher than in 
controls (asterisks, p<0 .05), which indicated lowered 
(improved) hyper-sensitivity to a thermal hind paw stimulus. 
In both graphs the error bars indicate the standard deviation 
of the mean.
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Fig. 5. The presence o f a BM SC transplant improved the amount o f spared tissue. The volume of spared tissue was 
assessed at 8 weeks post-transplantation and expressed as a percentage of the volume of an uninjured comparable 
spinal cord segment. We found that rats with a BMSC transplant had significantly more spared tissue than control rats 
(asterisks, p<0 .05 ) . The other treatment groups were not different from the control group. The error bars indicate the 
standard deviation of the mean.
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BM SC  transplants improved recovery from  thermal allodynia
C o n tu se d  rats a lso  d e v e lo p  th erm al al lodynia ,  which can be m e a su r e d  with a H a r g re a v e 's  heat 
sou rce ’60. O n e -w a y  A N O V A  show ed d ifferences  a c ro sr  g rou ps  (F ( 3 .23= 20 .7 ;  p < o . o o o ’ ). Fiats; 
witS  a son tu s io n  o n ly  (no treatm en t)  w ith drew  their  hind p a w s  at 6 . ’ ± 0 .3  s (Fig. 4B).  Rats  
th at  rece ived  the B M S C  t r a n s p la n t  w ith drew  their  hind p a w  at  7 .6  ± 0 .3  s which r e p r e se n te d  a 
2 5 %  im p r o v e m e n t  over  contro ls  (Fig 4B).  The  o ther  g ro u p s  w e re  not  d i f ferent from  the control 
group) (Fig 4B).
BM SC  transplants elicited tissue sparing.
S p a r e d  t i s su e  v o lu m e s  a t  th e  con tu s ion  site were m e a su re d  a t  e igh t  w e e k s  after injection into 
the contusion  using; S te re o  I n v e s t ig a to r ®  softw are  ( M B F  B ioscience)  in a blinded fa sh io n . For 
all m e a s u r e m e n t s  the Coefficient; o f  Error (G u n Se rse n  Coeff ic ient)  w a s  < 0 .0 5 .  T h e  vo lum es  
w e re  e x p re s s e d  as  a p e r c e n t a g e  o f  the v o lu m e  of7 a c o m p a r a b le  s e g m  e n t  o f  a na ive  (uninjured) 
sp inal  cord. O n e -w a y  A N O V A  show ed difhere nc e s  s c r o ss  g ro u p s  (F (3,’ 9 ) =  2 0 .7 ;  p = o .o o o 5 )  In 
control rats  (contusion only) the vo lu m e  of7 sp a r e d  t is su e  w a s  ’ ¿4.9) ± ’ .6 %  (SEM) o f  that o f  an 
uninjured sp inal  cord (Fig. 5). With a B M S C  t r a n s p la n t  th e  vo lu m e  w a s  2 4 .8  ± ’ .4  % ,  which 
re p r e se n te d  a s ign if ican t  6 6  %  in c re a se  in sp a r e d  t i s su e  v o lu m e  c o m p a r e d  to controls  
(p<o.c>5; Fig. 5). In rats with daily C sA  t r e a t m e n t  the sp a r e d  t i s su e  v o lu m e  w a s  ’ 7 .8  ±  ’ .7 %  
and  ia rats  with a B M S C  t r a n s p la n t  and  C sA  tr e s l m e n t  th e  vo lu m e  w a s  ’ 9 .2  ± ’ .6 %  o f  that o f  
an unin jured spinal cord s e g m e o t  (Fig. 5). T h e  v o lum es  ie th e se  tw o  g r o e p s  w e re  s im ilar  as  
the v o lu m e  in contro l rats .
CoorelatioEs between tissue sparing and motor and sensory function.
The re la t io nsh ip  b e tw e e n  t i s su e  s p a r in g  end  m o to r  and  s e n so ry  function per  t r e a t m e n t  grou p 
(Tabl e ’ ) an d per  function (Tab le 2) w a s  a s s e s s e d  using  th e  p e a rso n  correlat ion coeff ic ient (r). 
B M S C  t r a n sp la n ta t io n  resulted in s  s t ro n g  a s s o b a S.on (r >  0.75) b e tw e e n  t is su e  o par ing  and 
BIBB sub-score, har izonta l  ladder  wa lk ing , a n g le  erf7 rotation, and  m e c h a n ic a l  al lodynia . A  
m o d e r r te  as soc ia t ion  (a >  0 .5 0 ,  < 0.75) w a s  found b e tw e e n  t is su e  s pa r in g  and  therm al 
al lodynia (Tnble ’ ). With C sA  t f e a t m e n t  t i s su e  s p a t in g  w a s  strongly  a s s a c ia t e d  with the a n g le  
o f  rotation, m o d e ra t e ly  with B B B  sub-score, and  w e ak ly  (s < 0.5(0) with horizo ntal ladder 
w alk ing , m ech an ica l  al lodynia ,  and th erm al al lodynia  (Table  1).  With both B M S C  
t r a n s p la n ta t io e  and  CsA  t r e a t m e n t  t i s su e  s p a r in g  w a s  s . r o e g ly  a s so c ia te d  with the a n g le  o f  
rotation, m o d e ra te ln w ith  the B B B  sun-score,  horizontal ladder  wa lk ing , and  thernfal al lodynia , 
and  w e a k ly  w XE m enhanical al lodynia  (Table  1). In our control rats  'tine re ln tionsh ip  w a s  stron g  
b e tw e a n  t i s su e  s p a e in g  add th erm al al lndynia bot w e a k  for all o ther  fn n c t io n s l
If7 all four t r e a t m e n t  g ro u p s  w e re  poo led  to g e th e r  per  spec if ic  hunction (Tabln 2),  t i s su e  
spari  ng  w a s  strongly  as so c ia te d  .with BIBB sxb-score  (Fig. 6A), m oderate ln  a s so c ia te d  with
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horizontal ladder  w a lk in g  (Fig. 6B) ,  a n g le  of7 rotation (Fig. 6C), and  therm al a l lodynia  (Fig. 
6D ),  and  w e ak ly  as so c ia te d  with m ech an ica l  al lodynia (Fig. 6 E ) .
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Fig. 6. The amount o f tissue sparing correlated with motor and 
sensory outcomes. The relationship between tissue sparing and 
motor and sensory function (with all four treatment groups 
pooled) was assessed using the Pearson correlation coefficient 
(r). Correlations between tissue sparing and individual groups 
are described in text. Scattergrams show tissue sparing was 
strongly associated with (A) BBB sub-score, moderately 
associated with (B) horizontal ladder walking, (C) angle of 
rotation and (D) thermal allodynia, and weakly associated with 
(E) mechanical allodynia.
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Fu n ct io n T re a tm  e n t r Fun ction T re a tm e n t r
BBB BMSC / saline 0.01 Foot Print (anale) BMSC / saline -0.92
DMEM / CsA 0.35 DMEM / CsA -0.96
B M S C / CsA - B M S C / CsA -0.95
DMEM / saline - DMEM / saline -
BBB Subsfore BMSC / saline 0.86 MechanicaV Allodrnia BMSC / saline 0.78
DMEM / CsA 0.73 DMEM / CsA 0.20
B M S C / CsA 0.67 B M S C / CsA 0.10
DMEM / saiine - DMEM / ¡saline; 0.10
Horizontal Ladder BMSC / saline -0.85 Thermal Allodrnia BMSC / saline 0.70
slips/step DMEM / CsA -0.04 DMEM / CsA 0.30
B M S C / CsA -0.74 B M S C / CsA 0.73
DMEM;/ / saiine -0.40 DMEM / saline 0.99
Table 1 . Correlation between tissue sparing motor and sensory function. The relationship between the different 
outcomes pertreatment group was determined by the Pearson correlation coefficient (r).
Abbreviations: *r  = Pearson correlation coefficient; BBB = Basso-Beattie-Bresnahan open field locomotor scale; BMSC 
= bone marrow stromal cells; CsA = cyclosporine; DMEM = Dulbecco’s minimal essential medium.
F u n c t i o n
*
r
BB B
B B  E S u b s c o  ro 0.85
Horizontal Ladder -0.70
Foot Pric( (angle) -0.73
Mechanical Allodynia 0.39
Thermal Allodynia 0.57
Table 2 . Correlation between tissue sparing motor an f s ensoryfunction.
The relationship between the different outcomes was determined per specific 
function by the Pearson correlation coefSicitnt (r). Abbreviafons: * f =
Pearson correlation coeffitient; BBB = Batso-Beattie-Brestchan lecomotot 
scale.
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D ISCU SSIO N
W e evaluated  lo com otor  and  s e n s o ry  recovery in rats with a con tu sed  thoracic  sp ina l  cord that 
received a B M S C  t r a n s p la n t  into the e p ic e n t e r  o f  the injury at th ree  d ays  post- im pact .  The  
m ain  f ind ing  in our study is that the p r e s e n c e  o f  a B M S C  t r a n s p la n t  results  in im pro ved  m otor  
and  s e n s o ry  function. Rats th at  received a B M S C  t r a n s p la n t  had im proved  B B B  sub-scores, 
sm a l le r  a n g le  o f  hind p a w  rotation, im pro ved  p e r fo rm a n ce  on the horizontal ladder, and  less  
h yp ersen sit iv ity  to m ech an ica l  and  th erm al stimuli .  B M S C -t ra n s p la n te d  rats  did not  benefit  
funct iona lly  from  daily C sA  t r e a tm e n t .  T h e  a m o u n t  o f  sp a re d  t is su e  a t  th e  con tu s ion  site in 
B M S C -t ra n s p la n te d  rats, but not  in a n y  o f  the o ther g rou ps ,  w a s  in c re a se d  s ignificantly  
c o m p a r e d  to contro ls.  M oreover ,  rats  with a B M S C  t r a n s p la n t  sh ow ed  a stron g  correlat ion 
b e tw e e n  th e  a m o u n t  o f  t issue  s p a r in g  and  the functional o utcom e.  O ur  data  s u g g e s t  th at 
B M S C -m e d ia te d  t i s su e  s p a r in g  in th e  con tu se d  adult rat sp ina l  cord is in t im a te ly  involved in 
recover  o f  m otor  and s e n s o ry  function.
So  far, the b en ef i ts  o f  B M S C  for m o to r  function restorat ion  had b een  u n c lear  a s  several 
s tu d ies ,0, 385 463 w e re  at v a r ia n c e  with ear lier  rep o rts  th at described  m otor  function 
im p r o v e m e n t s ’69, 170 472 473. W e n o w  d e m o n s t r a t e  that B M S C  t r a n sp la n ta t io n  has  w id e sp re a d  
benefits  for m otor  function restorat ion  after  sp inal  cord con tu s ive  injury. A  poss ib le  
m e c h a n is m  that m a y  underl ie  th e se  m o to r  function im p r o v e m e n t s  is B M SC-el ic ited  nervous 
t i s su e  s p a r in g 286 , 304. Indeed  w e  found th at  rats  with B M S C  had in crea sed  a m o u n ts  o f  sp ared  
t is su e  at th e  contusion  site and , interest ingly ,  th is  s trongly  correlated with functional 
o utcom es .
W e did not  o b serve  a benefic ia l  effect o f  t r a n sp la n te d  B M S C  on a u to m a te d  hind limb 
m o v e m e n t s  as  a s s e s s e d  in th e  o p e n  field (BBB-test) .  A lso ,  B M S C  t r a n s p la n ts  had no effect on 
str ide length  and  b a s e  o f  sup port .  A n a ly s is  o f  o p e n  field locom otion with the B B B -te st  revea led  
th at  all rats  reached a p la te a u  o f  a b o u t , , .  Such a score  for rats  th at  rece ived  only  the 
contusion  and  not  a B M S C  t r a n s p la n t  a n d / o r  C sA  t r e a t m e n t  is in a g r e e m e n t  with a previous 
pu blicat ion60. O ur  o bservat ion  that B M S C -t ra n s p la n te d  rats  did not  exhibit im pro ved  BBB- 
scores  over  control rats  is in full con cu rren ce  with prev ious  re p o rt s ’0, 385 463 but in conflict with 
o th e rs ’69, ’7°, 472, 473.
The lack o f  im p r o v e m e n ts  o f  a u to m a te d  w a lk in g  in th e  o p e n  field is surpr is ing  in light o f  
the o b served  im p r o v e m e n ts  in spec if ic  fea tu res  o f  locom otion, lo com otor  p a ttern ,  and 
se n s o r im o to r  p e r fo rm a n ce .  It a p p e a r s  likely th at  B M S C -in it ia ted  m e c h a n is m s  that c a u se  the 
o b served  im p r o v e m e n ts  w ould  a lso  be fu n d a m e n ta l  to o p e n  field a u to m a te d  locom otion. 
Future resea rch  will n e e d  to focus on this u n e x p e c te d  f ind ing  and  eluc idate  p o ss ib le  
underly ing  m e c h a n is m .
W e found that the p r e s e n c e  o f  a B M S C  t r a n s p la n t  resu lted in im pro ved  r e s p o n s e s  to 
m ech an ica l  and  th erm al stimuli  to the hind p a w s  a t  8 w e e k s  after  t r a n sp la n ta t io n .  To our 
kno w led ge  this is the first re p o rt  that d e sc r ib es  effects  o f  B M S C  t r a n sp la n ts  in th e  injured
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adult rat sp ina l  cord on s e n s o ry  function restorat ion .  A  po ss ib le  m e c h a n is m  th at  underl ies  the; 
in c re a se d  s en so ry  function is t i s su e  s p a r in g  elicited by the B M S C  te a n s p la n t286,3°4. W e did finp 
th at  rata with B M S C  had in c r ta e e d  a m o u n ts  oh sp a re d  t is su e  a t  the cnntusion eite and , 
interesaingly, this s trongly  corre lated  with functiona l o utco m e s .
Rats  th at  rece ived  daily C sA  exhibited im pro ved  o u tco m e s  in s o m e  o f  the m o to r  tes ts  but 
not  in th e  s e n s o ry  tes ts .  Overall ,  the: C sA  t r e a t m e n t  did not b en ef i t  th e  o u tco m e  in a n y  o f  the 
functional pests op B M S C -tra n sp la n th d  rats . Previourly, it haa O cet  reported  th at  te e a tm e n t  
with C sA  su p p o rt s  ceilular  an d  functiona l re p a ir  after  s f i n a l  cord injury’77. H ow ever,  w e  did not 
o bserve  a n y  such functional b en ef i ts  o f  C sA  t r e a t m e n t  in t r a n s p la n te d  rats. A t  p r e s e n t  it is 
u nc lear  through which m e c h a n is m  C sA  t r e a t m e n t  w ould influence functional g a in s  m e d ia te d  
by t r a n s p la n t e d  B M S C .
The p r e s e n c e  o f  a B M S C  t r a n s p la n t  in c re a se d  the a m o u n t  o f  sp a re d  t i s su e  at the 
fo n tu s io n  site at 8 w n ek s  p o s t- t ra n sp la n ta t io n  c e m p a r e d  to control rats .  This w a r  not 
o b served  in t;he o t h t r  t r e a t m e n t  grou ps .  Important;ly, correlat ive  anatys is  revea led  that the 
a m o u n t  o f  tisoue sp a r in g  w a s  strongly  a s so c ia te d  with functional o u tco m e  in rats  with a B M S C  
tra n sp la n t .  T h e s e  f ind ings  revea led that B M S C -m e d ia te d  t i s su e  s p a r in g  in th e  con tu sed  adult 
rat sp inal  cord is in t im a te ly  involved in recover  o f  m o to r  and  s e n s o ry  function.
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Sp in a l  cord injury (SCI) results  in ne rvou s  t i s su e  loss and  im m e d ia te  functiona l im p a ir m e n ts .  
E n d o g e n o u s  re p a ra t iv e  e v e n t s  occur within the d a m a g e d  sp ina l  cord but g e n e ra l ly  they do not 
result in m e a n in g fu l  restorat ion  o f  function. Thus,  SC I-m ed iate d  loss  o f  function is p e r m a n e n t  
and  p e o p l e  w h o  e x p e r ie n c e  SCI m a y  be  d est in ed  to s p e n d  the re m a in d e r  o f  their  lives in a 
w h eelchair .  A p p r o a c h e s  a im ed  a t  re p a i r in g  th e  sp inal  cord a n a to m ica l ly  and  funct iona lly  are  
b e in g  inv e st ig a te d  in laborator ies  a roun d the world . S o m e  o f  the m o re  p ro m is in g  a p p r o a c h e s  
a re  b e in g  te s te d  in the clinic but so  far  n o n e  o f  th e se  have e m e r g e d  as  o n e  th at  reve rse s  the 
d e v a s ta t in g  functiona l c o n s e q u e n c e s  o f  SCI.
O n e  o f  the po ten tia l  t r e a t m e n t s  th at  could s u p p o rt  sp inal  cord rep a ir  is the 
t r a n sp la n ta t io n  o f  cells  that are  known to contr ibute  to cellular, a n a to m ica l ,  and  functional 
restorat ion . B o n e  M a rro w  S trom a l Cells  (BM SC ) have rece ived  a m p le  a t te n t io n  for their 
p r e s u m e d  potentia l  to rep a ir  centra l  ne rvou s  sys tem  (CNS) les ions .  An im p o r ta n t  a d v a n ta g e  
over  other cellu lar  c a n d id a te s  for sp inal  cord repair  is that B M S C  can be o b ta ined  from routine 
b o n e  m a rro w  b iop sies  from  the p a t ient .  This a d v a n ta g e  a l low s for a u to lo go us  t r a n sp la n ta t io n  
in which rejection o f  the t r a n s p la n t e d  cells  m a y  be m in im a l.
The  overall goal o f  this th es is  w a s  to in v est ig ate  the poten tia l  and  suitabil ity o f  B M S C  to 
repa ir  th e  injured sp inal  cord. This w a s  a d d ressed  in a ser ies  o f  e x p e r im e n ts  th at  focused  on 
rat B M S C  g e n e  profi ling, B M S C  survival after  t r a n sp la n ta t io n ,  and  their  effects on t is su e  
sp a r in g  and  on lo com otor  and  s e n s o ry  function restorat ion . For the in vivo e x p e r im e n ts  a rat 
sp inal  cord contusion  m odel sys tem  w a s  e m p lo y e d  to m im ic  the m o s t  freq uen tly  occurring 
ty p e  o f  h um an sp inal  cord injury. In the fo l low ing sect ion , the m ain  resu lts  from  th e se  studies  
a re  s u m m a r iz e d  and  d iscu ssed  in light o f  w h a t  is known from  the current l i terature  and  w h a t  
w ould be n e c e s s a ry  to ach ieve  a n a to m ica l  and  functional re p a ir  o f  the sp ina l  cord.
In C h a p te r  1, SCI and  a variety  o f  re lated a s p e c t s  are  introduced. In th e  U nited S t a t e s  the 
inc id ence  and  p re v a le n c e  o f  SCI h as  b een  studied in dep th .  A n nu al ly ,  a p p r o x im a te ly  1 1 , 0 0 0  
n e w  c a s e s  o f  SCI occur in the US. The s ize  o f  the g rou p  o f  sp inal  cord injured p e o p le  in th e  US 
has c on servat ive ly  b een  e s t im a te d  b e tw e e n  2 5 0 , 0 0 0  an d  4 0 0 , 0 0 0 .  L ess  is known a b o u t  the 
inc id ence  o f  SCI in Eu rop e  and  T h e  N e th e r la n d s .
M a in ly  b e c a u se  o f  the la rge  variabili ty a m o n g  SCI it is difficult to def ine  the b est  clinical 
practice .  D u rin g  the early p h a se ,  t re a t m e n ts  that s tab i l ize  th e  p a t ie n t 's  health and  a t t e m p t  to 
limit the overal l loss  o f  t is su e/ fu nction  n e e d  to be im p l e m e n t e d .  O p tim a l  t r e a t m e n t  n e e d s  to 
be d e te rm in e d  on a case -to -case  bas is .  D e c o m p r e ss io n  surgery  with or  w ithout fixation o f  the 
sp inal  co lum n m a y  a c ce le ra te  functional im p r o v e m e n t s  an d  result in shorter  hospital and 
rehabilitat ion per iods.  A s  long as  p ro p e r  clinical trials  have not b een  execu ted  th e  effects o f  
the t im in g  o f  d e c o m p r e s s io n  surgery will rem ain  elusive.
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P h arm aco log ica l  t r e a t m e n ts  to limit se co n d a ry  injury a fter  the initial d a m a g e  have b een  
studied intensively .  Best-know n is t r e a t m e n t  with high d o s e  m e t h y lp re d n iso lo n e  (M P).  The  
effects o f  M P  in p a t ie n t s  with SCI w e re  inv e st ig a te d  in 3 c on secu t ive  N a t io n a l  A cute  Sp in a l  
Cord Injury S tud ies  (NASCIS).  The  results  d e m o n s tra te d  th at  acu te  M P  t r e a t m e n t  resu lted  in 
neurological im p r o v e m e n ts  up to 6 m o n th s  after  injury and, as  a result o f  th e se  f ind ings ,  M P  
w a s  the s tan dard  o f  c a re  for m a n y  yea rs .  H ow ever,  a fter  a thorough review o f  the results  from 
the N A S C IS  studies  and  a m o re  c o m p r e h e n s iv e  a s s e s s m e n t  o f  the b en efits  and  risks involved 
in high dose  M P -t re a tm e n t ,  th e  th e ra p e u t ic  benefits  o f  M P  t r e a t m e n t  have b een  discredited. 
Espec ia l ly  in p a t ie n t s  with c o m p le te  SCI high d o s e  steroid t r e a t m e n t  can lead to ad ve rse  
effects such as  m y o p a th y  and  w o u n d  infection th at  m a y  n e g a t iv e ly  in fluence  functional 
o u tco m e  and in s o m e  c a s e s  m a y  be li fe -threatening .  Currently, m o s t  clinics have d iscon tinued  
the ‘ s tan dard '  acute  a d m in ist ra t ion  o f  M P  after  SCI.
C hapter 1 a lso  introduces s tem  cells  (SC) as  a p o ten tia l  th e ra p y  for SCI.  O ver  the last  
y ea rs ,  S C  have g a in e d  a t te n t io n  in the field o f  o rgan  re p a ir  and  o r g a n o g e n e s i s .  Em bryonic  
s tem  cells  (ESC) are  th e  cells  within th e  in n e r  cell m a s s  o f  the blastocyst.  D uring d e v e lo p m e n t  
th e se  cells  a re  rest ra in ed  to germ  layers  w h e re  their  fa te  is d irected. U ndifferentiated  SC-like 
cells  can be found a m o n g  differentiated cells  o f  a sp ec if ic  t i s su e  after  birth. T h e s e  cells  are  
known as  adult SC, although a better  term  w ould be ‘ s o m a tic  SC ' s in ce  th ey  are  a lso  p r e s e n t  in 
children an d  umbilical cords. It h as  b een  re p o rte d  that SC  are  able  to cross  germ  layers  in vitro 
given the right ‘ induction cocktail ' o f  growth factors. Even though this is still profoundly 
d e b a ted  a m o n g  sc ient ists ,  this p r e s u m e d  poten tia l  has  o p e n e d  m a n y  n e w  a v e n u e s  for 
research  in different d isc ip l ines .
O n e  o f  the i s su e s  that surround the u se  o f  ESC is the t im e  p o in t  a t  which w e  harvest  the 
cells  from  the em bryo .  C an a t  th at  t im e  th e  e m b ry o  in fact be  con s id e re d  to be al ive, to be a 
pe r s o n ?  D isc u ss io n s  on w h a t  con st itu tes  ‘ life' and  w h en  ‘ life' s tarts  are  often in t e n s e  a s  they 
are  driven by m oral c on cern s  fueled by relig ious and  political ideas .  T h e se  i ssu es  ne ed  to be 
a d d re sse d  with r e sp e c t  to all o p p o n e n t s .  Ethical i ssu es  th at  surround the use  o f  S C  involve 
po ss ib le  m isuse ,  such a s  with th e ra p e u t ic  c lo n ing  and  g e n e t ic  m a n ip u la t io n .  Adult SC  have 
le ss  ethical barr iers  and  are  th erefore  in t e re s t in g  c a n d id a te s  for in tervent ion  p a ra d ig m s .
C hapter 2 review s the use  o f  B M S C s  in ne u ro sc ie n c e  in g e n e ra l  and  for repa ir  o f  the injured 
sp inal  cord specif ically. B M S C  are  m e s e n c h y m a l  SC-like cells  that reside  in th e  b o n e  m arrow . 
This part icu lar  location a l low s for e a s y  harvest  from the p a t ie n t  an d ,  c on seq u en t ly ,  for 
a u to lo go us  t r a n sp la n ta t io n  with m in im a l re jection . Ethical i ssu es  are  a lso  u n d e rm in e d  as  
B M S C  can be h arvested  from  b o n e  m a rro w  from  adults.  W h eth er  B M S C  can tran sd i f fe rent ia te  
into cells  from  the neural cell l ine ag e ,  o r  other l in e a g e s  for th at  m atter ,  is still u n c lear  and 
d e b a ted  a m o n g  sc ient ists .  H ow ever,  the ear ly  rep o rts  that B M S C  a re  in fact c a p a b le  o f  
tran sd if fe rent ia t ion  h ave  launched  a p lethora o f  invest igat ion  exp lo r in g  their  re p a ir  potentia l .
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S o m e  e x a m p le s  are  th e  studies  on th e  u se  o f  B M S C  for repa ir  o f  the h eart  m u sc le  after 
myocardial infarction in cardiology, o s t e o g e n e s i s  im p e r fe c ta  in orthopedics,  o r g a n o g e n e s i s  in 
internal m ed ic ine ,  intervertebra l  d isc  d i s e a s e  in neurosurgery ,  and  stroke/ n e u ro d e g e n e ra t iv e  
d i s e a s e s  in neurology.
A s  the d e b a te  on th e  po ten tia l  o f  B M S C  to t ran sd i f fe ren t ia te  con t in u es ,  they could a lso  be 
used for repa ir  for their natura l ability to produce an d  s e cre te  m a n y  repa ir-re la ted  m olecu les .  
This ability could be b en ef i tte d  from in for in s ta n c e  th e  injured sp inal  cord as  th e se  m o lecu les  
could s u p p o rt  cellu lar  and  a n a to m ica l  repair .  H ow ever,  w h en  B M S C  are  used for sp inal  cord 
repa ir  w ith ou t d ifferentiat ion into neural cells  prior to t r a n sp la n ta t io n ,  it is po ss ib le  th at  the 
in jected cells  d if ferentiate  in vivo into m e s e n ch y m a l  cell ty p e s  such as  fat, m uscle ,  cart i lage,  or 
b o n e  cells .  This would be a real concern  as  th e se  cells  would im pair  the overal l rep a ir  o f  the 
sp inal  cord. So  far, reports  th at  this in fact  occurs  have not  b een  published. A lso ,  in the in vivo 
studies  described in this  th es is  w e  have n o t  found a n y  s ig n s  th at  this ta ke s  place.
C hapter 3 describ es  the g e n e  e x p re ss io n  profi le  o f  adult  rat  B M S C  for which 44k wh ole  g e n o m e  
rat m icroarrays  w e re  e m p lo y e d .  The  m a jo r  goal o f  this s tudy w a s  to in c re a se  our 
u n d e rs ta n d in g  o f  the po ten tia l  and  suitabil ity o f  B M S C  for sp ina l  cord repair.  In addition, w e  
a im e d  to a s s e s s  the effects o f  long-term culturing on g e n e  e x p re ss io n  by c o m p a r in g  B M S C  
from the 3 rd (P3) and  1 4 th (P14) p a s s a g e  in culture. Both P3 and  P 1 4  B M S C  e x p re s s e d  g e n e s  
involved in neural d e v e lo p m e n ta l  e v e n ts  such as  glial d if ferentiat ion and  m y e linat io n ,  and 
neuronal  proliferation and  neurite  fo rm at ion ,  ind icat in g  the poten tia l  o f  B M S C  to differentiate  
into neural l in e a g e .  B M S C  a lso  e x p re s s e d  g e n e s  e n co d in g  for growth factors  and  for p rote ins  
involved in growth factor  s ig n a l in g .  A  total o f  6 6 8 7  g e n e s  w e r e  e x p re s s e d  in P3 and  in P 14  
B M S C ,  with a 9 7 %  o ve r la p  o f  g e n e s  e x p re s s e d  a t  a s im ilar  in ten s ity  and  3 %  ( 20 2  g en es)  
e ither  higher in P3 B M S C  (159 g e n e s )  or  higher in P 1 4  B M S C  (43 g e n e s ) .  Functional data  
m in in g  by G e n e  O n to lo g y  (GO )-analysis  revea led  th at  8 5 / 15 9  and 2 2 /4 3  w e re  a n n o ta te d  in 
the G O  d a ta b a se .  In P3 B M S C ,  43  G O -c la sse s  w e re  o v e r r e p r e se n te d  with 9 involved in organ 
d e v e lo p m e n t  an d  cell proliferation. In P 1 4  B M S C ,  2  G O -c la sse s  w e re  o v e r r e p r e se n te d  with 1 
involved in o rg a n  d e v e lo p m e n t .  Overall ,  our g e n e  profi ling data  s u p p o rt  the u se  o f  B M S C  for 
neural repair .  A  n u m b e r  o f  g e n e s  are  e x p re s s e d  in B M S C  from  which the product could 
su p p o rt  cellu lar  rep a ir  o f  the sp ina l  cord. A lso ,  w e  found ev id ence  th at  long-term  culturing o f  
B M S C  m a y  d e c r e a s e  their  p las t ic  abili ties after  t ra n sp la n ta t io n .  Further g e n e  profi ling 
research  will be  n e e d e d  to im pro ve  our u n d e rs ta n d in g  o f  the nervous  sys tem  repair-poten tia l  
o f  B M S C  and to poss ib ly  provide a bas is  for m a n ip u la t io n  o f  th e  B M S C  to in c re a se  their 
eff icacy prior to t ra n sp la n ta t io n .
O n e  po ss ib le  w a y  by which B M S C  could su p p o rt  sp ina l  cord repa ir  is by l im iting  the 
pro g re ss iv e  t i s su e  loss  (e.g., e lic it ing t i s su e  spar ing)  that no rm al ly  occurs after th e  initial
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d a m a g e .  Im portantly ,  to profit from  this ability p o o r  survival o f  B M S C  after t r a n sp la n ta t io n  
into the con tu s io n  e n v i ro n m e n t  is a poten tia l  lim iting factor. In C hapter 4  the survival o f  
B M S C  and the effects  on t i s su e  s p a r in g  after  t r a n s p la n ta t io n  into the c o n tu se d  rat sp inal  cord 
are  described .  W e in jected  B M S C  into the m o d e ra te ly  c on tu sed  adult rat thoracic  sp inal  cord 
a t  15 m in (acute) and  at 3, 7 and  21 days  (delayed) post-in jury and  quantif ied  t i s su e  s p a r in g  
and  B M S C  survival up  to 4  w e e k s  p o s t- t ra n sp la n ta t io n .  B M S C  survival within th e  contusion  at 
7 d ays  p o s t - t ra n sp la n ta t io n  w a s  s ignif icantly  h igher with an acute  in jection (32%) and  3-days 
delayed  injection (52%) than with a 7- or 2 1 -d a y s  d e layed  injection (9 %  both; p < o . o i ) .  
Unfortunately ,  B M S C  p r e s e n c e  a t  28 days  p o s t - t ra n sp la n ta t io n  w a s  c lo se  to 0  in all 
p a ra d ig m s ,  ind icating  m a s s iv e  cell death.
In con tu se d  rats w ithout a B M S C  t r a n s p la n t  (controls),  the v o lu m e  o f  sp a re d  t is su e  
gradual ly  d e c r e a s e d  until 4 6 %  ( p < o . o o i )  o f  the v o lu m e  o f  a c o m p a r a b le  unin jured spinal cord 
s e g m e n t  a t  4 9  days  post-injury. Acute  and  3-days delayed  but not  7- and  2 1 -d a y s  delayed  
injection o f  B M S C  sign ificantly  im pro ved  t is su e  spar ing ,  which w a s  strongly  correlated (r =
0 .7 9  - 1 .0)  to B M S C  survival in th e  first  w e e k  after  in jection into the con tu s ion .  This se t  o f  
results  d e m o n s tr a te d  th at  B M S C  t r a n sp la n te d  into the con tu se d  sp inal  cord o f  an adult rat  
survive poorly  and  B M S C  death w a s  g re a te r  w h en  cells  w e re  in jected de layed  c o m p a r e d  to 
ear ly  after  con tus ion .  T h e  data  further show ed that the ne uro p rotect ive  effects  o f  B M S C  
t r a n s p la n te d  into a m o d e ra te  rat sp inal  cord contusion  d e p e n d  s trongly  on their  survival 
during th e  first w e e k  post-in ject ion ; acu te ly  in jected B M S C  elicit m o re  t i s su e  s p a r in g  than 
delayed  in jected B M S C .
The results  o b ta in ed  in th is  study to s o m e  d e g re e  c h a n g e  s o m e  id eas  on ce ll-based repair  
a p p r o a c h e s  for the injured sp ina l  cord. For long it w a s  thought th at  d e layed  t r a n sp la n ta t io n  o f  
cells  within  a con tu s ion  e n v i ro n m e n t  w ould be beneficial  for t r a n s p la n te d  cell survival and, 
c on seq u en t ly ,  for the effects  m ed ia ted  by the cells , a s  it would c ircum ven t the height o f  the 
injury-initiated e n d o g e n o u s  in f la m m a to ry  and  im m u n e  r e s p o n s e s .  This w isd o m  w a s  g e n e ra l ly  
a c ce p te d  within  the field o f  sp inal  cord in ju ry/repa ir  m a in ly  b e c a u se  o f  its logical rat ionale  and 
a s  long a s  the actual de lay  o f  cell introduction within th e  injury would not  p a s s  the t im e  po int  
w h e re  g e n e ra l  deter ioration  o f  the sp ina l  cord would limit or even p re v e n t  a n y  b en efits  from 
cell t r a n sp la n ts .  Even though this idea w a s  g e n e ra l ly  a ck n o w led g ed ,  s tron g  s u p p o rt in g  
qu an ti ta t ive  e v id e n c e  has  b een  lacking. O ur  data  indicate  th at  it m a y  be  m o re  benefic ia l  to 
t r a n s p la n t  B M S C  ear ly  rather  than la te  a t  le a s t  to benefit  from  their  t i s su e  s p a r in g  abili ties.  
Further resea rch  will be  n e c e s s a ry  to d e te r m in e  the und erly ing  m e c h a n is m s  o f  the im proved  
B M S C  survival with early  a s  o p p o s e d  to de layed  t r a n sp la n ta t io n .  A lso ,  it r e m a in s  to be 
d e te rm in e d  w h e th e r  this w ould  a lso  perta in  o th er  ca n d id a te  cell t y p e s  for sp inal  cord repair.
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Tlie goal o f  C hapter 5 w a s  to im pro ve  B M S C  survival after  t r a n sp la n ta t io n  into a contusion  
e n v i ro n m e n t .  W e h yp o th es ized  th at  reducing  m a c r o p h a g e  infi ltration prior to introduction o f  
B M S C  would im prove  their  survival in ^ e  con tu sed  ^ o r a c i c  adult rat  s p in a l  cord. Quickly after 
a con tu s ive  im p a c t  to the sp ina l  cord an iovas ion  o f  m a c r o p h a g e r  can be  observed .  W e 
f e m o n s t ra te d  that t r e a rm e n t  re g im e s  o f  cyc losporine  (CsA), m inocyc line  (MC), or 
m e t h y lp re d n iso lo n e  (MP) resulted in a s ign if ican t  d e c r e a s e  ( p < o . o o i )  in m a c r o p h a g e  
infi ltration at th ree  d ays  post-injury. D e s p i te  th is  p ro m is in g  result , survival o f  B M S C  ( i x i o 6/5 
ml) in jrc ted  into tha contusion  e p ic e n t e r  nt this 3-day t im e  point; w n s  not; s ign if icantly  d ifferent 
from t f at o f  B M S C  in jected into an  i m a ls  wUli out the m a c ro  p h a ge-redu c in g  t re a tm  e n ts  . In 
fact, t h t  fe r e s t  nce of" E3M S C  resulteri in r  s ign if ican t  a v e r a g e  f .9-fold in c re t s o  ( p < o . o o i )  in 
m a c r o p h a g e  infi ltration into the c on tu s io n  o f  treateri  rats  to lative to contro ls.  O n e  conclus ion 
from tl iesh results  is th at B M S C  injected within th e  c o e tu s io n  e p ic e n t e r  at tract  adri;tional 
in f la m m a to ry  cells  even  with con cu rren t  a d m in is t ra t io n  of7 m a c ro p h a g e -re d u c in g  drugs.  It m a y  
be th at  th os  e n M S C  that die soon after  injection recruit th e se  extra m a c ro p l ia g e s .  D eath  o f  
I sn ah n lan ted  IBM/ISC is a multi-factorial .oroblem which sh ot ld  be a d d re sse d  in a 
m ult id irc ip linary  m a n n e r .  Future studies  should Ire directed to w ard s  f ind ing  and  su b seq u en t ly  
m a n ip u la t in g  o ther  cues  for coN dea th  tech  as  p a th w a ys  in ne cros is  or  a p o p to s i s  o f  the 
t r a n s p  la n ted  cells.
In C hapter Or w e  invest igated  the effects  o f  B M S C  grofts  con hin d l im °  lo c o m otor  a n f  sen sory 
l u e c t io r  in adult  rate witd a con tu se d  thoracic  sp inal  cord. Rats w e re  c o n tu se d  using  the 
Infin ite H or izo n s  im c a c t o r  at a force  o f  2 n n  kDyn and  n ^i  D M E M  w i t t  w r o 6 B M S C s  or 
D M E M  nlone w a s  in jected into the injury c p ic e n te r  threo d ays  l a ter.  S o m e  rats  receivad C sA  
daily th rou g h o s t  the survival p e  riod. Even th o u g t  it w a s  show n that C sA  trc a tm n n r  did not 
im p ro ve  B M S C  survival, its a S m in is t ra t io n  nould support; repair-re lated  e v e n ts  th at  to fe t h e r  
with t f c s e  o f  OMSC could result in imprnvnd o utcom ea .  T wo m o n th s  after  d M S C  
t r a n sp la n ta t io n  rats  had in crea sed  B a s o c - le a t t i c - B r e s n a h a n  (BIBB) sub-scGres, a 1 7  %  sm alle r  
l a s a  o f  o u p p art  d f  the hinh limbs, a 3O %  sm a l le r  a n g le  o f  hind p a w  rotation, and  perform ed 
38 %  better  on the horizontal ladder. In addition, a t  4  w e e k s  p o r t- t ra n sp la n ta t in n ,  th e se  rats  
exhibited a 31 %  a nd 50  %  im p r o v e m e n t  in their  r e s e o e s e  to a nrechanical an d therm al 
s t im ulus,  respeceively , to the niod p a w s .  At 8 w e e k s  p o s t- t ra n rp la n te t io n ,  the rats still 
exMbited a 2 2  %  im p r o v e m e n t  in tCeir r o s p o n s e  to a m echn nica l  s t im ulus  but not a n y  Ionger 
ter n th erm al stim ulus.  Ratr  thot rnceived C sA  t s e a t m e n t  a lonn did not  d e m o n s tra tn  functional 
c h a n g e s  c o m p a r e d  to contro ls  e x c e p t  for a 2 9  %  sm a lle r  a n g le  o f  hind p a w  rotation. T here  
w a s  no overall additive effect o f  C sA  t r e a t m e n t  on B M S C -m e d ia te d  functional im p ro v e m e n ts .  
O ur  data  revea led  th at  t r a n sp la n ta t io n  o f  B M S C  into a 3-day old contusion  in the adult  rat 
sp inal  cord im proved  s o m e  a s p e c t s  o f  locom otor  and  s e n s o ry  function. O ur  results  su p p o rt  
further  exp lora t ion  o f  B M S C  for the d e v e lo p m e n t  o f  sp inal  cord rep a ir  s t ra teg ies .
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This th es is  m a y  se rv e  as  a s tar t in g  p o int  o f  m a n y  studies  th at focus on u n d e rs ta n d in g  and 
im pro v ing  the eff icacy o f  B M S C  to repa ir  th e  injured sp inal  cord. The  studies  in th is  th esis  
d e m o n s tr a te  th at  B M S C  have the g e n e t i c  ability to be effect ive in ne rvou s  sys tem  repair,  that 
they elicit  t i s su e  loss which great ly  d e p e n d s  on their  survival, and  th at  th ey  d e s p ite  their  
sh ortco m ings  resu lt  in behavioral im p r o v e m e n ts  after  sp inal  cord contusive  injury. It is c lear 
from our results th at  B M S C  survival is an im p o r ta n t  i ssu e  th at  n e e d s  to be a d d re sse d  such that 
their  e ffects  on re p a ir  can be  o p t im iz e d .
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Chapte r 8
Letsel van  het ru g g e n m e r g  kan resu lte ren  in functiever l ies  van  d e  ext re m ite i te n .  Indien het 
verl ies  van  functie  h e r m u h e n t  is, k u u t e n  patiU nten voor  de  rest  van  hun leven 
ro lstoe lgeb u nh en  zi jn .  In te rven t ie  s tra te g ie n  zi jn gerinht o p  fh u n t io u t t l  t e  puptomisclc  
herstel van  het  h escpadigh  e r u g g e n m e rg ,  m pa r h ebhen to t h u td e nie  t ge le id  to f  fun(rtiuhel e 
verbeteuiug. CunPanks de ve le  u n d e rz h e k e n  pp  b asaa l  wetenscpapher l i jk  g eb ied  is t ra n s la t ie  
ppa r h e klinie k v o o ra ls o o  g  niet m ugeli jk  .
hen van  he m gge li jkh ed en  mm het b escP adigd  r u g g e n m e r g  te  h erste l len  is door middel van  he 
t ra n sp lu n ta t ie  van  ce l len .  o u h e  M a rro w  Strnm al C el len  (BM SC ) z:ijn s ta m c e l le n  die 
gem ankeli jk  te verkrijgen ^ijn m inh e ls  bdenm erphun(rties .  H ierd oor  is au to lg g e  
c e l t r a n sp la n ta t ie  m oge li jk  en is het nisico pp  a f s to t ig g  door  het l ichaam  m in im a a l .
In dit proefschrift  is h e  gesch iktheid vun B M S C  voor  herstel van  het  h escPad igd  
ru g g e n m e r g  hestuhderd . hen sehie e x d e r im e n te n  zijn  u itgevoerd, waauin h e  g e n e x p r e s s i e  van 
B M S C ,  o v e h e v ig g  van  h e  ce llen pa t r a n s p la n ta t ie  en hun invloed p p  de funcO udele  uitknmst 
is bestnhoerd in hen r u g g e n m e r g le ts e l  m ohel in de rat.
In Hoofdstuk 1 w o r d ^ e n  a l g e m o e n  overz ich t van  r u g g e n m e r g le ts e l  geuntroducherd. In h e 
V e r e n ig d e  S ta te n  zijn  h e  inc ih entie  en p r e v a le n t ie  vun r u g g e n m e rg le ts e l  u itgebreid 
underzocho m e t  hen inc ih entie  vun u n g e v h e r  1 1 , 0 0 0  p a t ië n te n  h e r  jpar. D e  m l e s t  
voo rkn m en h e  o orzaken  zi jn ^ g e v a l l e n , g e w e ld ,  s o o r l  en ziekte .
W e t e n s c P a p le i n  k bewij s voo  r h e b este  b e P a n h e lm e to o h  e i s e r niet,  m eh  e v a o w e g  e h e 
grote  variabilite it  van  de  u n g e v a l le n .  In he v ro e g e  fa s e  is de  h eh a n h e lrn g  gericho pp 
O em odupam isch e  stab i l isa t ie  van  h e  pa t iënt .  H ie r r a  kom r de h e h a n h e irn g  van  h e  ( instabiele) 
we rve lk o lo m  pan he orde, wparbij  hen h e c o m p r e s s ie v e  la m io e c to m ie  al p an  niet 
g e c o m b io o e rd  m e t  fixatie  vun het  in stab ie le  s e o m e n t  van  h e  w e rve lk o lo m  he f  funcOunoel 
herstel ka n bevordere  n e n ka n resu lte re  n in he n kortet verb>lijf in het  z ieke  h huis e n 
revalipatiekliniek.  In he chron isch e  fa se  stpun t>reventie van  infe(rties un doorligp lekken 
ce tl trp£il, wparbij  a s h e c t e  n a ls  pijn e n in ferti l iteit ook  in g g e  n s ch o o w  g e  o o m e  n d ie  hen  te 
worh en .  h e te re  kiin ische studies  zi jn o ooZzakei i jk  o m  het v o o rh le l  van  hen p p e ra t ie  in he 
v ro e g e  fa s e  ad e q u p a t  te  h e s tu d e r e n .
D e lp ats te  ja re n  is het gebruik  van  s ta m ce l le n  (SC) in he w e t e n s c p a p  sterk t o e g e o o m e n . 
n m bryupale  s ta m c e l le n  (ESC) zijn cellen  in he zich untw inkelenhe b lastocyste .  Al v ro eg  in de 
untwinkelrng bev in den  h e z e  S C  zich in h e  k iem lag en  ec to -/m eso -  en e n d o h e rm .  Na he 
g eb o o rte  z ijn  s ta m ce l le n  oo  k p a o w e z ig  in versch il lenh  e o p a l e n  . V ersch i l lenh  e hublicatie  s 
hebben p u g g e t o u n d  dan m e t  hen ju is t  ^ d u c l e  protocol SC  in s tpa t  z ijn  zich te  untwinkelen tot 
cel lij he  fh uip a n h e re  k ie m la g e n ,  hoewel hieroveu o o g  gh en  c u n s e n s u s  is bereikt.  H ierdoor  is er 
hen n ie o w e  g o l f  van  in t e r m s e  voor  heg gebrui k van S C  u n t s t p a n .
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H e t b e langr i jks te  a r g u m e n t  t e g e n  het  gebruik  van s ta m c e l le n  is de  d iscussie  over  
w a n n e e r  e e n  e m b ry o  ee n  m e n se l i jk  pe rso o n  g e n o e m d  kan w o rden .  Is het  begin  van  het  leven 
bij de  bevruchting van  d e  eicel o f  bij le v e n sv a tb a a rh e id  van  de fo etu s?  Dit is een  d iscu ss ie  vol 
em o tie .  Potentiee l  misbruik  van  s ta m ce l le n  is de  v o o r n a a m s t e  o o rz a a k  van  de  ve le  eth ische 
discussies .
In Hoofdstuk 2 is de  beschikbare  l i teratuurkennis  over  d e  m ogeli jkh ed en  van  B M S C  voor 
herstel van  het b esch adigd  r u g g e n m e r g  b estu deerd .  B M S C  zi jn m e s e n c h y m a le  SC  die in het 
b e e n m e r g  a a n w e z ig  zi jn . H ierdoor  zi jn z e  gem akkel i jk  te  verkrijgen m idd els  
b e e n m e r g p u n c t ie .  D oor  de m ogeli jkheid  van  au to gra ft in g  is het risico o p  ee n  a fs to t in g sre a ct ie  
g e m in im a l i se e r d .  T e n s lo tte  zi jn er bij het gebruik  van  v o lw a sse n  s ta m ce l le n  g e e n  eth ische  
b e z w a re n ,  a a n g e z i e n  er  g e e n  e m b ryo n a a l  w e e fs e l  w o rd t  gebruikt.  D oord at  v ersch il len de  
publicaties  heb b en  a a n g e to o n d  da t  B M S C  kunnen tran sd i f fe ren t ië ren ,  is er d e  la a ts te  ja ren  
t o e n e m e n d  a a n d a c h t  hiervoor o n ts ta a n  o p  het geb ied  van  herstel van  de h artsp ier  na 
m yocard infarcten  in d e  cardiologie ,  o s t e o g e n e s i s  im per fec ta  in de  o rthopedie ,  o r g a n o g e n e s e  
in d e  in te rn e  g e n e e sk u n d e ,  n e u r o d e g e n e ra t ie v e  a a n d o e n in g e n  in de  neuro log ie  en 
g e h e r n ie e r d e  d iscus  intervertebra lis  in d e  neurochirurgie.
D oor  hun m e s o d e r m a l e  orig ine  zijn  B M S C  e erder  g e n e ig d  te  d i f ferentiëren  in c e lty pen  
van  d e  betre f fend e  k iem laa g .  H e t  is o n z e k e r  o f  d e z e  cellen  in ee n  o m g e v in g  van  het 
ru g g e n m e r g  niet zullen  differentiëren  in vet,  bot, kraakbeen  o f  sp ie rw e e fse l .  H e t  is 
noodzakeli jk  de  gesch iktheid van  B M S C  voor herstel van  het  b esch a d igd  ru g g e n m e r g  g o ed  te 
o n d e rz o e k e n  e e r  dit in e e n  k linische s e tt in g  te  te s te n .
In H oofdstuk 3 w o rd e n  d e  resu lta te n  b esch reven  van  o n d e rz o e k  n a a r  d e  g e n e x p r e s s i e  van 
B M S C  m e t  behulp  van  44 k  totaal r a tg e n o o m  m icroarrays .  T ot n o g  toe  is d if ferentiat ie  van 
ce lty pen ,  w a a r o n d e r  ook B M S C ,  beoord eeld  aa n  d e  hand van  m orfo logie  en 
m e m b ra a n m a rk e r s .  D e z e  z ijn  ech ter  n iet  spec if iek  en s o m s  ze l fs  o n b etro u w b aa r .  H et 
b e p a le n  van  het g e n e x p r e s s i e  pa troo n  van  B M S C  is ee n  b ete re  m a n ie r  o m  de geschiktheid 
van  dit ce lty p e  voor  ne ura le  d if ferentiat ie  te  b e p a le n .  D a a r n a a s t  is ook het effect van 
la ngd ur ige  celkweken o p  de  g e n e x p r e s s i e  van  B M S C  bestu deerd  door p a s s a g e  (P) 3 en P 1 4  te 
vergelijken . Z ow el P3 a ls  P 1 4  B M S C  b re n g e n  v e rs c h e id e n e  g e n e n  to t  e x p re s s ie  die e e n  rol 
s p e le n  in n e u r (o n )a le  p ro ce sse n  z o a ls  g lia le  d i f ferentiat ie  en m y e lin isa t ie ,  n e u ro n a le  
pro liferatie  en n e urietform at ie .  D e  g e n e x p r e s s i e  van  d e z e  g e n e n  b evest ig d  de  p o te n t ie  van  
B M S C  om  te  tran sd i f fe rent ië ren  in d e  n e u ra le  celli jn. In to taal kom en 6 6 8 7  g e n e n  tot 
e x p re s s ie  m e t  e e n  9 7 %  o ver la p  in g e n e x p r e s s ie .  V an  de over ige  3 %  kom en 159  g e n e n  hoger 
tot e x p re s s ie  in P3 en 43  g e n e n  hoger in P 14 .  Fu n ct ione le  data  s tructurering  la a t  ee n  
o v e r r e p r e se n ta t ie  van  4 3  G O -k lassen  in P3 B M S C  z ien ,  w a a r v a n  9 e e n  rol sp e le n  in o rg a a n  
ontwikkeling  en ce lpro liferatie .  In P 1 4  B M S C  zijn s lechts  2  G O -k lassen  o v e r g e r e p r e s e n t e e rd ,
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waarbij  1 ee n  rol s p e e l t  in o rga ano ntw ik k e ling .  D e  resu lta te n  s te u n e n  de  p o te n t ie  van  B M S C  
als gesch ikte  k andidaten  vo o r  verder o n d e rz o e k  o p  het geb ied  van  d e  n e u r o w e t e n s c h a p p e n .  
T e v e n s  blijkt uit de  studie d a t  la n g d ur ig e  celkweken d e  plastic ite it  van  de  cellen d o et  
a fn e m e n .
H oofdstuk 4  beschrijft  de  o ver lev ing  van  B M S C  na t r a n s p la n ta t ie  in het b esch a d ig d e  
r u g g e n m e r g  van  de rat. O p  v ro e g e  (15 min) en la te  (3, 7, 28 da g en )  t i jd st ip p en  na 
ru g g e n m e rg le ts e l  z ijn  B M S C  g e t ra n s p la n te e r d  in het  e p ic e n t ru m  van  d e  la e s ie  en is 
ce lo ver lev ing  en w e e fse lv e r l ie s  g e a n a ly s e e r d  tot 4  w e ken  na c e l t r a n sp la n ta t ie .  C e lover lev in g  
is h oger  7 d a g e n  na c o n tu s io n e e l  ru g g e n m e r g le ts e l  als  de  cellen d irect (32%) o f  3 d a g e n  (52%) 
na het  init ië le  t r a u m a  zi jn g e ïn je c te e rd .  V e rg e le k e n  m e t  ee n  in jectie  o p  7 d a g e n  o f  21 d a g e n  
na initiële  t ra u m a  (9 %  beiden , p <  0 ,0 1 )  is dit verschil  s ignificant.  H e la a s  zijn 28 d a g e n  na 
c e l t r a n sp la n ta t ie  o p  alle  t i jd sp u n te n  bijna g e e n  B M S C  m e e r  te  tra ce re n ,  m ogeli jkerw ijs  door 
m a s s a le  celdood.
In het c o n tu s ie m o d e l  z o n d e r  B M S C  t r a n s p la n ta t ie  (controle  rat) n e e m t  het v o lu m e  
g e s p a a r d  w e e fse l  gele id e li jk  a f  to t  4 6 %  (P< 0 . 0 0 1 )  ve rg e le k e n  m e t  e e n  o n b e sch a d ig d  
ru g g e n m e r g  o p  e e n  verge l i jkb a ar  s e g m e n t  in d e  rat. D irecte  en B M S C -in je ct ie  na 3 d a g e n ,  
m a a r  n iet  in jectie  na 7 o f  21 d a g e n ,  le iden tot e e n  s ign i f ican te  t o e n a m e  van  het g e s p a a r d e  
ru g g e n m e rg v o lu m e ,  m e t  e e n  sterke  correlat ie  (r =  0 .7 9  - 1 .0)  tot B M S C  over lev ing  g e d u re n d e  
de  e e r s te  w eek.
H e t  doel van  H oofdstuk 5 w a s  o m  B M S C  over lev ing  te v e rb e te re n  in het b esch adigd  
r u g g e n m e rg ,  door de  invas ie  van  m a c ro fa g e n  na het initieel t r a u m a  te  reduceren a lvorens  
B M S C  te t r a n s p la n te r e n .  B e h a n d e l in g  m e t  cyc losp or ine  (CsA), m inocyc line  (MC) o f  
m eth y lp re d n iso lo n  (M P) resu lteert  in een  s ig n i f ican te  a f n a m e  ( p < 0 .0 0 1 )  van  m a c r o fa a g  
infiltratie 3 d a g e n  na initieel letsel.  O n d a n k s  dit v e e lb e lo v e n d e  resu ltaat ,  is er bij B M S C  
t r a n s p la n ta t ie  3 d a g e n  na het  initieel letsel,  ee n  verge l i jkbare  ce lo ver lev ing  tu sse n  de 
b e h a n d e ld e  en con tro le  g r o e p  (sa l ine  injectie) na 7 d a g e n .  D e  a a n w e z ig h e id  van  B M S C  
a l leen  z o rg t  voor  een  3.9 m aa l  t o e n a m e  van  m a c r o fa a g  infi ltratie in het  b esch a d ig d e  
ru g g e n m e r g  v e rg e le k e n  m e t  con tro le  ratten , o n d a n k s  de  to e d ie n in g  van  im m u n o s u p p r e s s iv a .
In Hoofdstuk 6 w o rd t  b esch reven  o f  het b e w e z e n  n e u r o p r o te c t ie f  effect  van  de B M S C  de 
fu n ct ione le  u itkom st be ïnv loedt  o n d a n k s  d e  m a s s a l e  ce ldood na t r a n sp la n ta t ie .  V e rg e le k e n  
m e t  contro le  ratten blijken B M S C  tot 2  m a a n d e n  na t r a n s p la n ta t ie  te  resu lteren  in een  
verh o o g de  B a ss o -B e a t t ie -B r e s n a h a n  (BBB) subscore,  m e t  ee n  v e rb e te rd e  s ta n d  en rotatie  van 
de  o n d e rs te  le d e m a t e n ,  w aarb ij  de  ratten  3 6 %  b ete r  fu n ct io n e e rd e n  o p  de  ho r izo nta le  
laddertest .  V ier  w e k e n  na t r a n s p la n ta t ie  is bij de  B M S C  g e t r a n s p la n te e r d e  g r o e p  ee n  5 0 %  
ve rb e te rd e  r e s p o n s e  o p  m e c h a n is c h e  en th e rm isch e  stimuli  verge lek en  m e t  d e  contro le
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groep .  A ch t  w e ken  na c e l t r a n s p la n ta t ie  h ad den d e  b e h a n d e ld e  ratten  n o g  ee n  2 2 %  
ve rb e te rd e  r e s p o n s e  o p  m e c h a n is c h e  stimuli m a a r  n iet  m e e r  o p  th e rm isch e  stimuli .  Er is g e e n  
to e g e v o e g d e  w a a r d e  van  to e d ie n in g  van  C sA  o p  B M S C -g e m e d ie e r d e  fu n ct io ne le  uitkomst. 
T r a n s p la n t a t ie  van  B M S C  in ee n  3-dagen  o ud e  c on tu s ie  van  het r u g g e n m e r g  van  de  rat leidt 
tot e n ig  herstel in s e n s o m o to re  functie . V e rd e r  o n d e rz o e k  is no d ig  o m  het  effect  van  B M S C  
t r a n s p la n ta t ie  te  o p t im a l i se re n .
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G D N F  glial cell-line der ived neurotrop hic  factor
G F A P  glial fibril lary ac idic  protein
G F P  g re e n  f lu o rescen t  protein
G M -C S F  granu locyte  m a c r o p h a g e  - colony st im u lat in g  factor
G L G T  g e rm  line g e n e  th e ra p y
G O  g e n e  o n to lo g y
H LA  h u m an leucocyte a n t ig e n
iPS induced p lur ipo ten t  cells
L E M S  lower ex trem ity  m o to r  score (ASIA)
LV lentiviral
M A P -2  microtubule  a s so c ia te d  prote in  2
M B P  m y e lin -b a s ic  protein
M C  m inocyc line
M H C  m a jo r  h istocom patib il ity  c o m p le x
MOI mult ip licity o f  infection (ratic  o f  infect ious virus part ic les  to cells)
M P S S  m e th u lp re d n iso lo n e  sod iu m  succ inate
m V  mili Volt
N e u N  n euronal  m ark er  N
NF n e u ro f i la m e n t
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N G F  n e rv e  growth factor
N G S  norm al g o a t  se ru m
N S C  neural s te m  oells
N SE  neuron sp ec if ic  e n o l a s e
NT-3 ne urotrophin  3
N Y U -im p  N e w  York  U niversity  - impacSoe (for (ton tusion injury)
P p a s s a g e
PB a h o s p h a t e  buffer
QIF qu ad rip leg ic  index  o f  function
RAG re g e n n ra t io n  a s so c ia te d  g e n e
RIP rat insul in p rom otor
R N A  ribonucleio acid
SC  s tem  cell
SCI sp ina l  cord injury
S D  s tan d ard  deviation
SE M  stond ard  ereor o f  the m e a n
T  thoracic
V EG F vascu lar  endothel ia l  growth factor
WISCI w a lk in g  inden aor sp ina l  cord injury
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